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ABSTRACT 
 
The clinical manifestations of malaria infections are largely the result of the causative 
agent, Plasmodium parasites, extensively remodeling their host erythrocytes. Upon 
parasite invasion, the morphology of the infected erythrocyte is altered to become 
rigid and adhesive, characteristics that allow the infected cell to sequester within the 
microvasculature and hence escape mechanical filtration by the spleen. The parasites 
synthesise and export hundreds of effector proteins into the host erythrocyte in order 
to facilitate this remodeling, a process that is also essential for immune evasion and 
the survival of the parasite.  
 
Recent studies have demonstrated that a protein translocon at the host-parasite 
interface known as PTEX acts in trafficking these effector proteins into the host 
erythrocyte. The translocon consists of five known components, three of which 
perform essential roles in trafficking all known types of exported cargo (HSP101, 
EXP2 and PTEX150), and two additional components that fulfill auxiliary roles. 
PTEX88, one of the additional auxiliary components, had not been formally 
demonstrated to be part of the translocation machinery and its role in the protein 
export process is unknown. 
 
The work presented in this thesis demonstrates that PTEX88 is expressed 
concurrently with the core constituents of PTEX and co-localises with these proteins 
at the host-parasite interface. Through immunoprecipitation approaches, PTEX88 
could be confirmed to be a genuine component of the translocation machinery. 
Further immunoprecipitation analyses demonstrated that PTEX88 interacts most 
strongly with the motor component HSP101. To determine the function of PTEX88, 
transgenic Plasmodium parasites were generated to allow PTEX88 expression levels 
to be regulated. Depletion of PTEX88 did not affect the ability of parasites to export 
cargo, and thus PTEX88 does not function in the same manner as the core 
constituents of PTEX in mediating export of all classes of exported proteins. 
Depletion of PTEX88 both in vitro and in vivo resulted in parasites that had reduced 
cyoadhesive properties, although this could not be linked to a defect in export of the 
major cytoadhesion protein, PfEMP1 in P. falciparum. PTEX88-depleted P. berghei 
 
 
 ii
parasites were rendered avirulent, being unable to cause the neurological pathologies 
associated with severe malaria. 
 
Overall, these studies have shown that while PTEX88 is a constituent of the protein 
export machinery, its direct contribution to protein export is still unresolved. One 
possibility it that it mediates the trafficking of a specific protein(s) involved in 
cytoadherence. The results generated in these studies have been used to generate an 
updated model of how PTEX assembles and suggest that PTEX88 plays a less 
prominent role in trafficking malaria effector proteins.  
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1.1. Malaria is a major global health issue 
Malaria is a disease resulting from infection with parasites from the Plasmodium 
genus.   In 2014, an estimated 200 million malaria infections occurred, with 584,000 
deaths attributed to malaria (World Health Organization, 2014). Almost 50% of the 
world’s population is at risk of infection and slightly fewer than a hundred countries 
are endemic for the disease, particularly parts of sub-Saharan Africa, South America, 
Southeast Asia and the Indian subcontinent in developing regions (World Health 
Organization, 2014, White et al., 2014).  
 
There are numerous species of Plasmodium, five of which can infect humans: P. 
falciparum, P. vivax, P. malariae, P. ovale (which has recently been divided into two 
subspecies (Sutherland et al., 2010)) and P. knowlesi. The latter is primarily a primate 
malaria species but has recently been described as a zoonotic parasite that can also 
infect humans (Cox-Singh et al., 2008, Singh et al., 2004).  Whilst P. vivax is widely 
distributed and causes a greater number of infections (Mendis et al., 2001), P. 
falciparum is the most virulent species of malaria parasite, and is responsible for the 
majority of deaths caused by malaria (Greenwood et al., 2008). 
 
1.2. The life cycle of Plasmodium   
1.2.1. Transmission of Plasmodium to the human host  
Plasmodium parasites have a complex life cycle, involving both a mosquito vector 
and a vertebrate host. The vector for transmission of malaria parasites is the female 
Anopheles mosquito, which injects parasites into the vertebrate host upon taking a 
blood meal (Figure 1.1A) As a result she injects parasites in the form of sporozoites 
from her salivary glands into the host where they travel through the bloodstream. 
Upon reaching the liver, parasites utilize the high levels of heparan sulfate 
proteoglycans on the surface of the epithelial cells to bind and invade the liver (Coppi 
et al., 2007) (Figure 1.1B). Parasites must traverse multiple cell layers including 
sinusoids and Kupffer cells (Prudencio et al., 2006) before ultimately taking up 
residence in hepatocytes, utilizing the EphA2 receptor on the hepatocyte surface to 
establish infections (Kaushansky et al., 2015). After successful invasion of the 
hepatocyte, parasites encase themselves within a parasitophorous vacuole (PV) 
(Rankin et al., 2010). There are no clinical symptoms associated with liver-stage 
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malaria infections. Parasites undergo many rounds of binary replication, resulting in 
the host hepatocyte being filled with thousands of parasites in the form of merozoites. 
The host cell eventually ruptures, releasing merozoites into the bloodstream. These 
merozoites are then able to take up residence in their preferred host, the erythrocyte 
(Figure 1.1C).  
 
1.2.2. Invasion of erythrocytes by merozoites 
The invasion of erythrocytes by newly released merozoites commences with the 
initial and reversible attachment of a merozoite to the surface of the erythrocyte. The 
merozoite then actively re-orients itself so that its apical tip faces the erythrocyte 
surface, so that the apical organelles required for successful invasion are adjacent to 
the erythrocyte membrane.  Invasion is a highly coordinated process that involves 
secretions of proteins from three apical organelles; the rhoptries, micronemes and 
dense granules (reviewed in Cowman and Crabb, 2006). These include the 
Erythrocyte Binding Ligand (EBL) and Reticulocyte binding-like Homologue (Rh) 
family of proteins, which interact with native receptors on the erythrocyte surface to 
form irreversible interactions, thereby committing the parasite to invade the 
erythrocyte. (Tham et al., 2010, Egan et al., 2015, Crosnier et al., 2011, Camus and 
Hadley, 1985).  The release of a rhoptry neck protein (RON2) into the erythrocyte 
membrane and subsequent secretion of apical membrane antigen 1 (AMA1) from the 
micronemes allows the formation of a tight junction between the parasite and the 
erythrocyte. The activity of an actin-myosin motor in the merozoite drives its entry 
into the new host cell. Upon successful invasion of the erythrocyte, the parasite 
becomes encased in a parasitophorous vacuole, largely derived from the erythrocyte 
membrane (Lingelbach and Joiner, 1998).  This vacuole is bound by a membrane 
known as the parasitophorous vacuole membrane (PVM). Subsequently the contents 
of the dense granules are released into the PV (Torii et al., 1989) where they play a 
variety of roles in establishing the parasite within the host erythrocyte (Riglar et al., 
2013, Boddey and Cowman, 2013). 
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Figure 1.1: Malaria life cycle 
Infection with Plasmodium parasites involves transmission from a mosquito vector 
(A), which injects sporozoites upon taking of a blood meal. Sporozoites travel to and 
invade the liver, where they multiply, forming hundreds of merozoites. After leaving 
the liver, merozoites invade erythrocytes (C), where they initially appear as ring-
shaped forms before undergoing further growth and development into trophozoites 
and ultimately schizonts, which contain new merozoites that egress and invade new 
erythrocytes. A population of parasites terminally differentiate into sexual forms 
termed gametocytes, which are ingested by mosquitoes taking another blood meal 
(D). These gametocytes develop within the mosquito, ultimately forming sporozoites 
to complete the parasite life cycle.  
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1.2.3. Parasite growth during the asexual stages  
Soon after establishing an infection in the host erythrocyte, the parasites are termed 
ring-stage parasites, so named due to their appearance as ring-shaped forms when 
viewed by light microscropy after staining with Giemsa. As the parasite matures, it 
enters the trophozoite stage, where it undergoes rapid growth and induces profound 
alterations to the morphology of the host cell (reviewed in Maier et al., 2009). To aid 
in the rapid growth during this period of development, the parasite harbors a special 
organelle known as the food vacuole, where a variety of peptidases degrade 
hemoglobin from the host cell to obtain the amino acids it requires for growth 
(Francis et al., 1997, Biagini et al., 2003). Degradation of hemoglobin leads to 
formation of a toxic intermediate known as ferriprotoporphyrin IX. This molecule is 
then polymerized to form hemozoin crystals (Francis et al., 1997, Sigala and 
Goldberg, 2014). Whilst hemoglobin degradation by a multitude of peptidases 
(Kolakovich et al., 1997, Klemba et al., 2004, Ehlgen et al., 2012, Sigala and 
Goldberg, 2014) is sufficient to provide some amino acids, exogenous amino acids for 
parasite growth are also required (Francis et al., 1997). 
The final stage of the blood-stage development is known as schizogony, when the 
fully developed parasite divides multiple times to form schizonts containing between 
8 and 20 daughter merozoites (Figure 1.1C). The maturation of these schizonts leads 
to a cascade of events that culminate in the egress of merozoites from the schizont 
into the bloodstream. These free merozoites can then invade new erythrocytes, and 
hence the blood cycle is perpetuated. This cycle of growth and replication within 
erythrocytes is also associated with the clinical symptoms observed in malaria 
infections.  
 
1.2.4. Sexual development of parasites is required for transmission of parasites 
between human hosts 
In addition to the asexual replication that occurs within the erythrocyte, a proportion 
of parasites are committed to forming sexual forms of the parasite, known as 
gametocytes. These male and female gametocytes are ingested by the female 
Anopheles mosquito when she takes a blood meal (Figure 1.1D). The female and male 
gametes fuse to form a zygote. The zygote develops into an ookinete, a motile form of 
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the parasite that traverses the midgut of the mosquito and develops into an oocyst. 
Oocysts then undergo multiple rounds of asexual replication, forming sporozoites 
within the oocyst. The mature oocyst then ruptures, allowing the migration of the 
sporozoites to the salivary glands of the mosquito, where they are able to infect 
another vertebrate host when the mosquito takes another blood meal.  
 
1.3. Pathogenesis and immune evasion 
Infection with P. falciparum commonly leads to severe pathologies such as fever, 
severe anemia, respiratory distress and metabolic acidosis (Mackintosh et al., 2004) 
These pathologies are associated with the blood stages of the life cycle. The virulence 
of P. falciparum is largely due to the ability of the parasite-infected erythrocyte to 
cytoadhere to endothelial cells lining the microvasculature, which is conferred by 
expression and presentation of an effector protein, Plasmodium falciparum 
erythrocyte membrane 1 (PfEMP1) on the surface of the host erythrocyte. The family 
of PfEMP1 proteins are of high molecular weight and are encoded by approximately 
60 variable var genes (Gardner et al., 2002, Hviid and Jensen, 2015, Baruch et al., 
1995), with only one allele expressed at any given time within a particular infected 
erythrocyte, although many var genes are observed within the population of infected 
erythrocytes in Plasmodium-infected patients (Scherf et al., 1998, Smith et al., 1995). 
In addition, the highly polymorphic multigene family STEVOR (sub-telomeric 
variable open reading frame) and rif (repetitive interspersed family) have also been 
implicated in cytoadherence (Niang et al., 2009, Kyes et al., 1999). The 
cytoadherence phenotype has been demonstrated to be reliant on a number of 
receptors expressed on endothelial cells lining the vasculature, including intercellular 
adhesion molecule-1 (ICAM-1) in the brain (Berendt et al., 1989), CD36 in the lung 
and adipose tissue (Barnwell et al., 1989, Ockenhouse et al., 1989, Cooke et al., 1994, 
Miller et al., 2002) and chondroitin sulphate A in the placenta (Rogerson et al., 1995, 
Cooke et al., 2000, Buffet et al., 1999, Reeder et al., 1999). Accordingly, P. 
falciparum is able to utilise these receptor molecules to sequester in the capillaries 
within numerous organs such as the lungs, heart, adipose tissue, placenta and brain of 
infected patients (Pongponratn et al., 1991, Franke-Fayard et al., 2005). As a 
consequence, infected pregnant women may end up having babies of low birth 
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weight, or patients may succumb to cerebral malaria (CM) of which symptoms 
include seizures and coma (Ponsford et al., 2011) and is often fatal. Furthermore, 
PfEMP1 binds complement receptor-1 and to a smaller extent to CD36 on the surface 
of erythrocytes to create rosettes (Rowe et al., 1997, Chen et al., 1998, Handunnetti et 
al., 1992), an outcome frequently associated with severe malaria (Chen et al., 2000, 
Rowe et al., 1995).  The ability to cytoadhere and sequester within the vasculature is 
important for the survival of the parasite because it prevents the host cell from 
passaging through the spleen. The spleen plays a critical role in the immune response 
to malaria infections as it filters abnormal or infected erythrocytes and  contains 
resident macrophages that typically identify and remove these cells. The spleen also 
contains fibroblasts known as barrier cells that fuse to form syncytial layers during 
periods of immunological or hematopoietic stress, which helps to reduce the blood 
flow into erythropoietic regions of the spleen to protect them from further pathogenic 
disruption (Alves et al., 1996, Engwerda et al., 2005b).  
In addition to sequestration, the pro-inflammatory immune responses to the infection 
also contribute to malaria pathogenesis. (Miller et al., 2002) Of particular importance 
to CM is an increase in the levels of tumour necrosis factor alpha (TNF-α) (Grau et 
al., 1987), interferon gamma (IFN-γ) (Grau et al., 1989) and lymphotoxin alpha (LT- 
α) (Engwerda et al., 2002) in the serum of infected patients. Increases in the 
population of particular circulating lymphocytes also contribute to the onset of 
cerebral malaria. Increases in the levels of CD4+ T-cells (Yañez et al., 1996), CD8+ T-
cells (Nitcheu et al., 2003, Belnoue et al., 2002), natural killer (NK) T cells (Hansen 
et al., 2003) and NK cells (Hansen et al., 2007) are all implicated in the progression of 
cerebral malaria. Of particular note are the CD8+ T-cells, which appear to play a 
major role in the development of severe malaria (Spence and Langhorne, 2012). CD8+ 
T-cells are thought to infiltrate the brain in great numbers during malaria infections 
(Yañez et al., 1996, Belnoue et al., 2002, Lundie et al., 2008). Furthermore, it appears 
that the blood-brain barrier becomes compromised in people infected with P. 
falciparum who suffer from cerebral malaria (Brown et al., 1999). Thus while 
protection from blood-stage malaria infections is largely due to adaptive immune 
responses (Good and Doolan, 1999), it appears that the severe disease associated with 
cerebral malaria is the result of a number of factors, in particular the localized pro-
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inflammatory response in parasitized organs and the recruitment and activation of 
immune cells involved in innate immunity (Schofield and Grau, 2005). 
  
1.4. Malaria control – past, present and future treatments 
The majority of deaths from malaria infections occur in children under the age of five 
years, which may be attributed to the inability for these children to develop adequate 
immunity to malaria infections (Snow et al., 2005, Crompton et al., 2010, Stanisic et 
al., 2014). Even adults in malaria endemic regions exposed to multiple malaria 
infections only develop partial immunity to malaria after repeated infections (Stanisic 
et al., 2014, Ahmed Ismail et al., 2013). This has heightened the need for more 
adequate protection against becoming infected and effective treatments to ensure that 
people infected with Plasmodium do not succumb to severe disease.  
 
1.4.1. Malaria vector management 
One strategy that was widely used to prevent the spread of malaria was through the 
use of insecticides, in particular dichlorodiphenyltrichloroethane (DDT) to eradicate 
the mosquito vector. However, resistance to the insecticide was observed and 
concerns about the effect of DDT on human health led to the ban of DDT (Roberts 
and Andre, 1994, Turusov et al., 2002).  
Other insecticides have been used in the rollout of insecticide-treated bed nets to 
prevent transmission of infections through prevention of contact with the mosquito 
vectors harboring malaria parasites (Lengeler, 2004). This has contributed to a 
significant reduction in infection rates, although there has been increasing mosquito 
resistance to the insecticides, which has hampered efforts to control transmission 
(World Health Organization, 2013). 
 
1.4.2. Development of malaria vaccines 
There have been a large number of efforts and a variety of strategies employed to 
develop a suitable vaccine for prophylaxis to provide more robust long-term 
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protection against malaria infections. These include the creation of attenuated 
parasites (Epstein et al., 2011, Hoffman et al., 2002, Annoura et al., 2012), 
recombinant vaccines (Genton et al., 2002, Stoute  et al., 1997) and DNA vaccines 
(Wang et al., 1998). Furthermore, the different hosts and different stages of the 
malaria life cycle offer multiple targets for intervention with a suitable vaccine. 
However, it has been difficult to develop a vaccine against malaria parasites, largely 
due to the parasites ability to switch the antigens it presents to the immune systems, 
most notably in the presentation of PfEMP1, which is encoded by 60 var genes, only 
one of which is presented on the erythrocyte surface at any one time (Pierce and 
Miller, 2009, Su et al., 1995). The vast sequence diversity of PfEMP1 variants and the 
nature of the antigenic switching is important for the evasion of the immune response, 
as PfEMP1 is one of few parasite proteins directly exposed to the host immune 
system (Scherf et al., 2008, Kyes et al., 2001, Arnot and Jensen, 2011).  
To date, the most successful vaccine candidate, targeting the central repeat region 
(Ferguson et al., 2014) at the carboxy-terminal of P. falciparum circumsporozoite 
protein (Sinnis and Nardin, 2002, Ajua et al., 2015) and termed RTS,S/AS01, passed 
through Phase 3 clinical trials, although it only showed modest protection from 
malaria infections (Alonso et al., 2004, The RTS, 2012). Furthermore, these trials 
showed the vaccine was effective for only a short period, and that more frequent use 
of the vaccine would be required to sustain protection against infection. Despite a 
relatively low efficacy of 36% (Neafsey et al., 2015, Moorthy and Okwo-Bele), 
RTS,S/AS01 was approved by the European Medicines Agency in 2015, with 
recommendations for use in African children.  
 
1.4.3. Current anti-malarial drugs and acquisition of resistance 
Patients diagnosed with malaria infections are administered chemotherapeutics to 
clear infections or reduce the clinical symptoms. However, P. falciparum has 
acquired multi-drug resistance to the traditional anti-malarials such as chloroquine, 
quinine and sulfadoxine-pyrimethamine, which has hampered efforts to control 
malaria infections (Bloland, 2001). Currently, the use of artemisinin-based 
combination therapies (ACTs) is recommended. However, the efficacy of artemisinins 
has become compromised, with artemisinin resistance recently emerging in Thailand 
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and Cambodia (Dondorp et al., 2009), and Vietnam (Ashley et al., 2014), with 
resistance linked to mutations in the K13 kelch propeller protein (Ariey et al., 2014). 
This has heightened the need for development of new treatments for malaria 
infections, as ACTs are the last line of anti-malarial therapies that currently exist. In 
order to develop the next generation of treatments for malaria, it is imperative to gain 
a much deeper understanding of the biology of the parasite across all stages of its life 
cycle. This will provide a more strategic approach to the development of new 
vaccines and drugs that target the different stages of the parasite life cycle to inhibit 
further spread of infection and prevent the emergence of multi-drug resistant 
parasites. As the pathologies of malaria infections are associated with the infection of 
erythrocytes, there has been particular emphasis towards understanding the events that 
occur within the erythrocyte, with the hope that further insight into this stage of the 
life cycle may reveal new strategies to block parasite growth within the blood and 
hence prevent the severe outcomes associated with malaria infections.  
 
1.5. Remodeling of host erythrocytes 
Healthy, uninfected erythrocytes are uncomplicated cells, lacking any major 
organelles or nucleus. They contain large amounts of hemoglobin required for 
successful transport of oxygen and carbon dioxide. Erythrocytes also contain a 
membrane-bound scaffold comprised of spectrin that gives the cell the ability to be 
extremely deformable, a property that is required for the erythrocyte to pass through 
capillaries. During the course of infection in the erythrocyte, the parasite imparts 
major structural and morphological changes, resulting in altered physical 
characteristics of the erythrocyte (Cooke et al., 2004a, Boddey and Cowman, 2013). 
These changes are the result of the synthesis and trafficking of hundreds of proteins 
with diverse functions into the host cell, which ultimately localize to the erythrocyte 
membrane or to parasite induced-membranous structures in the erythrocyte 
cytoplasm, or they remain soluble within the erythrocyte cytoplasm (Maier et al., 
2009).  
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1.5.1. Structural changes to the host erythrocyte 
The most obvious physical modification to the parasitised erythrocyte is the 
appearance of a number of electron-dense outward protrusions of the erythrocyte 
membrane, termed knobs (Figure 1.2). These knobs are formed primarily by the knob-
associated histidine-rich protein (KAHRP), which is trafficked to the erythrocyte 
membrane, and the interaction between KAHRP and host cell ankyrin and spectrin 
facilitates its attachment to the erythrocyte membrane (Weng et al., 2014, Pei et al., 
2005). Other exported proteins such as PF10_0381 and PFD1170c, and an exported 
Hsp40 chaperone (KAHsp40) are also implicated in the formation of knobs as 
deletion of the corresponding genes results in parasites lacking knobs at the 
erythrocyte surface (Acharya et al., 2012, Maier et al., 2008). These knob structures 
provide a scaffold for the correct presentation of the major virulence protein, PfEMP1 
on the surface of the infected erythrocyte (Maier et al., 2009, Baruch et al., 1995, Su 
et al., 1995, Voigt et al., 2000), allowing the parasite to cytoadhere within the 
vasculature of the host vertebrate as described above. 
In addition to KAHRP, other parasite proteins play roles in modulating the 
cytoskeleton of the host cell, increasing the rigidity of the infected erythrocyte, and 
thus improving the ability to bind to host endothelial receptors (Nash et al., 1989). 
The ring-infected erythrocyte surface antigen (RESA) is exported within minutes after 
invasion of the erythrocyte (Riglar et al., 2011) and ultimately binds to spectrin. As a 
consequence, the spectrin tetramer is prevented from dissociating, resulting in 
increased rigidity of the host cell as well as preventing other merozoites from 
invading the erythrocyte (Pei et al., 2007). Other proteins implicated in the 
modulation of rigidity of the host erythrocyte include P. falciparum antigen 332 
(Pf332) (Hodder et al., 2009), STEVORs (Sanyal et al., 2011), two exported kinases 
that are members of the Apicomplexan-specific FIKK group of kinases (Nunes et al., 
2010), and other members of the PHIST family of exported proteins (Maier et al., 
2008).  
Malaria parasites also produce large, flattened membranous structures in the 
erythrocyte cytoplasm known as Maurer’s clefts (Figure 1.2). Maurer’s clefts are 
thought to be responsible for sorting of proteins as they traffic to the erythrocyte 
membrane (Tilley et al., 2008). Maurer’s clefts are present in the parasite within 2-4 
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hours after invasion (Gruring et al., 2011), budding from the PVM early in the 
parasite development, and then migrating towards the erythrocyte membrane as the 
parasite matures, where they become tethered to the membrane through linkages with 
the erythrocyte cytoskeleton (Spycher et al., 2006, Blisnick et al., 2000, Hanssen et 
al., 2008, Pachlatko et al., 2010). This attachment is important as it allows for correct 
trafficking of proteins from within the cleft to the erythrocyte membrane (Wickham et 
al., 2001, Hanssen et al., 2008). The Maurer’s clefts play an essential role in the 
trafficking of STEVOR and A-Rifin (Rug et al., 2014, Przyborski et al., 2005) as well 
as PfEMP1 (Kriek et al., 2003), as parasites lacking SBP1, an integral membrane 
protein in Maurer’s clefts, are unable to present PfEMP1 on the surface of the host 
cell (Cooke et al., 2006). Subsequent studies have implicated other cleft-resident 
proteins in trafficking PfEMP1 to the erythrocyte surface, including REX1 (Dixon et 
al., 2011, McHugh et al., 2015), PfEMP1 trafficking protein 1 (PfPTP1) (Rug et al., 
2014)  and Pf332 (Glenister et al., 2009). In each of those studies, aberrant cleft 
morphology resulted in the failure to correctly traffic PfEMP1. Furthermore, 
accumulation of PfEMP1 at the Maurer’s clefts is also suggestive of PfEMP1 
trafficking via the clefts before reaching the erythrocyte membrane (McHugh et al., 
2015, Blisnick et al., 2000, Wickham et al., 2001). At the Maurer’s cleft, PfEMP1 is 
assembled into a ‘cytoadherence complex’ along with KAHRP and PfEMP3 which is 
then trafficked to the erythrocyte surface for its presentation on the surface of the host 
erythrocyte (Wickham et al., 2001, Waterkeyn et al., 2000, Knuepfer et al., 2005). 
 
P. falciparum also induces mobile dot-like structures in the host erythrocyte known as 
J-dots (Figure 1.2). These are present early in the parasite life cycle and exported 
parasite chaperones localize to these structures (Gruring et al., 2011, Külzer et al., 
2010). It has been speculated, therefore, that J-dots aid in the trafficking of protein 
complexes involved in cytoadherence to the surface of the erythrocyte by maintaining 
them in a soluble state (Boddey and Cowman, 2013, Külzer et al., 2012).  
 
Another visible parasite-induced structure present in the infected erythrocyte cytosol 
is electron-dense vesicles (EDVs) (Hanssen et al., 2010) (Figure 1.2). These vesicles 
appear during the trophozoite stage and have been shown to contain both PfEMP1 and 
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PfEMP3 (Trelka et al., 2000, Taraschi et al., 2001). EDVs appear to traffic to and then 
fuse with the erythrocyte membrane, suggesting that these vesicles may be involved 
in trafficking of proteins from Maurer’s clefts to the erythrocyte surface (McMillan et 
al., 2013).  
 
In order for Plasmodium to acquire nutrients from the serum and to exchange of waste 
products, the parasite also induces changes to the permeability of the erythrocyte to 
minerals and small organic molecules such as amino acids, nucleotides and 
monosaccharides (Desai et al., 1993). This also aids in maintaining the osmotic 
balance in the parasite and host cell as the contents of both change with rapid parasite 
growth (Desai, 2014). To achieve this, the parasite establishes pathways known as 
new permeability pathways (NPPs) or Plasmodial surface anion channels (PSACs) to 
facilitate the exchange of these substances more readily (Alkhalil et al., 2004) (Figure 
1.2). To date, the only molecular component of the NPPs that has been identified is 
Clag3, which comprises of two variants (Clag 3.1 and 3.2) (Nguitragool et al., 2011), 
of which only one of these proteins is expressed at any one time. Neither of these 
proteins shows features typical of a membrane channel-forming protein, so how they 
contribute to NPPs is unknown.  
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Figure 1.2: Malaria parasites extensively remodel host erythrocytes 
Parasites exist within a parasitophophorous vacuole (PV) in the host erythrocyte and 
traffic proteins into the erythrocyte that impart visible structural modifications upon 
the host cell. These include Maurer’s clefts (MC, yellow), electron-dense vesicles 
(EDVs, orange) and J-dots (blue) within the cytoplasm. PfEMP1 (white) is trafficked 
via Maurer’s clefts and EDVs to the erythrocyte surface, where it is presented on 
knob-like protrusions (K) formed by KAHRP. New permeability pathways (NPPs) are 
also induced in the erythrocyte membrane to facilitate the exchange of wastes and 
acquisition of nutrients.  
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1.6. Export of proteins into the host erythrocyte 
The structural and morphological modifications to the parasitized erythrocytes are the 
result of the parasite trafficking hundreds of its own proteins across its parasite 
membrane and bounding parasitophorous vacuole membrane into the host erythrocyte 
(Van Ooij and Haldar, 2007, Maier et al., 2009, Haldar and Mohandas, 2007). A 
subset of these exported proteins are essential for the development and survival of the 
parasite; a large scale knockout screen of ~70 known exported proteins identified that 
25% of these proteins could not be deleted, highlighting the importance of protein 
export to the parasite (Maier et al., 2008). As such, gaining further insight into how 
proteins are exported may help to find new pathways that can be targeted for the 
development of new malaria therapies. 
 
1.6.1. Protein targeting to the parasite plasma membrane 
Most parasite proteins that are ultimately destined for export are synthesized with a 
hydrophobic signal sequence at the N-terminus, which ensures that proteins are co-
translationally inserted into the endoplasmic reticulum (ER) (Lingelbach, 1993, 
Lopez-Estran et al., 2003, van Ooij et al., 2008). Proteins are then trafficked from the 
ER to the parasite plasma membrane within secretory vesicles, which fuse to the 
membrane and hence soluble proteins are released into the PV space. The trafficking 
of proteins containing a transmembrane domain may differ from soluble proteins 
(Spielmann and Gilberger, 2010) – they may be maintained within the vesicles in a 
membrane-bound form and hence inserted into the parasite plasma membrane and, 
therefore, require extraction from this membrane to enter the PV space, or they may 
be initially trafficked in a soluble form utilizing the activity of chaperones to remain 
competent for trafficking, and only assume a membrane topology when reaching their 
final localization in the host erythrocyte (Papakrivos et al., 2005).  
 
1.6.2. The Plasmodium export element (PEXEL)  
In order for proteins destined for export to be specifically trafficked across the PVM 
into the host erythrocyte, a mechanism must exist to differentiate these proteins from 
other proteins that traffic through the ER-secretory pathway that take up residence at 
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the PVM or within the PV space. To help identify this mechanism, two 
groundbreaking studies performed sequence alignments of a number of known 
exported proteins to identify whether proteins destined for exported 16harac a 
signature trafficking motif. These studies identified a highly conserved core set of five 
residues, those being RxLxE/Q/D (where x is any uncharged amino acid residue) near 
the N-terminus of these exported proteins, termed the Vacuolar Targeting Signal 
(VTS) (Hiller et al., 2004) or Plasmodium Export Element (PEXEL) (Marti et al., 
2004). Validation that this N-terminal region, including the hydrophobic recessed 
signal sequence is sufficient and required for protein export was obtained by 
demonstrating that chimeras containing the signal sequence and PEXEL motif fused 
to green fluorescent protein (GFP) were exported into the erythrocyte cytosol. In 
contrast, chimeras containing a signal sequence but lacking a PEXEL motif or 
containing a mutated form of the PEXEL motif localized to either the ER or the PV 
(Marti et al., 2004). This indicated that the PEXEL motif is a specific requirement for 
proteins to cross the PVM.  
The identification of this export motif subsequently enabled the design of algorithms 
to predict the likelihood of a protein being exported (Sargeant et al., 2006, van Ooij et 
al., 2008). These predicted exported proteins are collectively known as the 
‘exportome’, initially estimated to include 300 members in P. falciparum (Marti et al., 
2004), or approximately 5% of its encoded genome. Further revelations about the 
nature of protein export, including a refined definition of the PEXEL motif and the 
identification of exported proteins lacking the PEXEL motif (termed PEXEL negative 
exported proteins or PNEPs) has led to an expansion of the predicted exportome, 
which now stands at ~460 proteins (van Ooij et al., 2008, Boddey et al., 2013). 
 
As the PEXEL motif is also conserved in other Plasmodium species, this has enabled 
comparisons of the exportomes of all Plasmodium species (Sargeant et al., 2006). P. 
falciparum has the largest PEXEL exportome, presumably because this is the only 
species with PfEMP1 and several studies have shown that many additional exported 
proteins are also required to traffic PfEMP1 to its final destination (Maier et al., 
2009). Its larger PEXEL exportome may also explain why P. falciparum is more 
virulent compared to other species infecting humans (Sargeant et al., 2006).  
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The revelation that the PEXEL motif was required for export of proteins across the 
PVM suggested that a common pathway was being 17haracte to traffic these proteins 
(Charpian and Przyborski, 2008). Further studies that have 17haracterized the PEXEL 
motif reveal that it is proteolytically processed in the ER after the conserved leucine 
residue, after which the protein is acetylated at the new N-terminus (Chang et al., 
2008, Boddey et al., 2009) (Figure 1.3). The protease responsible for this processing 
is Plasmepsin V, an ER-resident aspartyl protease (Boddey et al., 2010, Russo et al., 
2010). Interestingly, employment of signal peptidase or an exogenous protease to 
generate a new N-terminus in a reporter protein that is identical to that generated by 
plasmepsin V has led to some contradictory findings, with the reporter proteins either 
still being exported (Grüring et al., 2012, Tarr et al., 2013), or failing to be exported 
(Boddey et al., 2010). Thus how Plasmepsin V cleavage couples to the next stage of 
the export pathway is unknown, but clearly the generation of the new N-terminus that 
becomes subsequently acetylated is crucial for export. Plasmepsin V can also cleave 
non-conventional PEXEL motifs, such as proteins harboring an arginine residue in 
place of the lysine, or those containing a so-called ‘relaxed’ PEXEL motif, where an 
additional amino acid is present in position four of the PEXEL motif (Boddey et al., 
2013, Schulze et al., 2015).  To account for these different motifs, the definition of the 
PEXEL motif has been expanded to RxLx(x)E/Q/D.  
 
Interestingly, studies in Toxoplasma gondii, another Apicomplexan parasite closely 
related to Plasmodium, identified a Golgi-resident aspartyl protease that cleaves 
effector proteins prior to their translocation into the host cell (Coffey et al., 2015, 
Hammoudi et al., 2015, Curt-Varesano et al., 2016). This protease, ASP5, was shown 
to cleave PEXEL-like motifs (RRLxx) present in effector proteins, aiding in their 
translocation (Coffey et al., 2015, Hammoudi et al., 2015). Furthermore, ASP5 was 
also found to be responsible for maturation of exported effectors lacking the PEXEL-
like motifs (Coffey et al., 2015, Hammoudi et al., 2015, Curt-Varesano et al., 2016). 
This is in keeping with results observed in P. falciparum, in which Plasmepsin V was 
found to be required for the export of PfEMP1 despite PfEMP1 lacking a PEXEL 
motif and not being cleaved by Plasmepsin V (Sleebs et al., 2014, Boddey et al., 
2013). PfEMP1 trafficking is complex and requires the activity of several PEXEL-
containing proteins, and the results in T. gondii suggest that the export of Toxoplasma 
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effectors is a complex system that also requires the activity of proteins both 
containing and lacking PEXEL-like motifs (Coffey et al., 2015). However, another 
interpretation may be that activity of the aspartyl proteases may not be limited to 
cleavage of PEXEL-like motifs.  
 
A study by Bhattacharjee et al (Bhattacharjee et al., 2012) found that the lipid 
phosphatidylinositol-3-phosphate (PI(3)P) binds to the processed PEXEL motif in the 
ER prior to Plasmepsin V cleavage, and that this process was essential for export. 
This study also showed that replacement of the PEXEL motif with RxLR could result 
in successful export of chimeric proteins. The RxLR motif had previously been shown 
to bind PI(3)P in Phytophthora infestans and was shown to target proteins into the 
host erythrocyte in P. falciparum (Bhattacharjee et al., 2006). However, this study 
also revealed that not all export events occurred through this pathway, suggesting that 
there are multiple sorting pathways in the ER, possibly relating to the final destination 
of the secreted protein (Bhattacharjee et al., 2012). However all of these results have 
since been disputed, as another study involving multiple research groups showed that 
export of proteins occurred independently of PI(3)P binding and that PI(3)P does not 
accumulate in the ER where Plasmepsin V activity occurs, but rather in the food 
vacuole and apicoplast (Boddey et al., 2016), consistent with previous observations 
(Tawk et al., 2010). The authors concluded that there was no evidence that PI(3)P 
plays a role in protein export, and that the conserved placement of the PEXEL motif 
downstream of the signal sequence facilitates co-translational processing by 
Plasmepsin V to likely expose a signal that guides proteins toward export into the host 
erythrocyte (Boddey et al., 2016). However, the trafficking steps that occur 
immediately downstream of PEXEL processing remain an enigma. 
 
1.6.3. PEXEL Negative Exported Proteins (PNEPs) 
Whilst the identification of the PEXEL motif provided some insight into the signals 
involved in the export of a subset of exported proteins, there are a number of known 
exported proteins that do not contain this motif, or contain a motif that does not 
exactly match the PEXEL motif (Marti et al., 2004). These proteins are termed 
PEXEL-negative exported proteins (PNEPs) and include the Maurer’s cleft proteins 
SBP1 (Blisnick et al., 2000), MAHRP1 (Spycher et al., 2003), and the ring exported 
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proteins REX1 and REX2 (Haase and de Koning-Ward, 2010, Hawthorne et al., 2004, 
Spielmann et al., 2006), amongst others. It is worth noting that other Plasmodium 
species also encode for multigene families known as pir (Plasmodium interspersed 
repeats) (Otto et al., 2014, Yam et al., 2016, Pasini et al., 2013) and pyst (Siau et al., 
2014). Most of these proteins are exported but do not contain PEXEL motifs (Otto et 
al., 2014, Yam et al., 2016). These proteins are largely involved in cytoadherence and 
like the var genes that encode PfEMP1 in P. falciparum, allow for antigenic variation 
to cycle between hundreds of alleles present in the parasite genome (Janssen et al., 
2004). Most PNEPs contain an internal transmembrane segment at their N-terminus 
that also acts to guide it to the ER (Spielmann and Gilberger, 2010), however some 
utilise use a standard hydrophobic signal sequence (Heiber et al., 2013). PNEPs 
contain no distinct morphological features and contain no conserved motifs that may 
predict export. However further PNEPs have been identified due to commonalities in 
transcription profile and chromosomal location with known PNEPs (Heiber et al., 
2013).  
The presence of exported proteins without a PEXEL motif has led to the hypothesis 
that the parasite may utilise multiple pathways in order to export its proteins (Haase et 
al., 2009, Spielmann and Gilberger, 2010). However, as PEXEL proteins contain no 
distinct features after Plasmepsin V cleavage, it is also possible that the export 
pathway that traffics PEXEL proteins may accommodate all exported proteins 
(Spielmann and Gilberger, 2010) (Figure 1.3). A recent publication by Grüring and 
collaborators (Grüring et al., 2012)  found that PEXEL cleavage can be bypassed due 
to a region in the N-terminus downstream of the PEXEL motif that distinguishes 
exported proteins from non-exported proteins, and this region is also present in the N-
terminus of PNEPs. This region is thought to help licence proteins for export after 
PEXEL cleavage and suggests a common mechanism for export of both PEXEL-
containing proteins and PNEPs (Grüring et al., 2012, Marti and Spielmann, 2013). 
(Figure 1.3B).  
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Figure 1.3: Pathway for secretion of proteins into the PV 
Most exported proteins contain an N-terminal signal peptide that facilitates co-
translational insertion into the ER lumen. Within the ER, proteins containing a 
PEXEL motif (pink) are proteolytically processed by Plasmepsin V (pink scissors). 
The exact pathway that proteins travel from the ER to the PV has not been 
conclusively demonstrated. One model has been proposed, whereby after Plasmepsin 
V cleavage, proteins destined for export are recognized and packaged into vesicles for 
trafficking to specific zones in the PV where protein export occurs, while PV-resident 
proteins are trafficked to other zones in the PV separately (A). Another model is that 
all proteins, including PV-resident proteins, are packaged into vesicles and are 
trafficked to the PV, where proteins destined for export are specifically recognized 
and exported across the PVM into the host erythrocyte (B).  
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Presumably after cleavage of the PEXEL motif, proteins destined for export are  
packaged into vesicles via the secretory pathway and trafficked to the PV (Benting et 
al., 1994, Lingelbach and Przyborski, 2006) (Figure 1.3). 
 
1.7. Trafficking of proteins across the PVM into the host erythrocyte 
Once proteins destined for export are released into the parasitophorous vacuole, they 
must traverse the PVM in order to access the host erythrocyte. Several hypotheses 
have been proposed as to the mechanism employed by the parasite to traffic these 
proteins across the PVM, including vesicular mediated trafficking (Trelka et al., 2000, 
Taraschi et al., 2001), or active translocation of proteins across the membrane 
(Lingelbach, 1997). Subsequent studies had shown that proteins need to be in an 
unfolded state in order to cross the PVM (Gehde et al., 2009) and export of proteins 
into the host erythrocyte is an ATP-dependent process (Ansorge et al., 1996). Such 
requirements for protein trafficking across a membrane provided support for protein 
export across the PVM to be mediated by a translocon rather than by vesicular-
mediated trafficking.  
 
1.8. The Plasmodium translocon of Exported Proteins (PTEX)  
In order to determine whether a protein translocation machinery exists at the PVM in 
malaria parasites to translocate proteins across this membrane, bioinformatic analyses 
were conducted to find orthologues to components of known translocon systems 
present in either eukaryotes and prokaryotes (de Koning-Ward et al., 2009). The 
failure to identify orthologues suggested such a translocon did either not exist in 
Plasmodium, or that such a machinery in these parasites had evolutionally diverged 
from other eukaryotic translocons to such a degree that it could not be identified by 
these type of searches. To investigate further, proteomic analyses were conducted on 
detergent-resistant membranes prepared from schizont-stage parasites as these are 
enriched for proteins known to localise to the PVM (de Koning-Ward et al., 2009, 
Sanders et al., 2007). From the proteins identified in this proteome, five criteria were 
used to predict the likely identity of putative translocon components. These criteria 
were that a translocon involved in protein export would include components that (1) 
are unique to Plasmodium as PEXEL-mediated protein export at the time appeared to 
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be unique to malaria parasites; (2) could provide a power source, likely an ATPase as 
protein export is known to be an energy-dependent process; (3) are expressed at times 
when protein export occurs, such as the ring/trophozoite erythrocytic stages of 
parasite development; (4) are essential for blood-stage growth of the parasite, given 
that a subset of exported proteins are essential for parasite survival (Maier et al., 
2008), and (5) are capable of specifically binding to their exported cargo (de Koning-
Ward et al., 2009).  
 
The proteins in the detergent-resistant membranes were scrutinised and one 
component, a HSP100 AAA+ ATPase termed HSP101 was identified. HSP100s 
typically form hexamers and are involved in unfolding proteins in the presence of 
ATP (Schirmer et al., 1996). Thus, it was hypothesized that HSP101 may potentially 
provide the energy force to translocate proteins across the PVM and accordingly it 
was investigated further. Another hypothetical protein was shown to have the same 
transcriptional profile as HSP101 and migrated in the same band in Blue-native 
PAGE gels as HSP101 (Sanders et al., 2007), suggesting they may  form a complex. 
This hypothetical protein was termed PTEX150, based on its predicted molecular 
weight of 150 kDa (Sanders et al., 2007, de Koning-Ward et al., 2009). 
 
In order to determine whether PTEX150 and HSP101 were part of a translocon 
system, reagents such as antibodies to these proteins and transgenic parasite lines 
expressing a triple hemagglutinin epitope-tagged protein were generated. Through the 
development of these reagents, an insight into the expression, localisation and 
interaction of these proteins was possible (de Koning-Ward et al., 2009). Analysis of 
expression of these two proteins showed strong expression of both proteins in later 
stages of the life cycle, and little change in expression levels throughout the life cycle.  
Immunofluorescence analysis (IFA) showed that both PTEX150 and HSP101 are 
synthesised in the mature merozoite stages at the apical end of the parasite and after 
invasion co-localise to the PVM. Moreover, genes encoding both of these proteins 
could not be genetically deleted (Matthews et al., 2013, de Koning-Ward et al., 2009, 
Matz et al., 2013). Together this strengthened the case that these components could be 
forming a translocon to traffic proteins across the PVM (de Koning-Ward et al., 2009) 
as protein export occurs quickly after the parasite has established itself in a 
 
  Chapter 1 
 
 23 
parasitophorous vacuole (Riglar et al., 2011). Immunoprecipitations revealed that 
PTEX150 and HSP101 interact with each other. Importantly, soluble PEXEL-
containing proteins were also immunoprecipitated with PTEX150 and HSP101, 
suggesting an interaction between PEXEL proteins and these putative PTEX 
components, however there was no data to show whether PTEX interacted with 
PNEPs (de Koning-Ward et al., 2009, Bullen et al., 2012). These data collectively 
suggested that HSP101 and PTEX150 satisfied the above criteria to be translocon 
components.  
 
Since other known translocons are comprised of numerous components, including a 
protein(s) that forms the channel through the membranes to facilitate passage, the 
proteins that immunoprecipitated with PTEX150 and HSP101 were scrutinised to 
identify further components of PTEX.  This proteomic approach revealed three new 
proteins that interacted with HSP101 and PTEX150.  The first protein, EXP2, was a 
known PVM protein with structural similarities to Hemolysin E (HlyE), an α-helical 
pore-forming protein in Escherichia coli that disrupts the lipid layer to form a pore for 
substrate exchange (Mueller et al., 2009), and due to its strong membrane association, 
EXP2 is thought to act as the pore component of PTEX through which proteins can 
pass across the PVM (Bullen et al., 2012). Consistent with this role, the gene 
encoding EXP2 cannot be deleted in Plasmodium during the blood stages (Matthews 
et al., 2013, Matz et al., 2013). 
 
Further characterisation of EXP2 have confirmed interactions with HSP101 and 
PTEX150 (Bullen et al., 2012), suggesting that these three proteins form a core 
complex. The immunoprecipitations of HSP101 and PTEX150 also pulled down two 
other proteins, a thioredoxin-like protein TRX2 and a novel protein, PTEX88 that, 
like PTEX150, shows no structural homology to any other proteins in gene and 
protein databases. Further analyses demonstrated that TRX2 specifically interacted 
with the core constituents of PTEX in the rodent malaria species Plasmodium berghei, 
providing evidence that TRX2 is a genuine component of PTEX (Matthews et al., 
2013). However, in contrast to PTEX150 and HSP101, the gene encoding TRX2 was 
able to be disrupted (Matthews et al., 2013, Matz et al., 2013), implicating it plays an 
auxiliary role in protein export. Moreover, given its homology to other thioredoxins, 
 
  Chapter 1 
 
 24 
this suggests it may play a role in redox regulation of either exported cargo or the 
translocon itself (Matthews et al., 2013).  
 
1.9. Functional dissection of some of the essential PTEX genes  
Although proteins were identified in Plasmodium that fit the critieria of components 
forming a translocation machinery at the PVM, formal proof that these proteins were 
acting as a portal for the passage of proteins into the host erythrocyte was lacking. 
Functional proof of this was difficult to achieve due to the essential nature of the core 
components (de Koning-Ward et al., 2009). During the blood stages of infection, 
malaria parasites possess a haploid genome, making traditional reverse genetic 
approaches to assess gene function difficult, as modification of essential genes is 
lethal to the parasite. Further analysis has been compromised by the lack of reliable 
techniques for the inducible regulation of gene expression in malaria parasites (de 
Koning-Ward and Gilson, 2009). Recent studies have shown successful adaptations of 
gene regulation systems in malaria parasites (reviewed in de Koning-Ward et al., 
2015). One such strategy is the use of unstable protein domains, which can be fused to 
a protein of interest such that the fusion protein is intrinsically unstable, which leads 
to its ubiquitylation and targeting to the proteasome for degradation. However the 
protein can be stabilised in the presence of a rapamycin analogue (Armstrong and 
Goldberg, 2007) or a folate analogue (Muralidharan et al., 2011) depending on the 
system being used, leading to normal expression of the protein, and therefore removal 
of  these analogues allows for controlled regulation of the level of the protein of 
interest (Armstrong and Goldberg, 2007, Muralidharan et al., 2011). However, not all 
proteins have access to the proteasome and thus this system does not function in the 
same manner for these proteins. Proteins without access to the proteasome can still be 
regulated using unstable protein domains as it has been shown that removal of the 
stabilising ligand can cause the protein of interest to become non-functional without it 
being degraded (Beck et al., 2014). Another strategy developed for the conditional 
depletion of proteins of interest is the use of a bacterial ribozyme incorporated into 
messenger RNA when transcription occurs (Prommana et al., 2013). The ribozyme 
can be activated by the addition of glucosamine, which leads to ribozyme-mediated 
degradation of the transcript and loss of translation. Transcription of a gene of interest 
can also be modulated in rodent malaria parasites to look at protein function in vivo. 
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This strategy involves the use of a transactivator, whose ability to bind to a minimal 
promoter to activate transcription can be blocked by the addition of 
anhydrotetracycline (ATc), leading to a significant reduction in the amount of 
transcript produced (Pino et al., 2012).  Other strategies have been recently introduced 
to regulate gene and protein expression in both P. falciparum and P. berghei (de 
Koning-Ward et al., 2015), which offer researchers a multitude of ways to assess the 
functions of essential genes to identify new targets for the development of 
antimalarial therapies.  
 
In order to understand the role that PTEX may be playing in protein export, these 
conditional knockdown systems were used to deplete parasites of either HSP101 or 
PTEX150, both core constituents of PTEX. These approaches were utilized by two 
independent research groups to show that PTEX is essential for the survival of the 
parasite in the blood stages of infection (Elsworth et al., 2014b, Beck et al., 2014). 
These studies showed for the first time that PTEX functions in protein export and 
PTEX translocates both PEXEL-containing proteins and PNEPs. Parasites depleted of 
HSP101 or PTEX150 could not survive past the ring stage of the life cycle, 
suggesting that PTEX would be an excellent target for the development of new 
therapeutics to treat malaria infections. However this will require further 
understanding of the composition and assembly of PTEX and how each component 
functions in successfully trafficking the wide variety of exported proteins into the host 
erythrocyte to identify the best strategy to block PTEX function.  
 
1.10. How may PTEX be acting in protein export? 
While PTEX has been shown to be the common portal for the different classes of 
exported cargo, little is known about how it may function as a translocon. There are a 
number of key requirements for protein translocation that are conserved amongst 
translocons found in nature, both in prokaryotes and eukaryotes (Ito, 1996 for a 
review). These include the presence of trafficking motifs on cargo proteins that guide 
them to the translocon, chaperones to ensure these proteins remain in a state 
competent for translocation, receptors to ensure the translocon recognises cargo to be 
translocated, membrane-spanning pores/channels to facilitate the passage of proteins 
across membranes and motor complexes to drive protein translocation as this is an 
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energy-dependent process. It is not known how PTEX addresses these requirements 
for translocation, although some bioinformatic modeling and identification of regions 
of homology to known proteins has offered some insight into how PTEX may traffic 
its cargo across the PVM. Further insight may be found by investigating the 
mechanisms of translocon function in other systems. 
 
Clearly the PEXEL motif serves as a trafficking motif in Plasmodium to direct 
proteins for export. This motif is present on a large subset of exported proteins, 
however, the fact that some PNEPs are also exported suggests that these proteins may 
be using an alternative signaling motif to guide them to the translocon (Grüring et al., 
2012, Bhattacharjee et al., 2012). Moreover, as the PEXEL motif is cleaved in the ER 
(Boddey et al., 2010), it remains unknown how PTEX is able to recognize cargo 
destined for export given that PEXEL cleavage results in an acetylated N-terminus 
comprising xE/Q/D, and whether this potentially involves specific soluble receptors 
docking to cargo in the ER that are then specifically recognised by PTEX in the PV. 
In most translocation pathways, proteins are translated as preproteins, containing a 
trafficking motif guiding these preproteins to the translocon. These trafficking motifs 
are usually proteolytically removed after translocation across the membrane, allowing 
the formation of the mature protein (Schatz and Dobberstein, 1996, von Heijne, 
1986). For example, in mitochondria and chloroplasts, precursor proteins contain 
either a cleavable or a non-cleavable targeting sequence to facilitate a specific 
interaction with the translocon, with trafficking motifs removed by processing 
peptidases after translocation (reviewed in Schleiff and Becker, 2011). However, 
there are also mitochondria targeting signals that remain part of the mature protein 
(Neupert and Herrmann, 2007). While the PEXEL motif is cleaved in the ER of 
Plasmodium, there appears to be a common sequence in the N-terminus of all 
exported proteins after this processing event (Grüring et al., 2012), suggesting that 
this sequence may help to guide these proteins to the translocon. The identity of the 
protein(s) recognizing a signaling motif to aid these proteins in reaching PTEX is not 
known. 
 
Protein translocation is an energy-dependent process, usually requiring ATP or GTP 
hydrolysis.  The only identified PTEX component that could power translocation 
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across the PVM is HSP101, an AAA+ ATPase (ClpB) that is a likely to help unfold 
proteins and provide the energy required for translocation via ATP hydrolysis. 
Hsp100 chaperones are typically involved in unfolding misfolded and aggregated 
proteins, and in re-folding improperly folded proteins in conjunction with other 
chaperones (Liberek et al., 2008). With HSP101 being localised on the vacuolar side 
of the PVM (de Koning-Ward et al., 2009), it is likely to act in a pushing motion. This 
is consistent with the activity of the Sec translocon in prokaryotes, where the pore 
formed by SecY engages an ATPase on the cis side of the membrane to provide the 
energy required for translocation of proteins (Denks et al., 2014). In eukaryotes, the 
activity of soluble chaperones powers translocation by pulling cargo through the pore 
from the trans side of the membrane, such as the activity of TIC complex at the inner 
membrane of chloroplasts that utilize ClpC chaperones to pull proteins into the 
chloroplast stroma (Jackson-Constan et al., 2001). In other cases, such as the 
presequence translocase-associated motor (PAM) complex in the mitochondrial 
matrix, Hsp70, which utilises ATP, is required to import proteins across the inner 
mitochondrial membrane (Schmidt et al., 2010, Schleiff and Becker, 2011). Such 
chaperones exist in Plasmodium-infected erythrocytes, including an Hsp70 chaperone 
termed Hsp70-x, synthesized and exported by the parasite (Külzer et al., 2012). 
However Hsp70-x is restricted to P. falciparum and is not conserved across 
Plasmodium. Moreover, it does not localize to the PVM, but rather to J-dots, 
suggesting that is not likely to be acting as an energy source for translocation, but 
rather serves a downstream application such as refolding or trafficking of exported 
proteins. Plasmodium parasites do, however, recruit a human Hsp70 chaperone in a 
membrane bound form (Banumathy et al., 2002), and it is possible that this chaperone 
is recruited to the trans side of the PVM to aid in pulling proteins across the 
membrane.  
 
In addition to powering translocation, chaperones are required to help maintain the 
stability of protein cargo, to regulate its unfolding so that it is competent for 
translocation and to refold proteins after crossing the membrane. In other 
translocation systems, the maintenance of cargo proteins in a translocation-competent 
state is often mediated by Hsp70s (DnaK), which is the case in mitochondrial protein 
import (Schneider et al., 1994, Young et al., 2003, Mayer and Bukau, 2005) and 
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chloroplast protein import (Zhang and Glaser, 2002), and also by Hsp40s (DnaJ) 
(Genevaux et al., 2007). P. falciparum contains six HSP70s, most of which localize to 
the nucleus or parasite cytoplasm (Shonhai et al., 2007). However some proteomic 
analyses have localized parasite-encoded Hsp70 proteins to the parasitophorous 
vacuole (Nyalwidhe and Lingelbach, 2006) and Maurer’s clefts (Vincensini et al., 
2005), although these findings have not been independently verified (Shonhai et al., 
2007). Another Hsp40 chaperone, PFA0660w, is a parasite-encoded Hsp40 that co-
chaperones Hsp70-x and is required for the ATPase activity of Hsp70-x (Daniyan et 
al., 2016). Furthermore, the putative PTEX component TRX2 is a thioredoxin-like 
protein (de Koning-Ward et al., 2009), and recent studies in Arabidopsis thaliana 
have suggested that thioredoxins may play dual roles as both redox regulating 
proteins and as chaperones (Park et al., 2009). Crystallography and small-angle X-ray 
scattering (SAXS) performed on recombinant TRX2 and substrate proteins has shown 
that TRX2 has a typical thioredoxin site that functions in redox regulation of 
substrates, suggesting that it functions in reduction of disulfide bridges and likely aids 
in unfolding of cargo prior to translocation (Peng et al., 2015).  
 
In order for proteins to traffic across a membrane, a pore or channel through the 
membrane is required. In the case of PTEX, EXP2 is currently the strongest candidate 
to form the pore as it has homology to HlyE, an α-helical pore forming protein in 
bacteria. α-helical pores also exist in the Sec translocation pathway (Papanikou et al., 
2007, Pugsley, 1993). A study in T. gondii identified proteins with limited homology 
to EXP2 (Gold et al., 2015). These proteins, termed GRA17 and GRA23, are also 
secreted from dense granules and have been shown to regulate the movement of small 
molecules across membranes and it was suggested that these proteins form pores in 
the membrane that aid in this process. P. falciparum EXP2 is able to rescue gra17-
null phenotypes, suggesting that GRA17 functions in a similar manner to that of 
EXP2. However GRA17 and GRA23 are not required for export of Toxoplasma 
effectors, implicating GRA17 and GRA23 only in the formation of a pore for the 
conductance of small molecules (Gold et al., 2015). The revelation that EXP2 
complements the function of GRA17 in T. gondii raises the question of whether EXP2 
has a dual function in facilitating the transfer of other small molecules across the 
PVM in addition to a role in protein export. The failure to knock out exp2 in the blood 
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stages (Matthews et al., 2013, Matz et al., 2013) and the reduced patency of FLP-
FRT-conditional exp2 mutants in mice (Kalanon et al., 2016) is consistent with a 
protein performing either or both of these functions, although it remains to be 
validated that EXP2 is the pore-forming component of PTEX.  
 
The roles of both PTEX150 and PTEX88 are not clear, although it has been 
speculated that PTEX150 may be required for maintaining the structural integrity of 
PTEX (Elsworth et al., 2014a). It is still unclear how PTEX is able to discriminate 
proteins destined for export from other secreted proteins that also traffic to the PV 
space and whether PTEX comprises constituents that regulates its activity. Studies in 
chloroplasts have shown that protein import is stimulated by reduction of disulphide 
bridges in components that contain conserved cysteine residues, namely Toc75, and 
the receptor components Toc159, Toc34 and Toc64 that reside at the outer membrane 
of this organelle (Stengel et al., 2009). Conversely, oxidation of the disulphide 
bridges blocks translocation (Seedorf and Soll, 1995, Stengel et al., 2010). 
Interestingly, conserved cysteine residues are present in both EXP2 and PTEX88 
(Matthews et al., 2013) and thus it is possible that PTEX88 may be acting in a similar 
manner to the receptor components in chloroplasts, and may be a substrate for TRX2. 
Furthermore, while five proteins have been confirmed to be members of PTEX 
(Matthews et al., 2013), there may be additional components that have not been 
formally identified that may fulfill any of the above roles.  
 
1.10.1. The function of PTEX88 is unknown 
The final protein identified as a putative component of the Plasmodium translocation 
machinery is a hypothetical protein termed PTEX88, so named due to its predicted 
molecular weight (de Koning-Ward et al., 2009). However its potential role in protein 
export is unknown, as this protein is unique to malaria parasites and bioinformatic 
analyses of the PTEX88 protein sequence has failed to identify any conserved protein 
domains that could indicate a potential function (de Koning-Ward et al., 2009). 
Furthermore, no reagents have been generated to P. falciparum PTEX88 that can be 
used for its characterisation or to demonstrate that it is a genuine component of the 
complex. Attempts to delete PTEX88 in P. berghei have also been unsuccessful using 
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conventional gene replacement techniques (Matthews et al., 2013), and thus the role 
that PTEX88 may serve in trafficking exported protein cargo is unknown.  
 
1.11. Hypothesis and project aims 
The identification of PTEX as the sole gateway for all classes of exported proteins to 
access the host erythrocyte highlighted its importance to the parasite and since this 
translocon is unique to malaria parasites, it represents an excellent target for the 
design of new anti-malarial therapies. However, the mechanisms by which PTEX 
translocates proteins have not been determined. Understanding the role that each 
constituent of PTEX plays will increase our understanding of the overall function of 
PTEX and will allow for more strategic targeting of PTEX. To date, the component of 
PTEX for which the least is known is PTEX88. Thus the aim of this project is to 
characterize PTEX88 and to dissect how it assembles as part of the complex as well 
as reveal its function through the use of reverse genetic approaches. 
 
The principal hypothesis of this study is that PTEX88 forms part of the PTEX 
machinery and is involved in the trafficking of parasite effector proteins into the host 
erythrocyte. This project aims to test this hypothesis by:  
 
a) using biochemical and proteomic approaches to confirm an interaction between 
PTEX88 and the core constituents of PTEX in P. falciparum to validate PTEX88 as a 
genuine member of PTEX; 
b) testing the essentiality of PTEX88 in P. falciparum and dissecting its function 
using reverse genetic approaches; 
c) investigating the function of PTEX88 in an in vivo setting;  
d) characterizing novel proteins that interact with PTEX88 as these could represent 
new constituents of the PTEX complex. 
 
By fulfilling these aims, this will provide a deeper understanding into PTEX 
composition and the mechanism(s) by which PTEX88 is able to assist in the 
translocation of proteins into the erythrocyte.  
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2.1. Materials 
Equipment and reagents for these studies were supplied from the following list of 
manufacturers 
 
• Amresco, Solon, OH, USA  
• Astral Scientific, Sydney, NSW, Australia 
• Becton Dickinson, Franklin Lakes, NJ, USA 
• Bioline, London, United Kingdom 
• Bio-Rad, Hercules, CA, USA 
• BOC, Sydney, NSW, Australia 
• Corning, NY, USA 
• eBioscience, San Diego, CA, USA 
• Fermentas, Ontario, Canada 
• Fisher Biotech, Wembley, WA, Australia 
• Fluka Biochemika, Buchs, Switzerland 
• General Electric Healthcare (GE), Fairfield, CT, USA  
• Grale HD Scientific, Melbourne, Victoria, Australia 
• Hospira, Mebourne, VIC, Australia 
• iBidi, Martinsreid, Germany 
• Interpath, Melbourne, Victoria, Australia 
• Invitrogen, Carlsbad, CA, USA 
• John Morris Scientific, Chatswood, NSW, Australia 
• Life Technologies, Carlsbad, CA, USA 
• Lonza, Basel, Switzerland 
• Millipore, Billerica, MA, USA 
• Miltenyi Biotec, Cologne, Germany 
• New England Biolabs, Ipswich, MA, USA   
• Pacific Laboratory Products, Blackburn, VIC, Australia 
• Promega, Fitchburn, WI, USA 
• Proscitech, Kirwan, QLD, Australia 
• Provet, VIC, Australia 
• Qiagen, Melbourne, Australia   
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• Red Cross Blood Service, Australia 
• Roche Molecular Biochemicals, Indianapolis, IN, USA   
• Sarstedt, Nümbrecht, Germany 
• Scientifix, Cheltenham, VIC, Australia 
• Sigma‐Aldrich, Sydney, NSW, Australia   
• Stratagene, La Jolla, CA, USA 
• Thermo Fisher Scientific, Waltham, MA, USA   
• Vector Laboratories, Burlingame, CA, USA 
• VWR, Tingalpa, QLD, Australia 
• Whatman, Fairfield, CT, USA 
 
2.2. Ethics statement 
All experiments involving the use of animals were performed in strict accordance 
with the recommendations of the Australian Government and the National Health and 
Medical Research Council Australian code of practice for the care and use of animals 
for scientific purposes. The protocols were approved by the Deakin University 
Animal Welfare Committee (approval number G37/2013 and G16/2014). 
 
2.3. DNA and protein sequence analysis 
All Plasmodium DNA and protein sequences were sourced from the Plasmodium 
Genomics Resource Database, PlasmoDB (http://plasmodb.org/plasmo/). In silico 
analyses of DNA, including polymerase chain reactions, restriction digests and DNA 
ligations were performed using Serial Cloner, version 2.5 (Serial Basics). 
Oligonucleotides were designed using OligoCalc (Kibbe, 2007) and Primer3 
(Untergasser et al., 2012). Alignment of protein sequences was performed using 
ClustalX software (Clustal) and visualized using CINEMA 5 (Parry-Smith et al., 
1998). 
 
2.4. Oligonucleotides 
Olignucleotides that were used in this study were supplied from Genesearch and 
Sigma-Aldrich and are listed in Table 2.1. 
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2.5. DNA applications 
2.5.1. Plasmid preparations 
Plasmid DNA was prepared from 2 mL (miniprep) and 200 mL (maxiprep) of 
bacterial culture (LB broth containing 100 µg/mL ampicillin (Sigma)) that had been 
grown overnight at 37°C with constant agitation at 200 rpm. Plasmid DNA was 
isolated using the PureLink™ Quick Plasmid Miniprep Kit/PureLink™ HiPure 
Plasmid Maxiprep Kit (Invitrogen) following the protocol outlined by the 
manufacturer. DNA was eluted in a final volume of 75 µL TE buffer (10 mM Tris-
HCl pH 8.0, 0.1 mM EDTA) for minipreps and 400 µL TE buffer for maxipreps. 
DNA concentration was measured using a Nanodrop 2000c spectrophotometer 
(Thermo Scientific). 
 
2.5.2. Amplification of DNA by Polymerase Chain Reaction (PCR) 
DNA was routinely amplified by PCR. Each reaction contained DNA template, which 
was either 50 ng genomic DNA (gDNA) isolated from wild-type Plasmodium 
falciparum or Plasmodium berghei parasites, 1 ng plasmid DNA, or in the case of a 
bacterial colony screen, a single bacterial colony. PCRs were performed in 50 µL 
reactions, containing 0.5 µM of the appropriate forward and reverse oligonucleotides, 
1x reaction buffer containing 1.5 mM MgCl2, 200 µM dNTPs and 2 U Phusion™ 
High-fidelity DNA polymerase (Thermo Scientific). The amplification process was 
performed using a C1000™ thermocycler (BioRad) using the following conditions: 
an initial denaturation at 98°C for 1 minute followed by 34 cycles of denaturation at 
98°C for 10 seconds, annealing at 52°C for 30 seconds, and extension for 2 minutes at 
60°C. A final extension at 60°C for 10 minutes completed the reaction. 
 
2.5.3. Restriction enzyme digestion and dephosphorylation 
Standard restriction digests on 1-5 µg DNA were performed in volumes of 20-50 µL, 
depending on the amount of DNA being digested. Reactions were performed in the 
appropriate buffers recommended by the manufacturer (New England Biolabs) at a 1x 
concentration, with bovine serum albumin (New England Biolabs) added at a final 
concentration of 1x. Appropriate restriction enzyme(s) were added (5-10 Units) and 
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the reactions were incubated at 37°C for 2 hours, unless otherwise indicated by the 
manufacturer. 
 
Digested plasmid DNA to be subsequently used in ligation reactions was additionally 
treated with 1 U of Shrimp Alkaline Phosphatase (Fermentas) for an additional hour 
at 37°C immediately following restriction enzyme digestion to prevent the plasmid 
from ligating back onto itself. In order to deactivate the phosphatase, the reaction was 
incubated at 85°C for 15 minutes. 
 
2.5.4. DNA Ligation 
Ligations were performed in 10 µL reactions, with a vector to insert ratio of 
approximately 1:3. Each 10 µL ligation reaction contained approximately 30 ng 
vector and the corresponding amount of insert, 1x reaction buffer (New England 
Biolabs), 200 U of T4 DNA ligase (New England Biolabs) and made up to 10 µL 
with Milli Q water. For each ligation, a negative control was performed, which 
contained the same amount of vector, but no insert DNA. Ligations were performed at 
room temperature for one hour prior to transformation into Escherichia coli (XL-10 
Gold strain). 
 
2.5.5. Bacterial transformation 
XL-10 Gold cells (Stratagene) were thawed gently on ice, and 50 µL of cells were 
added to each ligation reaction. The mixture was incubated on ice for 15 minutes, and 
then heat shocked at 42°C for 45 seconds. One millilitre of LB Broth (Amresco) was 
immediately added to the cells, which were then allowed to recover at 37°C for 45 
minutes with constant agitation at 200 rpm. After incubation, cells were centrifuged at 
17,000 g for 2 minutes, and approximately 900 µL of the supernatant was removed. 
The cell pellet was resuspended in the remaining supernatant and the cell mixture was 
plated onto an LB agar plate (Amresco) containing ampicillin (100 µg/mL) and 
incubated at 37°C overnight. 
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2.5.6. DNA sequencing 
DNA was prepared in a reaction containing 1 µg of plasmid DNA, 10 picomoles of a 
gene-specific oligonucleotide, and made up to 15 µL with Milli Q water. DNA was 
sequenced at the Australian Genome Research Facility using the Big Dye Termination 
sequencing protocol. Sequences were analysed using ApE (A plasmid Editor) 
software (M. Wayne Davis, University of Utah). 
 
2.5.7. Agarose gel electrophoresis 
PCR products and restriction digests were routinely separated on 0.7-2.0% (w/v) 
agarose gels (Amresco), depending on the size of the products being separated. Sybr-
Safe (Invitrogen) at a concentration of 1:25,000 was included in the gel for 
visualization of the DNA. Loading buffer (containing 10% (v/v) glycerol, 0.01% 
(w/v) bromophenol blue and 10 mM EDTA) was added to the samples prior to 
loading. Electrophoresis was performed at 80-200 V for 1-2 hours. In order to 
estimate the size of the DNA fragments being separated,5 µL of 1kb Plus DNA 
ladder (New England Biolabs) was run in one well alongside he samples. Gels were 
visualised and photographed using a Chemidoc XRS (BioRad) UV transilluminator.  
 
2.5.8. Southern blotting 
2.5.8.1. Generating digoxigenin-labeled DNA probes 
Probes used in Southern blots were synthesized using the PCR DIG Probe synthesis 
kit (Roche). Amplification was performed in 50 µL reactions, with each reaction mix 
containing digoxigenin-labelled dUTP at a concentration of 35 µM, along with the 
appropriate forward and reverse oligonucleotides and DNA template as outlined in 
section 2.5.2. RedTaq® DNA polymerase (2.5 U) (Sigma) was used to amplify the 
DNA.  The conditions used for amplification were an initial heat activation at 95°C 
for 15 minutes, followed by 34 cycles of 94°C (denaturation) for 30 seconds, 60°C 
(annealing) for 30 seconds and 68°C (extension) for 4 minutes. Reactions were 
completed with a final extension at 72˚C for 20 minutes. Amplification was 
confirmed by agarose electrophoresis and visualization of 5 µL of the mixture, and 
the remainder was stored at -20˚C until required.  
 
 
  Chapter 2 
 
 37 
2.5.8.2. Preparation of membrane 
Following electrophoresis, agarose gels containing digested gDNA underwent 
depurination in 0.125 M hydrochloric acid for 20 minutes. Gels were then incubated 
in denaturation solution (1.5 M sodium chloride and 0.5 M sodium hydroxide) for 30 
minutes.  Finally, gels were neutralised in 1.5 M sodium chloride and 0.5 M Tris (pH 
8.0) for 30 minutes.  DNA was then transferred overnight onto Hybond-N nylon 
membrane (GE Healthcare) in neutralisation buffer via capillary action.  After transfer 
of DNA, the membrane was incubated at 80°C for 2 hours to ensure DNA was bound 
to the membrane.  The membrane was then rinsed in distilled water and air dried prior 
to hybridization 
 
2.5.8.3. Hybridisation  
Membranes were initially pre-hybridised with DIG Easy-Hyb™ solution (Roche) at 
37°C for a minimum of one hour. The synthesized probe (5-10 µL) was denatured at 
95˚C for 5 minutes, then added to fresh DIG Easy-Hyb solution and the membrane 
was hybridized in this solution overnight at 37˚C under constant agitation.  
 
2.5.8.4. Detection 
Following hybridization, the membrane was washed with 2×SSC (Sigma) for 5 
minutes, followed by equilibration in wash buffer (0.1 M maleic acid (Sigma), 0.15 M 
sodium chloride and 0.3% (v/v) Tween-20 (Sigma)) for 1 minute.  The membrane was 
then incubated for 30 minutes in 1% (v/v) DIG blocking solution (Roche) followed by 
labeling for 1 hour with an anti-Digoxigenin-AP antibody (Roche) that had been 
diluted 1:10,000 in fresh 1% (v/v) blocking solution. The membrane was then washed 
twice in wash buffer for 15 minutes each and equilibrated in detection buffer 
containing 100 mM NaCl and 100 mM Tris (pH 9.5) for 2 minutes.  The membrane 
was then treated with Disodium 3-(4-methoxyspiro {1,2-dioxetane-3,2′-(5′-
chloro)tricycle [3.3.1.13,7]decan}-4-yl)phenyl phosphate (CSPD) (Roche) for 5 
minutes and the blot was imaged using a LAS-4000 Luminescent Image Analyzer 
(Fujifilm, Japan). 
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2.6. Protein applications 
2.6.1. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Prior to electrophoresis, protein samples were resuspended in or added to reducing 
sample buffer (1% (w/v) SDS, 10% (v/v) glycerol, 1 mM EDTA, 50mM dithiothreitol 
(DTT), 0.005% (w/v) bromophenol blue and 50 mM Tris HCl (pH 6.8)) at a 1x final 
concentration.  Protein samples were boiled at 100°C for 5 minutes and micro-
centrifuged at 17,000 g for 10 minutes. Sample supernatant (5-15 µl) and Precision 
Plus™ Protein standards (Biorad) were loaded and electrophoresed in either 4-12% 
precast gradient (Life Technologies) or 8-12% handcast SDS-PAGE gels at 140 V for 
90 minutes in 1x SDS-PAGE buffer (25 mM Tris base, 192 mM Glycine, 0.1% (w/v) 
SDS).  
 
2.6.2. Western blotting 
Electrophoresed proteins were transferred onto nitrocellulose membrane (0.45µm 
pore size) (GE Healthcare) using the Biorad wet transfer system. The transfer was 
performed at 100 V for 75 minutes using 1x SDS-PAGE buffer containing 20% 
methanol. After transfer, the membrane was washed briefly in distilled water and 
incubated for 5 minutes in Ponceau S stain (Sigma-Aldrich) to visualise the 
transferred protein on the membrane.  The stain was removed by washing the 
membrane with distilled water. 
 
The membrane was blocked for one hour in blocking solution (5% (w/v) skim milk 
powder in PBS), after which the primary antibody was diluted in blocking solution 
and applied to the membrane overnight at 4°C under constant agitation at 20 rpm 
(refer to Table 2.2 for a list of primary antibodies and the concentrations at which 
they were used in this study). The primary antibody was removed and the membrane 
was washed three times for 10 minutes in 0.05% (v/v) Tween-20 (Invitrogen) in PBS. 
Horseradish peroxidase-conjugated secondary antibodies (Millipore) were diluted in 
blocking solution at a 1:5000 dilution and applied to the membrane for one hour at 
room temperature under constant agitation at 20 rpm. The secondary antibody was 
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removed and the membrane was again washed in 0.05% Tween-20/PBS three times 
for 10 minutes. 
 
Detection of the samples was performed using the Clarity™ ECL Western blotting 
substrate (Biorad), according to the protocol outlined by the manufacturer. The 
membrane was imaged using a LAS-4000 Luminescent Image Analyzer (Fujifilm). 
Where required, ImageJ software (NIH, version 1.46r) was used to measure intensity 
of bands.  
 
2.6.3. Protein immunoprecipitations 
For immunoprecipitations, P. falciparum infected erythrocytes were lysed with 0.05% 
(w/v) saponin in PBS. Pelleted parasite material was resuspended in 1% (v/v) Triton 
X-100 in PBS containing cOmplete™ protease inhibitors (Roche). After a 30 minute 
incubation on ice, the material was centrifuged at 17,000 g for 10 minutes at 4°C. 
Anti-HA-conjugated agarose (20 μL) (Roche) or polyclonal serum (20 µL) from 
rabbits was added to the supernatant and incubated overnight at 4°C. When 
immunoprecipitations were performed with polyclonal serum, 50 µL Protein G-
conjugated agarose beads (Sigma) were added to the material the following day and 
incubated for a further 4 hours at 4˚C. The mixture was then placed on a spin column 
(Biorad) and unbound material was collected by gravity flow. Beads were then 
washed twice with 1 mL 0.5% (w/v) Triton X-100 in PBS containing cOmplete™ 
protease inhibitors (Roche). Bound proteins were eluted with 100 μL 1x non-reducing 
sample buffer (1% (w/v) SDS, 10% (v/v) glycerol, 1 mM EDTA, 0.005% (w/v) 
bromophenol blue and 50 mM Tris HCl (pH 6.8)). DTT was added to the elutions at a 
final concentration of 50 mM to reduce disulfide bonds and the proteins were 
electrophoresed by SDS-PAGE. 
 
2.6.4. Sequential solubility analysis 
P. falciparum-infected erythrocytes were lysed with 0.05% (w/v) saponin in PBS. The 
pelleted parasite material was resuspended in a hypotonic lysis buffer (1 mM HEPES, 
pH 7.4) to release cytosolic parasite proteins. After a 30-minute incubation on ice, the 
material was centrifuged at 100,000 g for 30 minutes at 4˚C.  The supernatant was 
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removed and the pellet was resuspended in 0.1 M Na2CO3 (pH 11.5) to release 
proteins peripherally associated with membranes. After a 30 minute incubation on ice, 
the material was centrifuged at 100,000 g for 30 minutes at 4˚C.  The supernatant was 
removed and the pellet was resuspended in 1% (w/v) Triton X-100 in PBS to release 
integral membrane proteins. After incubation of this material at room temperature for 
30 minutes, the samples were centrifuged at 100,000 g for 30 minutes at 4˚C.  The 
starting material, soluble fractions and the Triton X-100 insoluble fraction were 
electrophoresed by SDS-PAGE and analysed by Western blotting.  
 
2.6.5. Native-PAGE 
P. falciparum-infected erythrocytes were lysed with 0.05% saponin in PBS. The 
pelleted parasite material was resuspended in 20 pellet volumes of 1% (w/v) digitonin 
in PBS and incubated on ice for 30 minutes. The material was then centrifuged at 
18,000 g for 30 minutes at 4˚C.  Solubilised material was added to a 4x Native 
loading buffer (Life Technologies) and G-250 Coomassie additive (Life 
Technologies). This mixture was loaded into 3-12% NativePAGE™ Bis-Tris protein 
gels and electrophoresed according to the protocol outlined by the manufacturer (Life 
Technologies). This was done by making two buffers containing low and high 
concentrations of G-250 Coomassie additive, initially electrophoresing using the more 
concentrated G-250 buffer and electrophoresing at 150 V for 18 minutes. At this 
point, the buffer was replaced with the less concentrated G-250 buffer and 
electrophoresing at 150 volts for 42 minutes, followed by further electrophoresis at 
250 volts for one hour. All electrophoresis was performed at 4˚C.  NativeMark™ 
unstained protein standards (Life Technologies) were run alongside samples to allow 
the estimation of molecular weights. After electrophoresis, proteins were transferred 
onto methanol-activated polyvinlyidene fluoride (PVDF) membrane for 90 minutes at 
150 volts using the Biorad wet transfer system. After transfer was completed, the 
membrane was incubated in 8% (v/v) acetic acid for 15 minutes at room temperature 
to fix proteins to the membrane. The membrane was briefly rinsed in distilled water, 
before being washed in methanol to remove excess G-250 Coomassie additive from 
the membrane. The membrane containing the unstained protein standards was 
removed and stained overnight in Coomassie Blue protein stain to visualise the 
markers. The membrane containing electrophoresed sample was then blocked and 
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analysed by Western blot as described in 2.6.2.  
 
2.6.6. Chemical cross-linking  
P. falciparum cultures were washed in serum-free RPMI 1640 medium and passed 
through a MACS MS column (Miltenyi Biotec) to separate uninfected erythrocytes 
and ring-stage parasites from late-stage parasites. Late stage parasites were isolated 
and resuspended in 20 pellet volumes of dithiobis(succinimidyl propionate) (DSP) 
(Thermo Scientific) at concentrations of 0 µM, 125 µM, 250 µM and 500 µM 
dissolved in PBS. Samples were cross-linked in situ at room temperature for 30 
minutes. After centrifugation at 3,000 g for 2 minutes, the cross-linker was removed 
and the pellet was washed once in PBS. Cells were again pelleted and the residual 
cross-linker was quenched by resuspending the parasite pellet in a quenching buffer 
(150 mM NaCl, 1 M Tris pH 7.4) at room temperature for 20 minutes. The parasite 
material was again pelleted and washed in PBS, before hypotonic lysis in 5 mM 
sodium phosphate buffer (pH 7.4). After hypotonic lysis, the material was centrifuged 
at 18,000 g and the supernatant discarded. The insoluble material was resuspended in 
1% (v/v) Triton X-100/PBS. This material was immediately sonicated using a Vibra-
Cell™ VCX130 sonicator (Sonics, USA) to disrupt non-covalent protein-protein 
interactions. After sonication, the material was incubated at 4˚C for 1 hour followed 
by centrifugation at 17,000 g for 30 minutes at 4˚C. The supernatant was removed and 
subsequently used in immunoprecipitation reactions as described in section 2.6.3.   
 
2.6.7. Mass spectrometry 
After electrophoresis of proteins on a Nu-PAGE® 4-12% Bis-Tris polyacrylamide gel 
(Life Technologies), the gel was subsequently stained overnight in Sypro-Ruby 
protein stain under constant agitation at 15 rpm. The gel was then imaged under 
ultraviolet light to visualise proteins. Proteins of interest were excised from the gel 
and stored at -20˚C. Samples initially underwent in-gel processing, by reduction with 
10 mM DTT for 30 minutes, alkylation for 30 minutes with 50 mM iodoacetic acid 
and digestion with 375 ng trypsin (Promega) for 16 hours at 37˚C. These samples 
were then acidified in 0.1% (v/v) formic acid and concentrated to approximately 10 
µL by centrifugal lyophilization using a SpeecVax AES 1010 (Savant). Extracted 
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proteins were then injected and fractionated by nanoflow reversed-phase liquid 
chromatography on a nano-UHPLC system (Easy n-LC II, Thermo Fisher, USA). The 
nano-UHPLC was coupled online to an LTQ-Orbitrap mass spectrometer equipped 
with a nanoelectrospray ion source (Thermo Fisher, USA) for automated MS/MS. 
 
Data from LC-MS/MS were searched against a non-redundant protein decoy database 
comprising sequences from the latest version of LudwigNR (Human, Bovine, P. 
falciparum species), as well as their reverse sequences (249275 entries). Lists of mass 
spectra peaks were extracted from Bioworks 3.3.1 using extract-msn (Thermo Fisher 
Scientific) linked into Mascot Daemon (Matrix Science, UK). Parameters were set for 
peaks based on minimum and maximum mass and fixed modifications to identify 
peptides from peaks generated with mass spectrometry.  
 
2.7. Applications on Plasmodium falciparum 
2.7.1. Culture of P. falciparum 
P. falciparum (3D7) parasites were cultured in complete culture medium comprising 
RPMI 1640 medium (Life Technologies) supplemented with 20 mg/L gentamicin, 50 
mg/L hypoxanthine, 25 mM sodium bicarbonate, 0.25% (w/v) Albumax (Life 
Technologies) and 5% (v/v) heat-inactivated human serum. Parasites were cultured in 
O+ human erythrocytes at 4% (v/v) hematocrit. Cultures were maintained at 37˚C 
under an atmosphere of 5% CO2, 1% O2 in N2. Parasitemia was measured by making 
thin smears of cultured erythrocytes on glass slides and staining with Giemsa (1:10 
dilution in water) (Merck) to visualise parasitized erythrocytes. Parasitemias were 
measured as the percentage of erythrocytes infected with parasites.  
 
2.7.2. Freezing of cultured P. falciparum 
Cultured parasites were cryogenically frozen by pelleting cells at 2000 g followed by 
resuspension of the pelleted material in five pellet volumes of malaria freezing 
solution (28% (v/v) glycerol, 3% (w/v) D-sorbitol and 0.65% (w/v) sodium chloride). 
Aliquots of the resuspended material were then immediately stored in liquid nitrogen. 
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2.7.3. Thawing of frozen P. falciparum  
Vials containing frozen P. falciparum were removed from liquid nitrogen and gently 
warmed in a water bath at 37˚C. Once the material had fully thawed and warmed, it 
was added to 5 mL of pre-warmed thawing solution (3.5% (w/v) sodium chloride). 
This was centrifuged at 2000 g for 5 minutes. The supernatant was discarded and the 
pellet washed a further two times in thawing solution. The pelleted cells were then 
added to complete culture medium and erythrocytes were added to establish a cell 
culture at 4% hematocrit.  
 
2.7.4. Synchronisation of P. falciparum  
Cultured parasites were synchronized by resuspending parasites in 5-10 pellet 
volumes of 5% (v/v) D-sorbitol (Sigma) for 10 minutes at 37˚C to select specifically 
for ring-stage parasites. Cells were pelleted and washed twice in complete culture 
medium before being returned to culture. 
 
To achieve more tightly synchronous parasite cultures, parasites were initially 
synchronized using sorbitol. Then, when parasites developed into early schizonts, 30 
IU/mL of heparin (Hospira) was added to the culture to prevent newly released 
merozoites from invading erythrocytes. At the time point when schizont-stage 
parasites were predicted to be rupturing, heparin was washed out, allowing parasites 
to reinvade. Parasites were then sorbitol synchronized to lyse any remaining 
schizonts. The sorbitol synchronization was performed after either 10 minutes or three 
hours, depending on the window of synchronicity required. 
 
2.7.5. Transfection of P. falciparum 
Plasmid DNA to be transfected (100 µg) was obtained from maxiprep isolation. DNA 
was concentrated by ethanol precipitated and resuspended in 30 µL sterile TE buffer.   
 
Wild-type 3D7 P. falciparum parasites were cultured at 4% hematocrit to achieve a 
synchronous population of parasites at ring stages. Parasite culture (5 mL) was 
centrifuged at 2000 g and the pellet was resuspended in 370 µL sterile Cytomix buffer 
(120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM 
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K2HPO4/KH2PO4, 25 mM HEPES pH 7.6). The DNA was added to this mixture, 
which was then transferred to a 2 mm electroporation cuvette and transfected using a 
Biorad Gene Pulser Xcell™ electroporator. Electroporation was performed at 310 V 
and 950 µF with infinite resistance. Immediately after electroporation, the 
electroporated cell material was added to complete culture medium with 4% 
haematocrit and immediately placed into an incubator.  The next day after 
transfection, 2.5 nm WR99210 (Jacobus Pharmaceuticals) was administered to 
cultured parasites to select for parasites that had been transfected with DNA 
containing the human dihydrofolate reductase drug selection cassette. 
 
2.7.6. Isolation of parasite genomic DNA 
Parasitised erythrocytes (approximately 5% parasitemia) were lysed in 0.15% (w/v) 
saponin in PBS to remove haemoglobin and other host cell components. The 
remaining parasite material was resuspended in 500 µL lysis buffer (50 mM Tris, 150 
mM NaCl, 5 mM EDTA, and 1.0% (w/v) SDS, pH 8.0). To this, 10 µL of 10 mg/mL 
RNase A (Invitrogen) was added and the mixture was incubated at 37˚C for 30 
minutes. Proteinase K (Astral) was added to a final concentration of 2 mg/mL and 
incubated at 37˚C for a further 40 minutes. DNA was then extracted by adding an 
equal volume of 25:24:1 phenol:chloroform:isoamyl alcohol (Sigma) followed by 
centrifugation at 17,000 g for 5 minutes. The DNA-containing phase was removed 
and the remaining material discarded. A minimum of two extractions were performed 
to obtain a pure genomic DNA preparation. The DNA-containing phase then 
underwent ethanol precipitation. DNA was concentrated by precipitation with 2.5x 
volumes of 100% ethanol and 0.1x volumes of 3 M sodium acetate (pH 5.2). This was 
incubated at -20˚C overnight and centrifuged at 17,000 g to pellet precipitated DNA. 
The pellet was washed with 70% (v/v) ethanol, air dried and re-suspended in 50-100 
µL TE buffer. 
 
2.7.7. Cloning of parasite lines 
To achieve genetically identical transgenic parasite lines and ensure the absence of 
wild-type parasites, cultured parasites were diluted in complete culture medium and 
added to a 96 well flat-bottom tissue culture plate, with the dilutions calculated so that 
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on average, each well contained 0.3 parasites. Parasites were maintained for 15 days 
in the plate, with media replaced every 5 days. After 15 days, the presence of 
parasites in each well was assessed by Giemsa-stained blood films. Wells containing 
parasites were cultured further in 6 well flat-bottom tissue culture plates and 
integration of the targeting plasmid was confirmed by genotyping parasite genomic 
DNA by PCR or Southern blot, or confirming the addition of epitope tags via Western 
blot of parasite samples using the appropriate antibodies.  
 
2.7.8. Gelatin flotation of P. falciparum 
To select for parasites presenting knobs on the erythrocyte surface, cultured parasites 
were pelleted in centrifuge tubes and resuspended gently in 5 pellet volumes of 1% 
(w/v) gelatin (Sigma) in unsupplemented RPMI-HEPES as described previously 
(Waterkeyn et al., 2001). The tubes were then incubated standing upright at 37˚C for 
30 minutes to allow for sedimentation of uninfected erythrocytes, ring-stage infected 
erythrocytes and parasites not expressing KAHRP. The top layer containing late-
stage, knobby parasites was gently removed and placed into a new centrifuge tube, 
and washed twice with 15 mL unsupplemented RPMI-HEPES, before being returned 
to normal culture at 4% hematocrit. This protocol was repeated a further two times to 
ensure an enriched population of parasites capable of presenting knobs on the 
erythrocyte surface. 
 
2.7.9. Immunofluorescence 
Immunofluorescence was performed on parasites fixed with ice-cold 90% 
acetone/10% methanol or with ice cold 100% methanol. Cells were initially blocked 
in 1% (w/v) BSA in PBS for 30 minutes. Primary antibodies were diluted in 0.5% 
BSA/PBS and incubated with cells for 1 hour. After five washes with PBS, Alexa 
Fluor™-conjugated secondary antibodies were diluted 1:2000 in 0.5% BSA/PBS and 
added to cells for one hour at room temperature. Cells were washed another five times 
with PBS. Cells were then mounted in Vectashield® Mounting Medium with 4',6-
diamidino-2-phenylindole (DAPI), placed under a glass coverslip and sealed. Imaging 
was performed using an Olympus IX71 Microscope and images were acquired using 
CellSens™ Dimension software (Olympus). Images were subsequently processed 
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using ImageJ v1.46r (National Institute of Health) or Adobe Photoshop CS6.  
 
2.7.9.1. Quantification of protein export 
Analysis of exported proteins was performed using ImageJ on infected erythrocytes 
immunolabeled with antibodies against RESA, KAHRP, RIF50, STEVOR, SBP1 and 
PfEMP1 using previously established methods (Elsworth et al., 2014b). The method 
for measuring protein export was dependent on the type of protein being analysed. 
For all exported proteins, a line was traced around the infected erythrocyte, followed 
by tracing of a second line around the parasite delineated by the parasitophorous 
vacuole membrane as determined by EXP2 labelling to exclude the parasite from the 
analysis, leaving only the erythrocyte being assessed.  
 
Soluble proteins such as KAHRP and RESA and other proteins located predominantly 
in the erythrocyte cytosol were scored using the ‘Measure’ function in ImageJ in 
which case the Mean Fluorescence Intensity (MFI) of each cell was measured. 
Proteins localizing to distinct foci such as SBP1 and RIF50 were scored using the 
‘Find maxima’ function to count the number of foci. Noise tolerance was set to 200 
for these measurements, and output type was set to ‘Point selection’.  
 
2.7.10. Lactate dehydrogenase activity assays 
To quantitatively measure parasite growth, synchronous P. falciparum parasites were 
treated with glucosamine or vehicle control and grown in 96 well plates. When 
parasites had reached trophozoites in the following cycle, the plates containing 
parasites were frozen at -80˚C overnight. The following day after the plate was 
thawed to lyse parasites, 30 µL of thawed culture was added to 75 µL of a mixture 
containing 10 parts Malstat reagent (0.1 M Tris pH 7.5, 20 mg/mL lactic acid, 0.2% 
(v/v) Triton X-100, 1 mg/mL acetylpyridine adenine dinucleotide), 1 part 2 mg/mL 
nitroblue tetrazolium (Sigma) and 1 part 0.1 mg/mL phenazine ethosulfate (Sigma). 
The reaction proceeded on ice in darkness for 30 minutes. Measurement of lactate 
dehydrogenase activity was assessed by measuring absorbance at 600 nm.  
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2.7.11. Analysis of P. falciparum cytoadhesion 
Recombinant CD36 (125 μg/mL in PBS) was loaded into culture chambers (iBIDI μ-
Slide I) and incubated overnight at 4°C, as previously described (McHugh et al., 
2015).  PTEX88-glmS parasites were knocked down by the addition of 2.5 mM GlcN. 
Untreated and GlcN-treated parasites were synchronised to a 4-hour window. At 26–
30 h post-invasion, parasites (1% hematocrit, 3% parasitemia) were resuspended in 
bicarbonate-free RPMI-HEPES and flowed through the chambers at 0.1 pascal using 
a Harvard Elite 11 Syringe Pump. Assays were performed at 37°C and were 
visualised on a DeltaVision DV Elite Restorative Widefield Deconvolution Imaging 
System (Applied Precision) using a 60X objective. Parasites were flowed through the 
chamber for 5 minutes then washed for 10 minutes in bicarbonate-free RPMI-HEPES. 
The number of bound cells was then counted for the same 10 randomly chosen fields 
each experiment. 
 
2.7.12. Analysis of PfEMP1 presentation on the erythrocyte surface 
Mature trophozoite stage parasites (~106 iRBCs) were enriched from culture and 
treated with PBS alone or with TPCK-treated trypsin in PBS (Sigma, 1mg/mL), for 
one hour at 37°C. Following incubation the samples were incubated with soybean 
trypsin inhibitor (5 mg/mL) for 20 minutes at room temperature to inactivate trypsin. 
Samples were lysed with 1% Triton X-100 on ice for 20 minutes and centrifuged at 
16,000 g for 5 minutes. The pellet fraction was solubilized for 20 minutes at room 
temperature in 2% SDS. Parasite extracts were separated on 3–8% Tris-acetate gels 
(Invitrogen), transferred onto nitrocellulose membranes and probed with monoclonal 
anti- PfEMP1 acidic terminal segment (ATS) (1:100) primary antibody. 
 
2.8. P. berghei applications 
Female Balb/c and C57Bl/6 mice (6-8 week old) were used for infection with rodent 
malaria parasites. The reference strain 15cy1 from Plasmodium berghei ANKA 
(PbANKA) was used for generating transgenic parasites in this study. Mice were 
injected with 1x106 parasites intraperitoneally and parasitemia was monitored by 
Giemsa-staining of thin blood films obtained from tail blood of infected mice. Once 
parasitemia exceeded 20%, mice were humanely culled.  
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2.8.1. Culturing P. berghei 
P. berghei was cultured in complete P. berghei culture medium comprising RPMI-
1640 (Life Technologies) supplemented with 50 mg/L neomycin sulfate (Sigma), 5% 
(w/v) sodium bicarbonate, and 20% (v/v) fetal bovine serum (FBS). Cultures were 
incubated at 36˚C under an atmosphere of 1% O2, 5% CO2 in N2 overnight.  
 
2.8.2. Transfection of P. berghei 
Prior to transfection of P. berghei, the DNA to be electroporated (15-20 µg) was 
linearised with 2-3 µL (10-20 U) of the appropriate restriction enzyme(s) overnight at 
37°C. Confirmation of correct restriction digestion was done by electrophoresing a 
small fraction of the digested material on a 1% agarose gel. The remainder of the 
digested DNA was then precipitated as described in section 2.7.6 and resuspended in 
a final volume of 10 µL TE buffer (~5 µg digested DNA).  
 
Donor mice were intraperitoneally infected with 1x106 PbANKA parasites. When the 
parasitemia reached approximately 1-3%, mice were humanely culled under an 
atmosphere of 100% CO2 and blood was collected from the mouse by cardiac 
puncture. Infected blood was added to complete culture P. berghei medium. The 
following day, mature schizonts were obtained by purification on a Nycodenz density 
gradient as previously described (Janse et al., 2006). 
 
Prior to transfection, Nycodenz purified schizonts and linearised DNA were combined 
with 100 μL of Amaxa Basic Parasite Nucleofector ® Solution (Lonza) The mixture 
was transferred to an electroporation cuvette (Lonza) and transfection was performed 
using an Amaxa® Nucleofector device (program U33) to introduce the linearised 
DNA into wild-type parasite. Once electroporated, 50 μL complete culture medium 
was added and the total volume (150 μL) was injected intravenously into the tail vein 
of a 6-8 week old female Balb/c mouse.  
 
One day after transfection, administration of pyrimethamine in the drinking water of 
mice was used to select for parasites that had incorporated the transfected DNA. 
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Pyrimethamine was dissolved in DMSO at a concentration of 7 mg/mL, then diluted 
in tap water to a concentration of 70 µg/mL. The pH was adjusted to 3.5-5.0 using 
concentrated hydrochloric acid. 
 
2.8.3. Isolation of P. berghei genomic DNA 
To obtain parasite DNA from whole infected rodent blood collected by cardiac 
puncture, the leukocytes were first removed by chromatography using CF11 powder 
(Whatman). Eluted erythrocytes were centrifuged at 2000 g and genomic DNA was 
obtained as described in section 2.7.6. 
 
2.8.4. Cloning of P. berghei parasite lines 
To ensure that transgenic P. berghei parasite lines were pure and no wild-type P. 
berghei ANKA parasites were present, clonal parasite lines were established. For this, 
4-6 Balb/c mice were each infected intravenously with 200 µL mouse-tonicity 
phosphate-buffered saline (MT-PBS) containing 1-2 parasitised erythrocytes. A 
haemocytometer was used to ensure accurate erythrocyte counts. Genotyping by PCR 
or Southern blot confirmed that the parasite populations attained were clonal. 
 
2.8.5. P. berghei parasite growth analysis 
To assess whether transgenic parasites were affected in their growth in comparison to 
wild-type parasites, Balb/c mice (n=6 per group) were intraperitoneally infected with 
1x106 parasites and, if required, administered with 0.2 mg/mL anhydrotetracycline 
(ATc) (Sigma) in 5% (v/v) sucrose, or vehicle control (5% (v/v) sucrose) 
administered via the drinking water of mice. Parasite growth was monitored by 
making blood smears from tail veins of mice on a daily basis from Day 3 post 
infection and calculating parasitemia. Mice were humanely culled once parasitemia 
exceeded 20%. 
 
Alternatively, fluorescence-activated cell sorting (FACS) was used to calculate 
parasitemia using a previously defined protocol (Lelliott et al., 2014). 3 µL of blood 
was harvested from the tail of an infected mouse and immediately placed into 50 µL 
mouse-tonicity Ringer complete (MTRC) (154 mM NaCl, 5.6m M KCl, 1 mM 
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MgCl2, 2.2 mM CaCl2, 20 mM HEPES, 10 mM glucose, 0.5% BSA, 30 IU/mL 
heparin, pH 7.4) containing 12 µM JC-1 (Life Technologies) and 1 µg/mL FITC-
conjugated anti CD45 (Becton Dickinson) and incubated in this buffer at 37˚C for 30 
minutes. Cells were pelleted and the buffer was removed before resuspension in 500 
µL of MTRC containing 2 µM Hoechst 34580 (Sigma) and a further incubation for 20 
minutes at room temperature protected from light. Cells were washed a further two 
times in MTRC and then analysed by flow cytometry. Cells were initially sorted by 
forward and side scattering to exclude doublet-forming cells from further analyses. 
Further gating on a FITC channel identified CD45-positive cells, containing 
leukocytes that were also excluded from further counts. Additionally, JC-1 labels 
viable mitochondria and can be used to identify Howell-Jolly bodies that were also 
excluded. The JC-1-positive, CD45-negative cells were then analysed for Hoechst 
labeling to identify parasitized erythrocytes, which was calculated as a percentage of 
total erythrocytes. 100,000 cells were counted for each analysis.   
 
2.8.6. Virulence analysis 
As a measure of parasitic virulence, transgenic parasites were compared to wild-type 
parasites in their ability to cause cerebral malaria in C57Bl/6 mice.  Six-week old 
C57Bl/6 mice (n=6 per group) were infected intraperitoneally with 1x106 parasites 
and, if required, treated with ATc or vehicle control. The parasitemias from each 
mouse were calculated daily from Day 3 post infection. From Day 4 post infection, 
mice were checked four times daily for signs of cerebral malaria, symptoms of which 
include ruffled fur, ataxia, limb paralysis, and inability to self-right. Mice were culled 
when displaying symptoms of cerebral malaria or when parasitemia exceeded 20%.  
 
2.8.7. In vitro growth analysis 
Two donor mice were intraperitoneally infected with 1x106 parasites and treated with 
ATc or vehicle control. Once parasitemia reached ~10%, parasites were cultured 
overnight in the presence or absence of ATc. The following day, schizonts were 
purified on a Nycodenz density gradient, and injected intravenously into the tail veins 
of Balb/c mice that had been pre-treated with ATc or vehicle control. After 6 hours to 
allow parasites to invade, these mice were humanely culled. The blood from these 
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mice was obtained by cardiac puncture and immediately cultured in complete culture 
medium with ATc or vehicle control. Parasite growth was monitored by Giemsa-
stained blood smears at 2 hour intervals over 24 the next 24 hours. The stages of 
parasites were assessed to compare the development of parasites as they progress 
through the blood-stage life cycle.   
 
2.8.8. In vivo growth analysis 
Donor mice were infected and treated as in 2.8.7. However after intravenous 
administration of schizonts into pre-treated recipient mice (n=1 or 2 per group), the 
infection was allowed to proceed in mice across the entire asexual life cycle until after 
parasites had reinvaded in the subsequent cycle. Parasitemia was assessed at three 
hour intervals across the infection, except for a six-hour window around the expected 
time of reinvasion where parasitemia was assessed every 90 minutes.  
 
2.8.9. Parasite sequestration analysis 
Female C57Bl/6 mice were infected with 1x106 parasites as described in section 2.8.6. 
At Day 5 post infection, before the onset of cerebral malaria symptoms, mice were 
humanely culled and spleens were removed. Perfusion of organs was performed by 
administering MT-PBS intracardially. Lung and adipose tissue was then removed and 
organs were homogenized in TriSure reagent (BioLine) to extract RNA, using the 
protocol outlined by the manufacturer. cDNA was made from 1 µg of RNA using the 
iScript cDNA synthesis kit (BioRad). Analysis of parasite load was performed using 
quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Each 
reaction consisted of cDNA, the appropriate oligonucleotides and SensiFast Lo-Rox 
Sybr mix (Bioline). All qRT-PCR was performed using a Stratagene Mx3000P qPCR 
system The levels of parasite 18s ribosomal RNA (O629F/O630R) were compared to 
the levels of mouse hprt (O631F/O632R) using the 2-ΔΔCt method to assess the 
parasite load in each organ (Livak and Schmittgen, 2001).  
 
2.8.10. Immunofluorescence analysis 
P. berghei-infected erythrocytes were fixed in ice-cold 90% acetone/10% methanol as 
described in 2.7.9.  Immunolabelling was performed as described in 2.7.9 with the 
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exception that antibodies were diluted in 0.5% (w/v) BSA diluted in MT-PBS. Cells 
were mounted in Vectashield™ mounting medium with DAPI and imaged using an 
Olympus IX71 microscope. Quantification of export was performed by measuring the 
Mean Fluorescence Intensity of exported proteins as outlined in 2.7.10. 
 
2.8.11. Measuring protein export by flow cytometry  
The presence of P. berghei proteins on the surface of infected erythrocytes was 
assessed by flow cytometry. Parasites treated with ATc or vehicle control were 
harvested from infected mice by tail bleed, and incubated in blocking solution (1% 
(w/v) casein sodium salt in RPMI) for 30 minutes. The blocking solution was 
removed and the cells were then incubated in serum from naïve mice or semi-immune 
serum (both diluted 1:20 in blocking solution). After an hour incubation, cells were 
pelleted and washed three times with blocking solution, followed by incubation with 
an Alexa Fluor 647-conjugated anti-mouse secondary antibody (1:2000 dilution in 
blocking solution) for 1 hour. Cells were washed an additional two times before 
incubation with Sybr-Green (Life Technologies) at a dilution of 1:2000 in blocking 
solution for 5 minutes.  A further three washes of the cells completed the preparation 
of cells prior to analysis using a FACS Canto (BD) machine. Cells were initially gated 
on size using forward (FSC) and side (SSC) scatters. Cells were then gated on 
whether they were positive for Sybr-Green and positive for Alexa Fluor 647. These 
populations were counted to measure the levels of parasite proteins on the erythrocyte 
surface.  
 
2.8.12. Immune analysis 
Female C57Bl/6 mice were pretreated with ATc (0.2 mg/mL) or vehicle control (n = 5 
per group) and intraperitoneally infected the subsequent day with 1x106 PbPTEX88 
iKD parasitized erythrocytes. At day 5 post-infection the spleens and serum were 
collected. To analyse the production of cytokines and chemokines in the spleen, 
lysates were prepared as previously described (Haque et al., 2011). Briefly, a small 
portion of each spleen was harvested into ice-cold RPMI containing cOmplete™ 
protease inhibitor cocktail (Roche). Single cell suspensions were obtained following 
passage through 70 μm cell strainers, and cells were lysed using 0.5% (v/v) Triton X-
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100 for 15 minutes on ice. After centrifugation at 14,000 g for 5 minutes, 
supernantants were immediately snap-frozen and stored at -80°C. Spleen lysates and 
serum samples were then analysed using the ProcartaPlex Mouse Cytokine and 
Chemokine Panel 1 kit (26 plex, eBioscience) according to manufacturer’s 
instructions.  
 
For isolation and flow cytometric analysis of immune cell populations in the spleen, a 
portion of each spleen was harvested into ice-cold RPMI containing 2% (v/v) fetal 
calf serum (FCS), then mechanically chopped, and digested with collagenase and 
DNase and treated with EDTA as previously described (Vremec et al., 2000). Half of 
the single cell suspension was enriched for dendritic cells (DCs) using a 1.077 
g/cm3 density centrifugation (Nycodenz) and stained with fluorochrome-conjugated 
monoclonal antibodies (mAbs) against CD11c, MHC class II, CD8, CD172a, CD45R, 
CD40 and CD86. Splenic DCs were gated as NK1.1-CD49b-CD3-CD19-Ly6G-
CD11c+MHC class II+ cells, and then further subdivided into CD8+ or CD8-
 (CD172a+) conventional DC subsets, and CD45R+ plasmacytoid DCs. The remaining 
single cell suspension was treated with erythrocyte lysis buffer (eBioscience) and 
stained with combinations of fluorochrome-conjugated mAbs against CD3, CD4 or 
CD8 (T cells), CD45R and CD19 (B cells), NK1.1 and CD49b (NK cells), CD11c and 
MHC class II (DCs), or CD11b, CD64, Ly6C and Ly6G (macrophages, monocytes 
and neutrophils). Flow cytometry was performed on a FACS Canto II (BD 
Biosciences), excluding doublets and propidium iodide (PI)-positive dead cells, and 
data were analysed using FlowJo software (v9.4.10; Tree Star Inc., USA). 
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Table 2.1: List of oligonucleotides used in this study1 
Name Gene Oligonucleotide name Sequence (5' to 3') 
O1R Pb DHFR 3' UTR Pb DHFR3' R CGAACATTAAGCTGCCATATC 
O18F Pb DHFR 3' UTR Pb DT3'F CACCTAAATGTTACAAAGGATCC 
O52F hDHFR hDHFR F GGGGATCCATGGTTGGTTCGCTAAAC 
O54R N/A M13R AGCGGATAACAATTTCACACAGGA 
O55F N/A M13F CGCCAGGGTTTTCCCAGTCACGAC 
O110R PfPTEX88 PfPTEX88_3UTR_REV ACATTTTCGTCTAATTGAAGCCC 
O142F GFP PbGFP_F_NheI TGCGCTAGCATGAGTAAAGGAGAAGAACT 
O143R GFP PbGFP_R_SpeI GCCACTAGTCTATTTGTATAGTTCATCCATACCAT 
O145R Hemagglutinin tag HA_R_XhoI CTCGAGAGCGGCATAATCTGGAACATC 
O275F glmS glmS_F AATTATAGCGCCCGAACTAAG 
O276R glmS glmS_R GTGATTTCTCTTTGTTCAAGGA 
O295F PfPTEX88 PfPTEX88_A_F_BamHI GCCGGATCCGTGCAGATCATTATTAACAGA 
O296R PfPTEX88 PfPTEX88_A_R_EcoRI GCCGAATTCCTAGCTATCTTCGTCAATCTTAAC 
O297F PfPTEX88 PTEX88_B_F_BamHI GCCGGATCCGAACTCTTTCAATATATCTCACAT 
O298R PfPTEX88 PfPTEX88_B_R_EcoRI GCCGAATTCCTAACTTAAGTAATAACTAAACTTGG 
O299F PfPTEX88 pARL_Pf88_FragB_INT_F GTCACATATATATATAATATATATCAT 
O300F PfPTEX88 pARL_Pf88_FragB_INT_FOR2 GTAAATTAATTTTTTTAGGGTTTATATTTTATGT 
O301R PfPTEX88 pARL_Pf88_FragB_INT_REV ACATAAAATATAAACCCTAAAAAAATTAATTTAC 
O302F PfPTEX88 PfPTEX88-DD24_FWD TCTGCGGCCGCTTACCTTTTGTTAATGTAACCA 
O303R PfPTEX88 PfPTEX88-DD24_REV GCCCTGCAGAACTTAAGTAATAACTAAACTTGG 
O346F PfPTEX88 PfPTEX88 KO_5F_SpeI GCCACTAGTGAATTGAGAAAAAACATTCATA 
O347R PfPTEX88 PfPTEX88 KO_5R_AflII CAGCTTAAGAATGACAAAGCATATAAGTGTG 
O348F PfPTEX88 PfPTEX88 KO_3F_NcoI CAGCCATGGGGCTTCAATTAGACGAAAATGTA 
O349R PfPTEX88 PfPTEX88 KO_3R_AvrII CAGCCTAGGTATGCACAGATATAGGTATCTA 
O365F PfPTEX88 PfPTEX88 KO2_5F_SpeI GCGACTAGTCTTATATGCTTTGTCATTTATGTGC 
O366R PfPTEX88 PfPTEX88 KO2_5R_AflII GCACTTAAGATACATCTCCTACAATACTAATATCG 
O367F PfPTEX88 PfPTEX88 KO2_3F_NcoI CAGCCATGGGGGTAGGACCTATATCAACATCGG 
O368R PfPTEX88 PfPTEX88 KO2_3R_AvrII CAGCCTAGGGACCCATTAAGTGATGTTGATTCAG 
O445F glmS glmS_S1_F_NheI CACGCTAGCTAACAGACTAATTATAGCGCCCGAA 
0446R glms glmS_S1_R_SpeI TCCACTAGTAGATCATGTGATTTCTCTTT 
O447R glmS glmS_S2_R_XhoI TCACTCGAGAGATCATGTGATTTCTCTTT 
O451F PbPTEX88 PbPTEX88_IND_CDS_F_PstI GTGCTGCAGATGATGCTTTATTTTATTGTGT 
O452R PbPTEX88 PbPTEX88_IND_CDS_R_NheI GACGCTAGCATTTATCTATCGTTAATCCAGTG 
O453F PbPTEX88 PbPTEX88_IND_5UTR_F_NheI GACGCTAGCTTGTAATATTCGGGCTTTAAGTAA 
O454R PbPTEX88 PbPTEX88_IND_5UTR_F_BssHII TGAGCGCGCAATCGAATTTTGGGGATTTCAA 
O533F PfPDI-8 PfPDI-8_F_NotI TGAGCGGCCGCAAATTTAATGAGGTTGGGGATA 
O534R PfPDI-8 PfPDI-8_R_PstI TGGCTGCAGTTAACTCCTCGGATGTGCCGT 
O535F PfEXP3 Pf10_0242_F_NotI TGAGCGGCCGCCCCGATGAAGATAATGAAGC 
O536R PfEXP3 Pf10_0242_R_PstI TGACTGCAGTAGAACTTAACCATGGAGCTG 
O537F Pfj2 Pfj2_F_NotI TGAGCGGCCGCATCTGGTGGTCCTAGTTTT 
O538R Pfj2 Pfj2_R_PstI TGGCTGCAGTCAATTCATCATCATATTGC 
O587F PbPTEX88 PbPTEX88_qPCR_Frag1_F TTTTATTGTGTTGGCATTGG 
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Name Gene Oligonucleotide name Sequence (5' to 3') 
O588R PbPTEX88 PbPTEX88_qPCR_Frag1_R CGGGAAGTTCATCAAGTATT 
O649F PbPV1 PbPV1 KO_5F_SacII GATCCGCGGGAGGCTACCAATAAATCATAATG 
O650R PbPV1 PbPV1 KO_5R_HpaI CATGTTAACTGCTAACGCCACCTTAATCAT 
O651F PbPV1 PbPV1 KO_3F_AvrII GAGCCTAGGTGTATTTTCGCGTCTGTACATTAG 
O652R PbPV1 PbPV1 KO_3R_PstI CACCTCGAGGCACTACTAAATCTAGTAGATATG 
O672F PbPV1 PbPV1 5INT_F CGTTTCCGGTGCATCATTTATG 
O673R mCherry mCherry_R GCCATGTTATCCTCCTCGC 
O674F Pb DHFR 3' UTR PbDT3_INT_F2 CCGTGTGAATATGCTCATTTTG 
O675R PbPV1 PbPV1 3INT_R TGTAACACATATAACTTGTTCAGG 
O676F PbPV3 PbPV3 KO_5F_SacII GATCCGCGGCCTTAGTCTTAAAACTTATGGC 
O677R PbPV3 PbPV3 KO_5R_HpaI CATGTTAACAGCCATTTTGAAAAATAGTGTGAA 
O678F PbPV3 PbPV3 KO_3F_AvrII GAGCCTAGGAGTATATACACGCGCATGCAC 
O679R PbPV3 PbPV3 KO_3R_PstI CACCTCGAGGGACAGCAACAAAGGATATAC 
O680F PbEXP3 PbEXP3 KO_5F_SacII GATCCGCGGCCTGTGCGCAGTTTTAACACA 
O681R PbEXP3 PbEXP3 KO_5R_HpaI CATGTTAACGAGTTTTTTCTTCAATATCATTTTATCAG 
O682F PbEXP3 PbEXP3 KO_3F_AvrII GAGCCTAGGACATAAAGGAACTTCATTACCAG 
O683R PbPV3 PbEXP3 KO_3R_PstI CACCTCGAGGAGCTAGCCAACAATTTACTC 
O703F PbPV3 PbPV3 5INT_F TTAAGGCTGCTTTCTTTAATGTCCAT 
O704R PbPV3 PbPV3 3INT_R CAAGTTGGCAACAAGGTAAATTG 
O705F PbEXP3 PbEXP3 5INT_F GAAAGGATACATACAATAAGGGATT 
O706R PbEXP3 PbEXP3 3INT_R GTAACAAAATGAGAGGAGGATTAC 
O707R PbPV1 PbPV1 3INT_R2 AGATGTTGCAATTTTGCAGTTGG 
O796F PfEXP3 PfEXP3 5INT_F CCTCTTGGCTCATCTTAT 
O797R PfEXP3 PfEXP3 3INT_R TTTCCTTAAAACACAATTACATGA 
MK32F PfPTEX88 PfPTEX88_F_BamHI CACCGGATCCCAATTTAGCCTAGCCCCACA 
MK33R PfPTEX88 PfPTEX88_R_PstI GACCTGCAGGACTTAAGTAATAACTAAACTTGGAATC 
SH4R PbPTEX88 PbPTEX88 3’-R (EcoRI) GCCGAATTCCCCATCTTTTTTTATTTTCTACCC 
 
1Restriction sites are underlined 
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Table 2.2: List of primary antibodies used in this study 
Antibody Species Western blot dilution Immunofluorescence dilution 
anti-HA Mouse 1:1000 1:100 
anti-HA Rat N/A 1:100 
Anti-PTEX88 peptide Mouse 1:300 N/A 
Anti-HSP101 Rabbit 1:1000 1:400 
Anti-PTEX150 Rabbit 1:1000 N/A 
Anti-EXP2 Rabbit 1:1000 1:500 
Anti-EXP2 Mouse N/A 1:400 
Anti-ACP Rabbit 1:500 N/A 
Anti-Actin Rabbit 1:500 N/A 
Anti-RESA Mouse N/A 1:1000 
Anti-KAHRP Rabbit N/A 1:200 
Anti-SBP1 Mouse N/A 1:200 
Anti-STEVOR (PFL2610w) Rabbit N/A 1:200 
Anti-PFEMP1-ATS Rabbit N/A 1:750 
Anti-PfEMP1-ATS Mouse N/A 1:100 
Anti-RIF29 Rat N/A 1:500 
Anti-RIF50 Rat N/A 1:500 
Anti-PbANKA_122900 Rabbit N/A 1:500 
Anti-PbANKA_114540 Rabbit N/A 1:500 
Anti-GFP Rabbit N/A 1:250 
Anti-mCherry Rat N/A 1:250 
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Table 2.3: List of plasmids used in this study 
Plasmid Targeting gene Relevant information Reference 
pGEX4T1-PfPTEX88-FragA PfPTEX88 Expression plasmid 
pGEX4T1-PfPTEX88-FragB PfPTEX88 Expression plasmid 
pPTEX150-HA/Str PfPTEX150 
Starting plasmid for creating PTEX88 epitope tag 
in P, falciparum 
(de Koning-Ward 
et al., 2009) 
pPTEX88-HA/Str PfPTEX88 For epitope tagging PTEX88 in P. falciparum 
pCC1 N/A 
General plasmid for generating knockout 
parasites 
(Maier et al., 
2008) 
pCC1-PTEX88 KO PfPTEX88 Plasmid targeting PTEX88 for deletion 
pPTEX150-HA-DD24 PfPTEX150 
Starting plasmid for creation of PTEX88 
destabilisation mutant 
(de Azevedo et al., 
2012) 
pPTEX88-HA-DD24 PfPTEX88 
Final plasmid for creation of PTEX88 
destabilisation mutant 
pTEX150-HA-glmS PfPTEX150 
Starting plasmid for creation of PTEX88 
ribozyme parasite line 
(Elsworth et al., 
2014b) 
pPTEX88-glms-S1 PfPTEX88 
Final plasmid for creation of PTEX88 ribozyme 
parasite line 
pPTEX88-glmS-S2 PfPTEX88 
For modification of 3' UTR of PTEX88 ribozyme 
parasite line 
pPRF-TRAD4-Tet07-HAPRF-
hDHFR N/A 
Starting plasmid for creation of PbPTEX88 
inducible knockdown (Pino et al., 2012) 
pTRAD4-iPTEX88 PbPTEX88 
Final plasmid for creation of PbPTEX88 
inducible knockdown 
pPfPDI8-HA-glmS PfPDI-8 
Final plasmid for creation of PfPDI-8 ribozyme 
parasite line 
pPfEXP3-HA-glmS PfEXP3 
Final plasmid for creation of Pf10_0242 
ribozyme parasite line 
pBAT N/A 
Starting plasmid for creation of gene knockouts 
in P. berghei 
(Kooij et al., 
2012) 
pBAT-PV1 KO PbPV1 Plasmid for deletion of PV1 in P. berghei  
pBAT-PV1 KO-Kss-GFP PbPV1 
Final plasmid for deletion of PV1 in P. berghei, 
contains exported GFP reporter protein  
pBAT-EXP3 KO PbEXP3 Plasmid for deletion of EXP3 in P. berghei   
pBAT-EXP3 KO-Kss-GFP PbEXP3 
Final plasmid for deletion of EXP3 in P. berghei, 
contains exported GFP reporter protein  
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3.1. Introduction 
PTEX was originally described as containing three principal components, namely 
EXP2, PTEX150 and HSP101, and two additional putative components, TRX2 and 
PTEX88 (de Koning-Ward et al., 2009). Whilst these latter two proteins could be 
affinity purified with HSP101 and PTEX150 in immunoprecipitation experiments, the 
lack of reagents to PTEX88 and TRX2 meant that it remained to be confirmed that 
their interactions with the PTEX complex were genuine.  
 
Subsequent to the initial discovery of the PTEX complex, TRX2 has been extensively 
characterised in the rodent malaria species P. berghei. This protein has now been 
validated to be a bona fide component of PTEX through the demonstration that a HA-
epitope tagged version of TRX2 could specifically immunoprecipitate the other PTEX 
components, as determined by mass spectrometry analysis of the proteins that affinity 
purified with TRX2 (Matthews et al., 2013). A similar approach was used to 
demonstrate that P. berghei PTEX88-HA could specifically affinity purify HSP101, 
as detected by Western blot using anti-HSP101 and anti-EXP2 antibodies (Matthews 
et al., 2013). However, further characterisation of PTEX88 in P. berghei was not 
undertaken, and as there are no available reagents to characterise PTEX88 in P. 
falciparum, there is still very little known about this protein.  
 
The aim of this Chapter was to generate a means to be able to characterise PTEX88 in 
P. falciparum and hence determine how this protein is assembled into the PTEX 
complex. Since the generation of antibodies to recombinant P. falciparum PTEX88 or 
PTEX88 peptides had previously failed to yield robust reagents that could be used to 
specifically detect PTEX88 (data not shown), an alternative approach was sought. As 
advances in genetic manipulation of the parasite have made it possible to engineer 
parasites expressing proteins with exogenous epitope tags, antibodies to epitope tags 
rather than to the protein of interest can serve as alternative reagents and indeed this 
approach has been used to study other PTEX components. This Chapter describes the 
generation of a transgenic P. falciparum parasite line in which the PTEX88 gene is 
epitope tagged for validation that PTEX88 is a genuine component of PTEX, and to 
gain insight into how PTEX88 assembles into the overall structure of PTEX. The 
latter is important as understanding how the PTEX components come together to form 
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a functional translocon may help us understand how Plasmodium parasites are able to 
export a diverse range of effector proteins and hence how its activity can be blocked. 
 
3.2. Results 
3.2.1. Alignment of PTEX88 homologues in Plasmodium 
PTEX88 is conserved across the Plasmodium genus, suggesting that PTEX88 plays a 
common and potentially important role across all species of malaria parasites. A 
multiple sequence alignment of PTEX88 from all available Plasmodium sequences 
present in the Plasmodium Genomics Resource Database (PlasmoDB) (Aurrecoechea 
et al., 2009) was performed to determine whether PTEX88 harbours any conserved 
motifs or sequences that may offer insight into its role within the parasite (Figure 3.1). 
However, the alignments failed to reveal any conserved functional motifs, other than 
a conserved signal peptide from residues 1-20, consistent with this protein trafficking 
through the secretory pathway. Further searches of the P. falciparum PTEX88 
sequences using InterProScan (Mitchell et al., 2015) and PFAM (Finn et al., 2014) 
also failed to identify any additional putative functional domains. The alignments did 
reveal, however, that six cysteine residues across the length of PTEX88 are conserved 
across all homologues in the various Plasmodium spp. (Figure 3.1). Further analysis 
showed that four of these cysteine residues assembled as two individual CX10C motifs 
at residues C490 and C605. The conservation of these cysteine residues suggests that 
they play an important role in protein folding and/or the function of the protein.  
 
3.2.2. Epitope-tagging PTEX88 in P. falciparum 
In this study, transgenic P. falciparum parasites were engineered to express a triple 
hemagglutinin (HA) epitope tag at the carboxyl terminus of the PTEX88 protein, such 
that expression of this protein is still under the control of its native promoter. This is 
achieved through transfection of a PTEX88 targeting plasmid into wild-type parasites, 
with the PTEX88 targeting sequence facilitating integration into the parasite genome 
by homologous recombination. This strategy then allows for the detection of PTEX88 
in these transgenic parasites with the use of antibodies against the HA epitope. In 
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Figure 3.1: Multiple sequence alignment of Plasmodium PTEX88 sequences 
PTEX88 protein sequences from all Plasomdium species were aligned in ClustalX 
and viewed using CINEMA. The species corresponding to each sequence is shown on 
the left. Shading indicates the properties of the amino acid side chain; light blue: 
positively charged, red: negatively charged, green: hydrophilic, pink: hydrophobic. 
No conserved functional domains were found. The alignments reveal cysteine 
residues (yellow shading) are conserved across all species.  
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order to generate this transgenic parasite line, approximately 1kb of DNA sequence 
from the 3' end of the PTEX88 coding sequence without the stop codon was amplified 
by PCR and cloned into the pPTEX150-HA/Str plasmid (de Koning-Ward et al., 
2009) using the NotI/PstI restriction sites (Figure 3.2A). This region of sequence was 
designed so that the plasmid would integrate into the genome by single-crossover 
homologous recombination at the 3' end of the ptex88 gene, thereby incorporating the 
triple hemagglutinin/Streptactin tag and the P. berghei dihydrofolate reductase – 
thymidylate synthase (PbDT3) transcription terminator downstream of the 
endogenous ptex88 gene. This would also lead to the incorporation a human 
dihydrofolate reductase expression cassette that provides a means for selection of 
parasites containing the targeting plasmid using the drug WR99210 (Jacobus). The 
targeting plasmid was named pPTEX88-HA/Str. Wild-type P. falciparum parasites 
(3D7 strain) were transfected with 100 µg of the plasmid and transgenic parasites 
were selected for using WR99210. Due to the low transfection efficiency of P. 
falciparum, most parasites did not survive after WR99210 administration, however a 
population of parasites resistant to WR99210 was recovered three weeks after 
transfection.  After two cycles with and then without selective pressure to select 
against parasites expressing the selectable marker off episomes, protein lysates were 
made from WR99210-resistant parasites and analysed by Western blot using anti-HA 
antibodies. The predicted molecular weight of the epitope-tagged PTEX88 after 
cleavage of the signal sequence is 87.4 kDa. The presence of a species at this 
molecular weight in the transgenic parasite lysate and not wild-type lysate confirmed 
that the PTEX88 had successfully been epitope-tagged using this strategy (Figure 
3.2B). A second species was detected at ~50 kDa. This may represent N-terminal 
processing of PTEX88 at some stage during the life cycle but the presence of a 
putative cleavage site in this area of the PTEX88 protein sequence was not obvious. 
The transgenic parasites were subsequently cloned by limiting dilution to obtain a 
clonal population. Analysis of the cloned parasites by analytical PCR confirmed that a 
clonal parasite population had been obtained (Figure 3.2C) and these parasites were 
subsequently termed PfPTEX88-HA. 
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Figure 3.2: Generation of epitope-tagged PTEX88 in P. falciparum  
A: The targeting construct was designed to integrate into the ptex88 locus by 
single-crossover recombination, resulting in PTEX88 being fused in frame at its 
C-terminus with a triple haemagglutinin (HA) and a single Strep-II (Str) epitope 
tag. The structure of the endogenous locus before and after integration is shown. 
PbDT3, Plasmdium berghei dihydrofolate reductase – thymidylate synthase 3’ 
untranslated region; hDHFR, human dihydrofolate reductase selection cassette; 
zig-zag lines, plasmid backbone; black arrow, transcription start site; circle, 
transcription terminator. Oligonucleotide binding sites for diagnostic PCRs are 
shown 
B: Western blot analysis of wild-type (3D7) or transgenic (PTEX88-HA) 
parasite lysate using anti-HA antibodies confirms correct epitope tagging of 
PTEX88 with a species detected at the predicted molecular weight of 87.4 kDa. 
The smaller MW band at ~50kDa may represent degraded protein or a 
processed form of PTEX88. 
C: Diagnostic PCR on genomic DNA from PfPTEX88-HA and 3D7 P. 
falciparum gDNA using the indicated primer combinations confirms correct 
integration of the targeting construct. Absence of a product using primer 
combination A/D in PfPTEX88-HA gDNA indicates this parasite line is clonal. 
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3.2.3. PTEX88 localises to the PVM and is co-expressed with other PTEX 
components 
 
With the PfPTEX88-HA line in hand, it was now possible to characterize PTEX88 
using anti-HA antibodies. Firstly, the expression profile of PTEX88 was assessed to 
see whether PTEX88 is also constitutively present across the whole asexual blood-
stage life cycle, as is the case for the other components of PTEX. For this, 
PfPTEX88-HA parasites were tightly synchronized using sorbitol and at 8-hour 
intervals post-invasion, equal numbers of parasites were harvested to analyse 
expression at each stage of the parasite life cycle. Western blots of parasite lysates 
using anti-HA antibodies revealed that PTEX88 is present in the early ring-stages 
after parasite invasion and remains present for the duration of the blood-stage life 
cycle (Figure 3.3). This expression profile is similar to that of HSP101, PTEX150 and 
EXP2 (de Koning-Ward et al., 2009). 
 
The localisation of PTEX88 was also investigated across the blood-stage life cycle. 
Immunofluorescence analysis (IFA) was performed on fixed parasites harvested from 
the same experiment, using anti-HA antibodies to detect PTEX88 as well as 
antibodies raised against HSP101 and EXP2. The latter two PTEX components have 
previously been localized to the PV/PVM and thus serve as markers for these 
localisations. IFA of ring stages showed PTEX88 co-localises with HSP101 and 
EXP2 (Figure 3.4). Analysis in trophozoite stages showed PTEX88 co-localises much 
more closely with HSP101 than EXP2, and this was again demonstrated in schizont-
stage parasites, where EXP2 still remains associated with the PVM, whilst new 
HSP101 is being synthesized and trafficked to the dense granules (Figure 3.4). 
Together these data indicate that PTEX88 is localizing at the PV/PVM with the core 
constituents of PTEX in the early stages of the parasite life cycle and that PTEX88 
appears to co-localise with HSP101 throughout the entirety of the life cycle. 
 
3.2.4. PTEX88 is a genuine member of PTEX 
While the co-expression and co-localisation of PTEX88 with the core constituents of 
PTEX supported the hypothesis that PTEX88 was a genuine member of PTEX in P. 
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Figure 3.3: Time course of PTEX88 expression across the intraerythrocytic life 
cycle 
Western blot analysis of protein lysates extracted from PTEX88-HA parasites in 
reduced sample buffer at the times indicated after parasite invasion using anti-HA or 
anti-EXP2 antibodies as a positive control reveals presence of PTEX88 across the full 
intraerythrocytic life cycle.  
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Figure 3.4: PTEX88 localises predominantly to the PV/PVM 
Immunofluorescence performed on ring-stage, trophozoite and schizont-stage 
PfPTEX88-HA parasites and dual-labelled with anti-HA and either anti-HSP101 or 
anti-EXP2 antibodies. DAPI labeling denotes the parasite nucleus, DIC; Differential 
interference contrast. Scale bar – 5 µm 
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falciparum, formal proof was lacking, as there was no evidence that PTEX88 was 
forming part of the same macromolecular complex at the PVM. To investigate 
whether PTEX88 assembles as part of the PTEX complex, PTEX88-HA parasites 
were harvested and immunoprecipitations of PTEX88 were performed using anti-HA 
conjugated resin. The unbound material and eluates were analysed by Western blot 
using reagents to PTEX components (see Table 2.2 for a full list of primary antibodies 
used in this thesis). HSP101, PTEX150 and EXP2 were all found in the elution 
fraction of these blots, indicating that they co-immunoprecipitated with PTEX88, 
demonstrating that the interaction between PTEX88 and HSP101/PTEX150 was 
genuine and validating PTEX88 as a member of PTEX (Figure 3.5). 
 
PTEX has previously been resolved as a large macromolecular protein complex with 
an overall molecular weight of >1.2 megadaltons (Bullen et al., 2012). It is likely that 
the core structure of the complex is formed by oligomers of EXP2, PTEX150 and 
HSP101. These conclusions have been drawn from Blue-Native PAGE experiments in 
which the native state of the complex has been analysed by Western blot (Bullen et 
al., 2012). EXP2, PTEX150 and HSP101 are all observed in one high molecular 
species. Other species are observed at 600-700 kDa, ~500 kDa and ~250 kDa for 
EXP2, PTEX150 and HSP101, respectively (Elsworth et al., 2016, Bullen et al., 
2012). These species are only observed with antibodies against each particular 
protein, and not other PTEX components, indicating that these proteins are forming 
homo-oligomers, or hetero-oligomers with other non-PTEX proteins. To determine 
whether PTEX88 was assembling as part of this macromolecular complex, Blue-
Native PAGE was performed on PTEX88-HA parasites. For this, parasites were 
saponin-lysed and resuspended in 1.0% (w/v) digitonin to solubilize the complex. The 
solubilised material was then electrophoresed using Native PAGE gels and analysed 
by Western blot. Multiple experiments were performed and the blots typically showed 
PTEX88-HA existing either in a species of >1236 kDa, migrating at the same rate as 
the other core constituents of PTEX (Figure 3.6A), or as two smaller species between 
250-300 kDa (Figure 3.6B). As it is difficult to determine the precise molecular 
weight of smaller proteins by Blue Native PAGE, these smaller bands could 
potentially represent a monomer or dimer of PTEX88 or a complex of PTEX88 with 
another (non-PTEX) protein (Figure 3.6B). For these experiments, acyl carrier protein 
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(ACP), a protein in the apicoplast (Waller et al., 2000), served as a negative control to 
show that the high molecular weight species seen was specific to PTEX. The presence 
of PTEX150 in a ~500 kDa species and EXP2 in ~600 kDa and ~700 kDa species has 
previously been observed (Bullen et al., 2012) and is observed again here (Figure 
3.6A). In addition to the >1236 kDa species, HSP101 was detected in a species at 
~600 kDa and another species at ~750 kDa (Figure 3.6A) as previously observed 
(Elsworth et al., 2016), although whether either of these bands represents homo-
oligomeric HSP101 is unknown.  
 
The Blue-Native PAGE experiments were inconclusive about whether PTEX88 was 
forming any dimers or higher order oligomers due to the nature of how the dye front 
runs in these experiments. To further investigate the potential for PTEX88 to exist in 
a multimeric state, mixed-stage PfPTEX88-HA parasites were saponin lysed and split 
into seven identical protein pellets. These pellets were then resuspended in protein 
sample buffer containing dithiothreitol (DTT) at increasing concentrations from 0 
mM to 100 mM. After incubation at 80˚C for 30 minutes to allow for complete 
reduction of cysteine residues, the lysate was analysed by western blot using anti-HA 
antibodies (Figure 3.7). The blot revealed that when reducing agent was absent, a HA 
positive species was present at ~110 kDa with a small amount present at the expected 
molecular weight of 90 kDa. As the concentration of DTT increased, the proportion of 
the 110 kDa species decreased while the proportion of the 90 kDa species increased, 
with full reduction with 100 mM DTT resulting in complete loss of the 110 kDa 
species. This suggests that the reduction of PTEX88-HA caused it to migrate at faster 
rate than when in its native state. As proteins containing intramolecular disulfide 
bonds are more likely to run at a higher molecular weight owing to their more 
complex secondary structures, this indicates that the conserved cysteine residues in 
PTEX88 are involved in the formation of intramolecular disulfide bonds. 
Furthermore, as a higher molecular weight species representing a potential dimer or 
trimer of PTEX88 was not observed in non-reduced samples, it is reasonable to 
conclude that PTEX88 likely exists in a monomeric state within the complex or as a 
covalently bound hetero-oligomer with a smaller unidentified protein, and not as part 
of a covalently linked homo-oligomer.  
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Figure 3.5: Immunoprecipitation analysis confirms PTEX88 is a genuine 
component of PTEX  
Western blot analysis of anti-HA immunoprecipitations of PTEX88-HA, detected 
with anti-HA (PTEX88-HA), HSP101, PTEX150 and EXP2. Total material 
represents the Triton X-100 soluble starting material. The presence of PTEX 
components in the elution shows all components were affinity purified with 
PTEX88. Actin was used as a control to confirm the specificity of the 
immunoprecipitation. 
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Figure 3.6: Blue-Native PAGE reveals that PTEX88 exists with other PTEX 
components  in a high molecular weight complex  
Mixed stage PfPTEX88-HA parasites were solubilised with 1% digitonin and 
electrophoresed by BN-PAGE. Western blot analyses with antibodies against PTEX 
components typically showed either A) PTEX88-HA existing in a species >1236kDa 
with other PTEX components, or B) PTEX88-HA existing as a lower molecular 
weight species between 250-300kDa. Acyl carrier protein (ACP) served as a control 
to confirm the specificity of the high molecular weight species.  
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Figure 3.7: Reduction of PTEX88-HA alters migration rate 
Anti-HA Western blot analysis of PfPTEX88-HA lysate treated with indicated 
concentration of DTT shows that reduction of disulfide bonds within PTEX88 alters 
the apparent molecular weight of PTEX88 when subjected to SDS-PAGE and 
immunoblotting. 
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3.2.5. Investigation of the interactome of PTEX88  
In Section 3.2.4, analysis of PTEX88 interacting partners by Western blot confirmed 
an interaction with the core components of PTEX. In addition, proteins that affinity 
purify with PTEX88 were identified using a proteomic approach in order to 
investigate the full interactome of PTEX88.  Here, lysates from synchronous ring-
stage PTEX88-HA and 3D7 wild-type parasites were immunoprecipitated using anti-
HA conjugated resin and the eluted material was electrophoresed on an SDS-PAGE 
gel that was subsequently stained with Sypro-Ruby to visualise interacting proteins 
(Figure 3.8). Any bands unique to the PTEX88-HA pull-down were excised from the 
gel, along with the corresponding region of the gel in the wild-type pull-down and 
each band was prepared and processed by capillary liquid chromatography coupled 
online with tandem mass spectrometry (LC-MS/MS) to identify the peptides. The 
PTEX88-HA pull-down yielded 61 peptides specific to PTEX88, containing 18 
unique peptides covering 26% of the total PTEX88 sequence (Table 3.1). No PTEX88 
peptides were detected in the pull-down on wild-type parasites, indicating that the 
immunoprecipitation of PTEX88-HA was specific to the anti-HA resin. The 
proteomics also revealed specific enrichment of HSP101, PTEX150, EXP2 and 
TRX2, validating the results observed with Western blots. Strikingly, a large number 
of HSP101 peptides were pulled down with PTEX88. In total, 278 HSP101-specific 
peptides were seen with the PTEX88-HA pull-down, whilst only 27 HSP101-specific 
peptides were present in the wild-type pull-down (Table 2.1). This suggested that 
PTEX88 and HSP101 might be strong interacting partners. 
 
A number of novel proteins were also affinity purified with PTEX88-HA and are of 
interest as these may represent new PTEX components. Of particular interest was 
parasitophorous vacuolar protein 1 (PV1), a protein previously detected in 
immunoprecipitations with other PTEX components and which has been previously 
hypothesized to be part of PTEX (Bullen et al., 2012). Other proteins of interest 
include protein disulfide isomerase 8 (PDI-8) and a hypothetical protein termed 
PfEXP3 (PF3D7_1024800). Further characterization of these proteins are discussed in 
Chapter 6.  
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Other peptides identified in the eluates of both wild-type and PTEX88-HA pull-
downs were mostly ribosomal and nuclear proteins. The presence of these proteins in 
both eluates suggests that they have bound non-specifically to the anti-HA resin and 
do not interact with PTEX88.  
 
3.2.6. PTEX88 interacts strongly with HSP101 
The results from the protemic analysis of the PTEX88 interactome suggested that 
PTEX88 may have a close interaction with HSP101. However, mass spectrometry 
analysis of the interactome is not necessarily indicative of the closeness of 
interactions as this can be dependent on the abundance of proteins, the inherent 
stickiness of proteins and the nature of the peptides generated. In order to determine 
more closely the nature of the interaction between PTEX88 and the core constituents 
of PTEX to understand how PTEX88 assembles within the translocon, further 
experiments were performed. 
 
In order to determine the nature of the interaction between PTEX88 and the PVM, a 
sequential solubility analysis was initially performed. Synchronous ring-stage and 
trophozoite-stage PfPTEX88-HA parasites were incubated sequentially in a hypotonic 
lysis buffer, alkaline carbonate buffer and Triton X-100 to solubilize cytosolic 
proteins, peripheral membrane proteins and integral membrane proteins, respectively. 
The solubilised fractions were analysed by Western blot, which showed PTEX88-HA 
being almost entirely solubilised in alkaline carbonate buffer, indicating it has a 
peripheral association with the PVM (Figure 3.9). HSP101 was also solubilised in the 
same fraction, indicating they both localize within the PV. EXP2, which has been 
previously shown to be an integral PVM protein (de Koning-Ward et al., 2009, Bullen 
et al., 2012), was insoluble in the carbonate fraction as expected and required 
extraction from the membrane using Triton X-100. 
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Figure 3.8: Large-scale immunprecipitation of PTEX88-HA reveals potential 
new PTEX components 
Elution fractions of 3D7 wild-type and PfPTEX88-HA parasite lysate pull downs with 
anti-HA, electrophoresed, and stained with Sypro ruby. Proteins enriched in the 
PTEX88-HA fractions were excised along with the corresponding species in the 3D7 
control and analysed by liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) for identification of peptides.  
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Table 3.1: Immunoprecipitation of PTEX88-HA with anti-HA antibodies leads to 
the specific co-purification of PTEX components as well as additional proteins1  
 
Protein WT IP eluate PTEX88-HA IP eluate % sequence coverage 
PTEX88 0 61 26 
HSP101 27 278 78 
PTEX150 0 56 16 
EXP2 2 27 19 
TRX2 0 9 39 
PV1 0 2 4 
PfPDI-8 0 9 17 
PfEXP3 0 9 4 
 
1The number of peptides present in all excised bands are indicated  
 
 
To further confirm the association between PTEX88 and HSP101, an approach using 
chemical crosslinkers was utilized. Late-stage PfPTEX88-HA parasites were attained 
by magnet purification and cross-linked in situ in increasing concentrations of 
dithiobis(succinimidyl propionate) (DSP), a reduction-sensitive, cell permeable 
molecule that links primary amines. After cross-linking, parasite material was 
solubilised and immunoprecipitations were performed using anti-HA, anti-HSP101, 
anti-PTEX150 and anti-EXP2 antibodies. After cross-linking, parasite material was 
solubilised prior to immunoprecipitation. Western blotting confirmed the amount of 
protein being solubilised was not altered by the presence of crosslinker (data not 
shown). The unbound fractions and eluates were further analysed by Western blots. 
The Western blots showed that all components were specifically immunoprecipitated 
and that the cross-linking was only minimally affecting the amount of material being 
pulled down (Figure 3.10). When the blots were probed for other components of the 
complex, it was found that even when fully cross-linked, the interaction between 
EXP2 and PTEX88 was weak and was eliminated when DSP was titrated out. 
PTEX150 appeared to have a slightly stronger association with PTEX88, while 
HSP101 had the strongest association with PTEX88 as this interaction was preserved 
much more strongly as the cross-linker was titrated out (Figure 3.10A). Reciprocal 
immunoprecipitations using antibodies against HSP101, PTEX150 and EXP2 
validated these findings as well as previous models  
 
 
  Chapter 3 
 
 77 
 
 
 
 
 
 
 
 
 
Figure 3.9: PTEX88 is a peripheral membrane protein 
Western blot analysis of PTEX88-HA ring-stage and trophozoites subjected to 
sequential solubilisation. The solublised fractions from incubation in hypotonic lysis 
buffer (HT SN), alkaline carbonate buffer (Carb SN) and Triton X-100 (TX-100 SN) 
along with the Triton X-100 insoluble material was electrophoresed and Western 
blotted and analysed using the indicated antibodies. EXP2 served as a control for 
integral membrane proteins, HSP101 served as a control for peripheral membrane 
proteins, Actin depolymerizing factor-1 (ADF1) served as a soluble control. 
 
 
 
 
 
 
 
 
 
  Chapter 3 
 
 78 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 3 
 
 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Chemical cross-linking reveals PTEX88 closely associates with 
HSP101 
Individual PTEX proteins were immunoprecipitated with either A) anti-HA antibodies 
or polyclonal antibodies against B) HSP101, C) PTEX150 or D) EXP2. Parasites 
proteins were cross-linked with the indicated concentration of DSP prior to 
immunoprecipitation. Cross-links were broken prior to electrophoresis of the unbound 
material and the elutions were electrophoresed and immunoblotted using the indicated 
antibodies. For each immunoprecipitation, the ratio of eluted material and unbound 
material at each concentration of cross-linker for each protein was calculated to 
determine the percentage of bound protein at each DSP concentration, which was 
graphed and shown below each series of blots.  
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that show EXP2, PTEX150 and HSP101 interact in that order relative to the PVM 
(Figure 3.10B-D). These data are consistent with the data generated by mass 
spectrometry, suggesting that PTEX88 interacts directly with HSP101.   
 
3.3. Discussion 
PTEX88 was initially discovered and tentatively assigned as a PTEX component 
through proteomic approaches that identified it as an interacting partner of both 
HSP101 and PTEX150. In this Chapter, parasites expressing epitope-tagged PTEX88 
were generated and used for characterisation of PTEX88 in P. falciparum. This 
allowed clear detection of PTEX88 in parasite lysate by Western blots and on fixed 
parasites by immunofluorescence. This enabled confirmation of the localization of 
PTEX88 at the PV and visualization of PTEX88 within PTEX in a native state with 
the other components by Blue-Native PAGE. 
 
The immunoprecipitations of PTEX88 and subsequent detection of HSP101, 
PTEX150 and EXP2 in the eluates demonstrated that the interactions of these proteins 
with PTEX88 previously seen were indeed genuine and confirmed PTEX88 as a 
component of PTEX in P. falciparum. Further analysis of the PTEX88 interactome by 
mass spectrometry identified a number of other proteins that may also be additional 
translocon components. Of particular interest is PV1. This protein has previously been 
localized to the parasitophorous vacuolar space and thus far all attempts to delete PV1 
in P. falciparum have been unsuccessful, suggesting it is essential for development of 
the parasite during blood stages of infection, a trait it shares with the core constituents 
of PTEX (Chu et al., 2011, Nyalwidhe and Lingelbach, 2006). Additionally, a number 
of other proteins were found to interact with PTEX88, some of which are potential 
candidates to be additional components of PTEX. Attempts to characterize these 
proteins are outlined in Chapter 6. Other translocons in nature comprise a number of 
components, which are recruited under different conditions to optimize translocation 
or to help translocate specific cargo. Given the variety of exported proteins and the 
complex nature of protein trafficking, it is unlikely that the PTEX consists only of 
EXP2, PTEX150, HSP101, TRX2 and PTEX88 and further analysis will be required 
to fully understand the composition of PTEX.   
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In this study, several approaches were utilized to understand how PTEX88 is 
assembled within the PTEX complex. It has been proposed that EXP2 forms a 
membrane-spanning pore through the PVM facilitating the passage of proteins into 
the host erythrocyte. Subsequent biochemical analysis revealed that PTEX150 
interacts with both EXP2 and HSP101, but the interaction between HSP101 and 
EXP2 is weaker, which has led to the conclusion that the complex forms in the order 
of EXP2-PTEX150-HSP101 relative to the PVM. HSP101 and PTEX150 are thought 
to exist in a 1:1 stoichiometric ratio, based on the number of peptides of each protein 
recovered in HSP101 and PTEX150 pull-down experiments (Bullen et al., 2012). 
Based on what is known about other HSP100s, HSP101 most likely exists as a 
hexamer, and it has been observed in a species at approximately 600 kDa in Blue-
Native PAGE gels which may indeed be a hexamer of HSP101 (Elsworth et al., 
2016).   Blue-Native PAGE experiments reveal PTEX150 is also present in a species 
of approximately 500 kDa, and thus also exists as a likely homo-oligomer within the 
complex, however, the number of PTEX150 molecules in the complete, functional 
PTEX complex requires further validation. Blue-Native PAGE experiments have also 
shown that EXP2 (but not HSP101 or PTEX150) is present in a species at 
approximately 600 kDa and 700 kDa. Chemical cross-linking experiments have 
revealed that these higher order EXP2 oligomers are likely to be formed from a 
scaffold of EXP2 dimers consisting of at least eight EXP2 molecules, although it is 
likely to be more (Bullen et al., 2012). The presence of PTEX88 in a species at 
>1236kDa migrating at the same rate as the core constituents of PTEX suggests it also 
exists as part of this complex. However, PTEX88 could not always be observed in 
this high molecular weight species (see Figure 3.6 B), suggesting that the interaction 
between PTEX88 and the core constituents of PTEX may be relatively transient or 
that PTEX88 may dissociate more readily from PTEX in the presence of mild 
detergents. 
 
The data generated herein suggests that PTEX88 exists as a monomer within the 
complex and that it interacts most tightly with HSP101, consistent with it co-
localising with HSP101 and having the same solubility profile as HSP101 that places 
it in the PV and associating with the PVM. From this, an updated model for PTEX 
assembly has been generated (Figure 3.11). EXP2, which forms higher-order 
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oligomers, is still the most likely component that forms the PVM-spanning pore but 
the number of EXP2 molecules in the complex is not known. PTEX150 resides 
between EXP2 and HSP101 in the PV and may play an essential scaffolding role, 
maintaining structural integrity of the complex. HSP101 interacts directly with 
PTEX150. It was initially thought that HSP101 and PTEX150 both exist as hexamers 
(Bullen et al., 2012) although their stoichiometry has not been formally shown. It is 
possible that PTEX150 may initially assemble as a ~500kDa homo-oligomer 
complex, with peptide counts generated from mass spectrometry after 
immunoprecipitation of PTEX150 suggesting a 1:1 stoichiometry of HSP101 and 
PTEX150 (Elsworth et al., 2016), so it is possible PTEX150 exists in a hexameric 
form within the assembled complex. PTEX150 then likely aids in anchoring the 
HSP101 hexamer to the complex. PTEX88 directly interacts with the HSP101 
hexamer in a monomeric state but does not appear to link to HSP101 in a cysteine-
dependent manner, because if PTEX88 were forming intermolecular disulphide bonds 
with other PTEX components then they would have been observed in the same 
species during Blue-Native PAGE analysis. Since PTEX88 appears to disappear from 
the >1236kDa species relatively easily it is unlikely to be interacting with other 
components through disulfide bridges. Finally, while TRX2 has been shown to be a 
genuine member of PTEX, the nature of its assembly within PTEX remains 
unresolved.  
 
Based on other translocons in nature, it is likely that PTEX consists of more than the 
five proteins identified to date. Additional detailed analysis of the interacting partners 
of all known PTEX constituents may reveal the full composition of proteins 
comprising PTEX, however this will require significant further efforts. Furthermore, 
the dynamic nature of protein trafficking machineries and the recruitment of particular 
components under certain conditions or to aid in trafficking of particular cargo makes 
predicting the overall makeup of PTEX more difficult, as export of effector proteins 
can occur at specific times in the cell cycle and may vary under different conditions 
faced by the parasite. Thus, while there is still much to understand regarding the 
composition of PTEX, the insight gained into how PTEX88 assembles in the PTEX 
complex combined with future functional studies of this protein may help to shed 
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some light on the putative function of PTEX88 and whether it could serve as a 
potential drug target. 
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Figure 3.11: An updated model for PTEX assembly 
EXP2 has the strongest membrane association and oligomerises to form the pore. 
EXP2 binds to PTEX150, which in turn binds a hexamer of HSP101. PTEX88 exists 
in a monomeric state and binds to HSP101. The nature of TRX2 and PV1 assembly 
within the complex is not known. Proteins destined for export are secreted into the PV 
and are recognized by PTEX. They are translocated through PTEX and the PVM in an 
unfolded state, and refolded in the erythrocyte cytosol, presumably by Hsp70 and 
Hsp40 chaperones.  
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Analysing the function of PTEX88 in 
P. falciparum 
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4.1. Introduction 
Although it had been shown that PTEX functions in the export of a diverse set of 
proteins into the host erythrocyte (Beck et al., 2014, Elsworth et al., 2014b) and that 
PTEX88 indeed forms part of this complex, how PTEX88 contributes to protein 
export remains unknown. Since PTEX88 is a protein unique to Plasmodium parasites 
and contains no conserved functional domains that could be used to help predict its 
function, the role of PTEX88 in protein export could not be predicted without further 
functional characterisation.  
 
One conventional means of analysing protein function is to delete the protein of 
interest and analyse the phenotype of the mutant organism. However as Plasmodium 
parasites are haploid during the erythrocytic stage of the life cycle when transfection 
is performed, deletion of essential genes will be lethal to the parasite. Indeed, 
previous attempts to knock out PTEX88 in P. berghei in our laboratory proved 
unsuccessful, indicating that PTEX88 may play a crucial role in parasite growth 
and/or survival (Matthews et al., 2013). The inability to delete essential genes has 
necessitated the development of a number of molecular strategies in Plasmodium, 
aimed at generating loss of expression of a protein of interest in an inducible fashion 
so that proteins can be depleted from the parasite and a loss of function can be 
characterized in the following 1-2 cycles before the parasite dies. 
 
This Chapter aimed to establish whether PTEX88 is essential to P. falciparum 
through attempts to generate a mutant parasite line in which the ptex88 gene had been 
disrupted. This Chapter also describes attempts to regulate PTEX88 expression levels 
in P. falciparum in an inducible manner in order to gain insight into how PTEX88 
contributes to protein export. 
 
4.2. Results 
4.2.1. Generation of a PTEX88 knockout parasite in P. falciparum 
The ptex88 gene was targeted for gene disruption by targeted double crossover 
homologous recombination (Figure 4.1A). To create the PTEX88 knockout vector, 
two targeting sequences corresponding to the sequences immediately upstream and 
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downstream of the PTEX88 coding sequence were PCR amplified from P. falciparum 
3D7 genomic DNA (gDNA) using O346F/O347R and O348F/O349R (see Table 2.1 
for oligonucleotide sequences) and cloned into the SpeI/AflII and NcoI/AvrII sites of 
pCC1 (Maier et al., 2008), respectively, to create a targeting plasmid termed pCC1-
PTEX88KO. Parasites were initially treated with WR99210 to select for parasites that 
harboured the targeting plasmid. Following two cycles on and off WR99210 drug 
pressure to select for integrants and remove residual episomes, negative selection was 
performed using 5-fluorocytosine (Sigma) (Duraisingh et al., 2002) to select for 
parasites with a disrupted ptex88 locus.  Southern blots of genomic DNA harvested 
from transfected parasites after positive and negative selection revealed that the 
ptex88 locus remained intact after two transfection attempts (Figure 4.1B). Thus it 
was concluded that PTEX88 is likely to be essential for the in vitro growth of the 
parasite during the erythrocytic stages 
 
4.2.2. Creation of a PTEX88 destabilisation mutant 
As attempts to knock out PTEX88 in P. falciparum were unsuccessful, this 
necessitated the generation of transgenic parasites in which the expression of PTEX88 
could be regulated. There have been several systems adapted and applied to 
Plasmodium parasites to facilitate regulation of protein levels. One such strategy 
involves the fusion of an engineered version of the human FKBP12 protein to either 
terminus of a protein (Armstrong and Goldberg, 2007, de Azevedo et al., 2012). This 
makes the protein of interest intrinsically unstable, leading to its ubiquitylation and 
subsequent degradation by the proteasome. However, this destabilization can be 
moderated by the addition of a FKBP ligand, termed Shield-1 (Shld1) (Figure 4.2A).  
 
Since PTEX88 has an N-terminal signal sequence, a destabilization mutant of 
PTEX88 was designed so that PTEX88 would be fused to a triple hemagglutinin tag 
and the FKBP destabilization domain (FKBPdd) at its C-terminus. This required the 
generation of a targeting plasmid, designed to integrate into the ptex88 locus by single 
crossover homologous recombination (Figure 4.2B). The targeting plasmid was made 
by PCR amplifying the final ~1 kb of the ptex88 coding sequence from wild-type 
gDNA using oligonucleotides O302F and O303R, which was cloned into the 
NotI/PstI sites of pPTEX150-HA-DD24 (a gift from Paul Gilson). The resulting 
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Figure 4.1: The P. falciparum PTEX88 gene is not amenable to deletion 
A: Schematic of the targeting construct used to disrupt the P. falciparum ptex88 gene. 
The construct was designed to integrate into the endogenous locus by double 
crossover homologous recombination. The predicted configuration of the ptex88 locus 
before and after recombination is shown. The locations of oligonucleotides used to 
amplify the targeting sequences are shown as well as the location of the restriction 
sites used in Southern blot analysis. A, AvrII; X, XmnI; S, SpeI; SM, human 
dihydrofolate reductase selectable marker. 
B: Southern blot showing a failure to disrupt the ptex88 locus. Genomic DNA from 
two independent transgenic parasite lines, as well as genomic DNA from wild-type 
3D7 parasites was digested with the restriction enzymes AvrII, SpeI and XmnI and 
probed with the 3' targeting sequence. In both cases, the WT locus remained intact 
and bands at the size predicted for correct integration (9.8 kb) were not seen, 
indicating a failure to disrupt the gene.  
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construct was termed pPTEX88-HA-FKBPdd. Wild-type P. falciparum parasites 
(3D7 strain) were transfected with this plasmid and then immediately cultured in the 
presence of 0.5 µM Shld1. Transgenic parasites were selected for using WR99210. 
After three cycles on and off selective drug pressure to select against parasites that 
were replicating the DNA as episomes, parasite lysates were analysed by Western blot 
using antibodies raised against the HA epitope tag (Figure 4.2C). The presence of a 
species at 106 kDa confirmed that the PTEX88-HA-FKBPdd fusion protein was being 
expressed correctly. The parasites were subsequently cloned by limiting dilution and 
genotyped by analytical PCR to confirm that the parasite population was clonal and 
no wild-type parasites were present (data not shown). The clonal parasites were 
termed PfPTEX88-HA-FKBPdd.  
 
In order to test the effect of destabilizing PTEX88, PTEX88-HA-FKBPdd parasites 
were tightly sorbitol synchronized and equally split into two separate tissue culture 
dishes. Each dish was cultured in either the presence or absence of Shld1 for 48 hours. 
Infected blood was smeared periodically across this time period to monitor parasite 
morphology and at the conclusion of the experiment parasite lysate was analysed by 
Western blotting. However the Western blot revealed that the removal of Shld1 did 
not affect the level of PTEX88-HA present in the parasite, suggesting that the protein 
was not being degraded (Figure 4.3A). Multiple species were observed on these blots, 
including a species at 106 kDa corresponding to the full length PTEX88-HA-
FKBPdd, another species at ~90 kDa that may represent PTEX88-HA in which the 
FKBPdd had been cleaved off, and a final species at ~65 kDa which may represent an 
undefined N-terminal processing of PTEX88 discussed previously in Chapter 3. 
Intriguingly, the morphology of the parasite remained unchanged at all stages of the 
life cycle when Shld1 was removed, suggesting that removal of Shld1 was not 
affecting parasite growth, which was in keeping with PTEX88 not being degraded 
(Figure 4.3B). Thus, because PTEX88 could not be regulated with this system, other 
strategies were explored to determine PTEX88 function. 
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Figure 4.2: Generation of a PTEX88 destabilisation mutant in P. falciparum 
A: Schematic of targeting construct designed to integrate into the endogenous ptex88 
locus by single crossover recombination. hDHFR, human dihydrofolate reductase 
selection cassette; HA, haemaglutinin epitope tag; DD, FKBP12 protein 
destabilisation domain 
B: Overview of destabilization domain function. In the presence of Shld1 (orange 
triangle) expressed PTEX88-HA-FKBPdd fusion protein is stable and expressed 
normally. When Shld1 is removed, the fusion protein is unstable and can be degraded. 
C: Western blot using anti-HA antibodies on two independent transfections of 
PfPTEX88-HA-FKBPdd showing expression of the full length protein at the expected 
molecular weight of 106 kDa.  
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Figure 4.3: Destabilisation does not alter levels of PTEX88 
A: Western blot using anti-HA antibodies showing removal of Shield-1 (Shld) to 
destabilise PTEX88 does not alter levels of PTEX88. Red asterisk marks full length 
PTEX88-HA-FKBPdd at 106 kDa. 
B: Giemsa stained blood smears of P. falciparum-infected erythrocytes shows no 
effect on parasite growth when PTEX88 is stabilized by treatment with Shield-1 
relative to the untreated parasites where PTEX88 is unstable. 
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4.2.3. Utilising ribozyme-mediated knockdown of PTEX88 
Another system that has been adapted for Plasmodium parasites is the use of a Gram-
positive bacterial ribozyme (Prommana et al., 2013). The glmS ribozyme is inserted 
into the 3' untranslated region (UTR) of a gene of interest, such that it becomes 
incorporated into the transcribed messenger RNA of the gene. The addition of 
exogenous glucosamine (GlcN) causes the ribozyme to self-cleave, leading to the 
degradation of the mRNA molecule, therefore preventing translation into protein. 
This system was successfully used to regulate PTEX150 levels in P. falciparum 
(Elsworth et al., 2014b).  
 
Accordingly, to utilise this system to control PTEX88 levels, a targeting plasmid was 
generated by performing restriction digests on the pTEX150-HA-glmS (Elsworth et 
al., 2014b) vector using PstI and SacI sites and cloning the glmS ribozyme sequence 
and the P. berghei dihydrofolate reductase – thymidylate synthase 3' UTR into the 
corresponding sites of pPfPTEX88-HA/Str (Matthews et al., 2013). Successful 
integration of the construct into the endogenous ptex88 locus would result in 
replacement of the wild-type ptex88 locus with an epitope-tagged version that 
harboured the P. berghei dhfr-ts 3' UTR with the incorporated glmS sequence in place 
of the PTEX88 3' UTR. (Figure 4.4A). The targeting plasmid was termed pPTEX88-
glmS-S1. 
 
Sequencing of the pPTEX88-HA-glmS plasmid revealed the presence of large linker 
region between the stop codon that follows the hemagglutinin tag and the glmS 
sequence. Initial attempts at depleting PTEX88-HA with the addition of glucosamine 
showed only modest decreases in PTEX88-HA levels and it was thought that the 
presence of such a large region between the stop codon and the ribozyme might have 
been hindering the activity of the ribozyme. To address this possibility, a second, 
modified construct of PTEX88 was made that harboured a shorter linker region 
between the PTEX88 stop codon and the glmS ribozyme by PCR amplifying the glmS 
sequence using oligonucleotides O445F and O447R and ligating into pPTEX88-glmS 
using the NheI/XhoI restriction sites. This strategy shortened the linker region from 
56bp to 16bp (Figure 4.4A). The resulting plasmid was termed pPTEX88-glmS-S2. 
Both targeting constructs were transfected into P. falciparum (3D7 strain) and 
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cultured with WR99210 to select for transgenic parasites. After three cycles on and 
off selective pressure to select against parasites replicating the transfected DNA as 
episomes, parasite lysate was analysed by Western blot using antibodies against the 
HA epitope tag. Detection of a species at ~90 kDa confirmed that parasites were 
correctly expressing epitope-tagged PTEX88 (Figure 4.4B). Both parasite lines were 
subsequently cloned by limiting dilution to attain a clonal parasite population. 
Diagnostic PCR on parasite gDNA after cloning confirmed that the construct had 
successfully integrated into the genome and contained the ribozyme sequence (Figure 
4.4C). The absence of the wild-type ptex88 locus confirmed that a clonal parasite 
population had been attained.  
 
4.2.4. Optimising PTEX88 knockdown using glucosamine 
Both PTEX88-glmS lines were further tested in order to determine the best way to 
achieve a reproducible, high level of knockdown of PTEX88. In all experiments, 
parasites were synchronised using sorbitol to achieve an 8-hour window of 
synchronicity. According to data previously generated and archived in PlasmoDB 
(Aurrecoechea et al., 2009), ptex88 transcription begins during schizogony, and 
continues through the early ring-stages after invasion. Thus it was reasoned that the 
best strategy would be to add glucosamine to parasites prior to schizogony during the 
trophozoite stage, before the point at which PTEX88 is normally expressed. This 
would maximise the amount of glucosamine-mediated mRNA cleavage thus 
minimising the amount of PTEX88 protein present in the parasite in the following 
developmental cycle.  
 
Two experiments were performed whereby synchronised PfPTEX88-HA and both 
PTEX88-glmS lines were cultured to trophozoites and treated with different 
concentrations of glucosamine. After incubation with glucosamine for a full 
developmental cycle, parasite lysates were analysed by Western blot to determine the 
level of PTEX88 protein present. The blots and subsequent densitometry showed that 
PTEX88-glmS-S2 produced a slightly stronger knockdown of PTEX88 than the 
PTEX88-glmS-S1 parasites (Figure 4.5A and 4.5B). It was also found that parasites 
grown in culture media supplemented with 0.25% (w/v) Albumax and 5% (v/v) serum  
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Figure 4.4: Generation of a PTEX88 knockdown line in Plasmodium falciparum 
A: Schematic of targeting construct designed to integrate into the endogenous ptex88 
locus by single crossover recombination. Arrows indicate binding sites for diagnostic 
PCR primers. Red arrow indicates linker region between HA tag and glmS sequence 
modified to generate PfPTEX88-glmS-S2 parasites. SM, selectable marker; HA, 
haemaglutinin epitope tag; glmS, glmS ribozyme. 
B: Western blot analysis of wild-type (3D7) parasite lysate, PTEX88-glmS-S1 or 
PTEX88-glmS-S2 parasite lysate using anti-HA antibodies confirms correct epitope 
tagging of PTEX88 with a species detected at the predicted molecular weight. 
Parasites lysate containing an HA epitope-tagged version of HSP101 was used as a 
positive control.  
C: Diagnostic PCR on wild-type (WT), PfPTEX88-HA and PfPTEX88-glmS-S2 
DNA using the indicated primer combinations to test for integration of the targeting 
construct. Absence of a product using primer combination A/B in PTEX88-HA and 
PTEX88-glmS-S2 gDNA indicates these parasite lines are clonal. 
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Figure 4.5: Optimising conditions for PTEX88-HA knockdown using glmS 
ribozyme 
PTEX88-HA, PTEX88-glmS Original and PTEX88-glmS parasites were treated with 
the indicated concentrations of glucosamine in culture media supplemented with A) 
5% serum, 0.25% Albumax, or B) 0.5% Albumax. After 48 hours incubation, parasite 
lysate was harvested and analysed by Western blot using anti-HA and anti-EXP2 
antibodies. Densitometry was performed on the blots to quantify level of PTEX88-
HA protein relative to EXP2 loading control. GlcN, glucosamine (n=3). 
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(Figure 4.5A) achieved slightly higher levels of PTEX88 knockdown than parasites in 
media supplemented with 0.5% (w/v) Albumax (Figure 4.5B).  
 
In order to extensively test the effect of glucosamine concentration on the level of 
PTEX88 knockdown and the reproducibility of the knockdown generated, PTEX88-
HA and PTEX88-glmS-S2 parasites were sorbitol synchronised to within a 4-hour 
window of synchronicity and glucosamine was added to trophozoites at five different 
concentrations. These parasites were cultured for 48 hours in culture media 
supplemented with 0.25% (w/v) Albumax and 5% (v/v) serum before parasite lysate 
was analysed by Western blot (Figure 4.6A). Densitometry of the blots revealed a 
dose-dependent loss of PTEX88-HA, with maximal loss of PTEX8-HA protein 
achieved with the addition of 2.5 mM glucosamine (Figure 4.6B). Higher 
glucosamine concentrations were not tested due to previous reports of toxicity above 
2.5 mM (Naik et al., 2003). This experiment was repeated four times to quantify the 
loss of PTEX88, which showed a 95% reduction when treated with 2.5 mM GlcN 
relative to when parasites were cultured in the absence of GlcN.  
 
4.2.5. Depletion of PTEX88 does not affect parasite growth in vitro 
Once reproducible knockdown of PTEX88 had been achieved, the effect of PTEX88 
loss of parasite growth was tested. PTEX88-glmS parasites were tightly synchronized 
using sorbitol, then further synchronized using heparin to synchronise parasites to 
within a 4-hour window. Parasites were equally split and cultured in the presence or 
absence of 2.5 mM glucosamine for 48 hours. At 8-hour intervals thin blood smears 
were stained with Giemsa to monitor parasite morphology (Figure 4.7A). At the 
conclusion of the 48-hour incubation period, parasites were analysed by lactate 
dehydrogenase (pLDH) activity assays (Makler et al., 1993), to measure the level of 
pLDH, a enzyme that can be used to quantitatively measure parasite growth (Elsworth 
et al., 2014b). These assays revealed that there was no significant decrease in the 
levels of pLDH when parasites were treated with glucosamine to deplete PTEX88 
(Figure 4.7B). Analysis of the Giemsa-stained parasites showed that there was no 
visible change to the morphology of the parasites at any stage of the life cycle when 
treated with glucosamine. Furthermore, schizonts contained the same number of 
daughter merozoites (Figure 4.7C).  
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Figure 4.6: Reproducible knockdown of PfPTEX88-HA upon addition of 
glucosamine 
A: Representative Western blot showing levels of tagged PTEX88 in PTEX88-HA 
control parasites and PTEX88-glmS parasites after incubation with the indicated 
concentration of glucosamine. EXP2 was used as a loading control. GlcN, 
glucosamine. 
B: Densitometry performed on Western blots to quantify the protein levels of tagged 
PTEX88 in the control PTEX88-HA line and the PTEX88-glmS line relative to 
parasites not treated with GlcN. The protein level of PTEX88 does not decrease in the 
control PTEX88-HA line but decreases in the PTEX88-glmS with increasing GlcN 
concentrations by up to 95% when compared to the sample without GlcN. n=4, 
p<0.0001 at 2.5mM GlcN as measured by unpaired t-test, error bars represent 
standard error of the mean. 
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Figure 4.7: Knockdown of PTEX88 does not affect the growth of P. falciparum 
A: Giemsa stained blood smears of P. falciparum-infected erythrocytes shows no 
effect on parasite growth in the PTEX88-glmS line when treated with 2.5 mM 
glucosamine relative to the untreated parasites. 
B: Lactate dehydrogenase (LDH) activity assay of infected erythrocytes assayed 
approximately 24 hours after parasite invasion indicate that growth of control 
parasites and PTEX88-glmS parasites is unaffected upon glucosamine treatment. 
(n=4). Error bars represent SEM. NS, not significant as determined by unpaired t-test. 
C: Reduction of PTEX88 protein levels with 2.5 mM glucosamine does not affect the 
merozoite formation with a schizont (n=15 per group). Error bars represent SEM. NS, 
not significant as determined by unpaired t-test. 
D: Lactate dehydrogenase (LDH) activity assay of infected erythrocytes assayed 
treated with the indicated concentration of glucosamine for 2 or 3 full developmental 
cycles shows that prolonged PTEX88 knockdown does not affect parasite growth. 
(n=2). Error bars represent SEM. NS, not significant as determined by unpaired t-test. 
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As the depletion of PTEX88 across one developmental cycle may not be sufficient 
time to see a developmental defect, parasites were exposed to extended periods of 
glucosamine treatment, for 96 or 144 hours to represent 2 or 3 developmental cycles, 
respectively. At the completion of this time, parasites were harvested and analysed by 
pLDH assays. Again this showed that there was no loss in pLDH levels (Figure 4.7D) 
despite there being a consistent knockdown of PTEX88 expression by 95% (data not 
shown). Although a conditional PfPTEX88-HA mutant cannot be considered a null 
mutant, these results contrast to the failure to knockout PTEX88 in P. falciparum and 
suggest that PTEX88 is not crucial for maintaining normal parasite growth under 
routine culturing conditions of P. falciparum in vitro. 
 
4.2.6. PTEX88 knockdown in P. falciparum has no observable effect on protein 
export 
Previously it had been shown that knockdown of the essential PTEX components 
PTEX150 and HSP101 resulted in a failure to export a range of different protein 
cargo (Elsworth et al., 2014b, Beck et al., 2014). Thus, the effect of PTEX88 
knockdown on protein export was assessed on fixed parasites labeled with antibodies 
against various exported proteins. These included RESA (an early expressed PEXEL 
protein), STEVOR (a PEXEL protein containing transmembrane domains), skeleton 
binding protein 1 (SBP1; a PNEP), KAHRP (a soluble PEXEL protein) and RIF50 (a 
PEXEL protein containing transmembrane domains), with samples harvested at time 
points post-infection when these proteins are maximally exported (Elsworth et al., 
2014b, Bachmann et al., 2015). Immunofluorescence analysis (IFA) was used for 
assessment of export of these proteins as it allows visualization of where proteins 
localize within the infected erythrocyte. Furthermore, while differential extraction has 
been used to look at export of infected proteins by Western blot, this can only be used 
for soluble proteins and given the membrane association exhibited by most proteins 
analysed here, IFA was the most appropriate method. IFA revealed that export of all 
of these proteins was not obviously affected when expression of PTEX88 was 
knocked down by the addition of 2.5 mM glucosamine and this was confirmed by 
quantification using previously described methods (Elsworth et al., 2014b) (Figure 
4.8, right panels). This is in contrast to knockdown of the core constituents of PTEX, 
HSP101 and PTEX150 (Elsworth et al., 2014b, Beck et al., 2014). Conditional 
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knockdown of these proteins prevented parasites from trafficking all classes of 
exported proteins into the host erythrocyte and thus it appeared that PTEX88 does not 
act in the same manner in facilitating protein export. 
 
 
4.2.7. Loss of PTEX88 reduces the ability of the host erythrocyte to cytoadhere 
Given that PTEX88 did not appear to play an obvious role in protein export despite its 
status as a component of the protein export machinery, the role of PTEX88 remained 
unclear. Although there was no obvious defect in export of a number of effector 
proteins by IFA, this can be a crude method to measure protein export, and the 
possibility remained that loss of PTEX88 resulted in a subtle decrease in protein 
export that could not be measured using this methodology. Thus it was reasoned that 
export of PfEMP1 may be affected, as correct trafficking of PfEMP1 to the 
erythrocyte surface requires the correct function of many exported proteins (reviewed 
in Boddey and Cowman, 2013), and thus a subtle defect in the export of effector 
proteins may have a more profound impact on PfEMP1 export. The presentation of 
PfEMP1 as well as modifications to the erythrocyte surface such as appearance of 
knobs also aids in the parasites ability to cytoadhere within the vasculature. A defect 
in PfEMP1 export or cytoadherence would also be consistent with the maintenance of 
normal growth in vitro as the growth and replication of parasites would not be 
affected by these phenotypes. 
 
To investigate this further, trophozoite stage PTEX88-glmS parasites were analysed 
for their ability to cytoadhere to CD36, a major receptor for PfEMP1 within the 
vasculature. These experiments were performed in collaboration with Emma McHugh 
and Dr Matthew Dixon at the Bio21 Institute, Parkville. These experiments revealed 
that PTEX88-glmS parasites grown in the presence of 2.5 mM GlcN showed a 
reduction of approximately 50% in their ability to cytoadhere to CD36 with similar 
results observed for multiple PTEX88-glmS clones (Figure 4.9A).  
 
While IFA suggested that there was no reduction in the export of PfEMP1 into the 
host erythrocyte when PTEX88 was knocked down (Figure 4.9B), this will not inform 
whether the trafficking and presentation of PfEMP1 on the surface of the host 
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erythrocyte has been affected, which would lead to the observed reduction in 
cytoadherence. To address this possibility, parasites were treated with or without 
glucosamine to knock down PTEX88 and then PfEMP1 was cleaved from the 
erythrocyte surface using trypsin. These experiments were performed in collaboration 
with Dr Matthew Dixon at Bio21 Institute, Parkville. The resulting Western blots 
showed that there was no obvious difference in the amount of PfEMP1 being removed 
from the surface of infected erythrocytes after glucosamine treatment, further 
confirming that PfEMP1 is being trafficked to and presented on the surface of 
infected erythrocytes when PTEX88 is depleted (Figure 4.9C), although it should be 
noted that these experiments do not reveal if PfEMP1 is displayed correctly.  
 
4.3. Discussion 
This Chapter aimed to determine whether PTEX88 is essential in P. falciparum and to 
dissect the function of PTEX88 through the use of new techniques to regulate 
PTEX88 expression in an inducible manner. The regulation of both PTEX150 using 
the ribozyme method (Elsworth et al., 2014b) and HSP101 using the destabilization 
method (Beck et al., 2014) in P. falciparum resulted in the ablation of parasite 
development and maturation. Furthermore, depletion of both of these PTEX 
components led to a failure to export all types of examined protein cargo normally 
exported into the host erythrocyte (Elsworth et al., 2014b, Beck et al., 2014). Since 
PTEX88 has been shown to form part of this translocation machinery, it was of 
interest to determine whether loss of PTEX88 also resulted in such striking export 
phenotypes.  
 
After tagging PTEX88 with a hemagglutinin epitope tag and a destabilization domain, 
attempts to destabilize it through the removal of the stabilizing ligand Shld-1 were not 
successful. In order for unstable protein to be degraded using this system, it must be 
targeted to the proteasome (Muralidharan et al., 2011). Thus, in this instance PTEX88 
was either not being destabilized or targeted to the proteasome. A similar strategy was 
employed to knockdown HSP101 expression in P. falciparum. In that study, HSP101 
was fused to a destabilization domain derived from the dihydrofolate reductase 
enzyme (Beck et al., 2014). Similar to PTEX88, HSP101 degradation did not occur in 
the expected manner, consistent with neither protein having access to the proteasome 
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(Beck et al., 2014). Rather, the destabilization of HSP101 led to its loss of association 
with the other core constituents of PTEX, rendering it non-functional and causing an 
accumulation of effector proteins in the parasitophorous vacuole (Beck et al., 2014). 
Although investigations into whether a similar loss of association of PTEX88 with the 
rest of the PTEX complex after destablisation of PTEX88 was not examined, no 
obvious morphological phenotype was observed, suggesting that loss of functional 
PTEX88 may not affect parasite growth in vitro. This was corroborated by 
observations that depletion of PTEX88 using the glmS ribozyme also resulted in no 
difference in parasite growth. This was surprising given the repeated failure to knock 
out PTEX88, which indicated the protein is essential and is in keeping with the 
essential nature of PTEX150 and HSP101 (Elsworth et al., 2014b, Beck et al., 2014). 
It could be that the remaining ~5% of PTEX88 not depleted by the treatment with 2.5 
mM glucosamine is sufficient to maintain normal parasite growth in vitro. 
Conversely, deletion of the endogenous ptex88 gene may not have been achieved 
using a conventional double crossover gene replacement strategy because transfection 
is very inefficient in P. falciparum and even subtle growth phenotypes of a knockout 
parasite can lead to them being overgrown by wild-type parasites containing residual 
episomes in culture. It is noteworthy that a fluorescent reporter protein strategy was 
employed to generate a P. berghei PTEX88 knockout (Matz et al., 2013), which 
enabled PTEX88 knockout parasites to be selected for early after transfection. Since 
the type and amount of cargo exported by P. falciparum and P. berghei is different, 
with P. falciparum harbouring a substantially larger PEXEL exportome that includes 
multi-gene families, including PfEMP1, it may be that PTEX88 plays a more crucial 
role in dealing with the larger PEXEL exportome in P. falciparum that renders it 
essential in this species. 
 
Given that knockdown of PTEX88 did not lead to a growth phenotype, it was of 
interest to determine whether parasites exhibited a deficiency in protein export. Loss 
of PTEX88 resulted in no defect in export of all proteins tested by IFA. This included 
PEXEL-containing proteins and PNEPs, as well as soluble proteins and proteins 
containing transmembrane domains. While PTEX150 and HSP101 appear to be 
responsible for trafficking of all classes of all exported cargo, these data suggests that 
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PTEX88 does not function in the same manner, and is not responsible for the export 
of a particular class of cargo.  
 
In order to dissect further what role PTEX88 may be playing in PTEX function, 
parasite processes that rely on protein export were also investigated. One such process 
is cytoadherence, a process that is essential for the survival of the parasite in vivo but 
is not relevant to the survival of the parasites in an in vitro setting. This could be 
tested by the ability of the parasite to bind to CD36 under flow conditions, which 
surprisingly was reduced by approximately 50% when the parasite was depleted of 
PTEX88. Parasites lacking or expressing mutated forms of KAHRP cannot properly 
present PfEMP1 on the surface of the host erythrocyte and bind to CD36 with only 
10-20% of the efficiency of wild-type parasites (Horrocks et al., 2005, Rug et al., 
2006). However the reduced cytoadherence of PTEX88-depleted parasites could not 
be linked to a reduction in the export of PfEMP1 or its presentation on the surface of 
the infected erythrocyte. This was surprising given PfEMP1 is the ligand mediating 
adhesion to CD36. However, cytoadhesion is also influenced by rigidity of the host 
erythrocyte, which is also mediated by proteins such as RESA, PfEMP3, Pf332 and 
KAHRP, amongst many others (Maier et al., 2008). While the export of KAHRP and 
RESA has been tested in this Chapter, reagents were not available to test whether the 
export of PfEMP3 and Pf332 were affected by the loss of PTEX88, or indeed whether 
the rigidity of the infected erythrocyte was altered by PTEX88 knockdown. 
Determining whether the export of any of these individual proteins is affected by 
knockdown of PTEX88 would require generation of reagents which would require 
significant further efforts. Thus it remains to be established the mechanism by which 
depletion of PTEX88 leads to reduced cytoadherence and whether it is related to 
protein export. It is plausible that PTEX88 acts in the export of a specific cargo or 
subset of cargo not investigated herein that may mediate cytoadherence, either 
directly or indirectly. For instance, the Sec translocon in prokaryotes and eukaryotes 
is modular and engages additional subunits and partner proteins depending on the 
nature of the substrate to be translocated (Denks et al., 2014) and PTEX may function 
in a similar manner by recruiting proteins like PTEX88 to facilitate export of specific 
protein cargo or export of proteins under particular conditions. Alternatively, PTEX88  
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Figure 4.8: Effect of PTEX88 knockdown on P. falciparum protein export 
Immunofluorescence assays showing that exported proteins A: RESA, B: STEVOR, 
C: SBP1, D: KAHRP, E: RIF50 are still exported after knockdown of PTEX88. 
Mean fluorescence intensity was calculated for RESA, STEVOR and KAHRP, whilst 
the number of Maurer’s clefts was calculated for SBP1. Boxes and whiskers delineate 
25-75th and 10-90 percentiles, respectively. NS, not significant, as determined by 
unpaired t-test 
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Figure 4.9: PTEX88-glmS parasites exposed to glucosamine export PfEMP1 but 
are less cytoadherent to CD36  
A: Adherence of trophozoite-stage infected erythrocytes to recombinant CD36 under 
flow conditions (0.1 Pa) ± SEM, n=30 (P<0.001), unpaired t-test.  
B: Immunofluorescence assay showing that PfEMP1 is still exported after 
knockdown of PTEX88. Number of PfEMP1 foci in the host erythrocyte was 
calculated. Boxes and whiskers delineate 25-75th and 10-90 percentiles, respectively. 
NS, not significant as determined by unpaired t-test. 
C: Trypsin digestion of surface exposed PfEMP1 in erythrocytes infected with 
PTEX88-glmS parasites grown in the presence and absence of glucosamine (GlcN).  
P: pre-treated, T: trypsin treated. Full-length PfEMP1 (~270 kDa, black arrowhead) 
and a cross-reactive spectrin band (~240 kDa, asterisks) are indicated. Trypsin 
cleavage products (75 kDa) are indicated with an empty arrowhead. 
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may exist as part of the membrane-bound translocon, where it acts as a specific 
receptor for cytoadherence modulators. 
 
 In order to determine whether there are specific proteins that rely on PTEX88 for 
correct trafficking, this will require exhaustive comparative analysis of the full 
exportome of wild-type Plasmodium parasites and that of parasites depleted of 
PTEX88 since antibody reagents exist for only a limited proportion of proteins in the 
whole exportome to study their trafficking. However, attempts to investigate malaria 
proteins in the host environment through proteomic approaches has been hindered by 
the overrepresentation of host cell proteins in the subsequent analyses (Fontaine et al., 
2011). Proteomic analysis of the erythrocyte membrane in rodent malaria parasites 
has been successful in enriching for malaria effectors without major contamination 
from host cell proteins (Pasini et al., 2013, Fonager et al., 2012), however only a 
fraction of all exported proteins are indeed trafficked to the erythrocyte membrane. 
Similarly, proteomic analysis of Maurer’s clefts has enabled the identification of 
parasite proteins within these structures (Vincensini et al., 2005). While such 
approaches can be useful for identifying proteins localising to membranous structures 
or the cytoskeleton of the host (Millholland et al., 2011), proteomic analysis of the 
full exportome needs to account for diverse localisations as many exported proteins 
also localise to the cytosol of the erythrocyte or in soluble complexes that cannot be 
enriched using these methods. Thus further improvements that enable enrichment of 
all parasite-encoded proteins present in the host environment and that permit 
proteomic analysis of the entire exportome would help to determine the involvement 
of PTEX88 in protein export and how this relates to its apparent role in 
cytoadherence.  
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Dissecting the role of PTEX88 in vivo 
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5.1. Introduction 
The ability to culture and genetically manipulate Plasmodium falciparum is of great 
importance as it allows direct study of the most virulent Plasmodium species that has 
the greatest burden on malaria deaths. However, the major limitation to studying P. 
falciparum is the difficulties in assessing its interaction with the host as this requires 
either non-human primate models or humanized-mouse models of malaria infection 
and hence it is routinely cultivated in vitro. This has necessitated the development of 
more accessible in vivo models of infection to understand how malaria parasites 
establish an infection in the host and cause disease. Several species of rodent malaria 
parasite are now routinely used in in vivo models of infection, in particular P. berghei 
(Langhorne et al., 2011).  
 
The P. berghei ptex88 (Pbptex88) locus is amenable to manipulation, as evidenced by 
the ability to epitope tag PTEX88 (Matthews et al., 2013). However, previous 
attempts to disrupt the endogenous ptex88 loci in both P. falciparum and P. berghei 
using standard selection techniques have failed (Matthews et al., 2013) and thus  to 
investigate PTEX88 function in vivo alternate strategies are required. The recent 
development of a tetracycline-responsive system to knock down the expression of P. 
berghei genes in an inducible manner has provided a means to functionally dissect 
essential genes in this species (Pino et al., 2012).  
 
This Chapter aimed to reveal how PTEX88 contributes to protein export, parasite 
virulence and survival in vivo through the controlled regulation of PTEX88 levels in 
P. berghei in a rodent model of infection. The use of the in vivo model also provides a 
mechanism to further understand of the nature of the interaction between the parasite 
and the host as it relates to protein export and whether the role of PTEX88 in PTEX 
function becomes more prominent in an in vivo environment.  
 
5.2. Results 
5.2.1. Generating an inducible PTEX88 knockdown line in P. berghei 
To generate parasites that would allow for inducible knockdown of PTEX88 in P. 
berghei, a targeting plasmid was designed to integrate into the endogenous Pbptex88 
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locus, using the strategy first described by Pino et al in 2012 (Pino et al., 2012). 
Successful integration would place a transactivator (TRAD) under the control the 
native Pbptex88 promoter and the ptex88 coding sequence under the control of a 
minimal promoter (Figure 5.1A). Immediately upstream of the minimal promoter are 
tet operon sequences to which the TRAD transactivator binds, thus activating normal 
transcription. However, the binding of the transactivator can be drastically reduced 
through the administration of anhydrotetracycline (ATc) to the drinking water of 
mice, thus driving Pbptex88 transcription through the minimal promoter and reducing 
the amount of messenger RNA produced (Figure 5.1A).  
 
The targeting plasmid used to engineer the PbPTEX88 inducible knockdown (iKD) 
line was made by first PCR amplifying 1.2 kb of sequence immediately upstream of 
the PTEX88 start codon from P. berghei ANKA gDNA using the primers O453F and 
O454R. The resulting product was ligated into NheI and BssHII sites of pPRF-
TRAD4-Tet07-HAPRF-hDHFR (Pino et al., 2012) that had been modified to include 
a BssHII restriction enzyme site between the profilin 5' UTR and TRAD4 sequence 
(Elsworth et al., 2014b). Following confirmation of a successful ligation, the first 1.2 
kb of the PbPTEX88 coding sequence was amplified by PCR using the primers 
O451F and O452R and cloned into the intermediate vector using the PstI and NheI 
restriction sites to create the final targeting vector, termed pTRAD4-iPTEX88. Before 
transfection into P. berghei ANKA parasites, 2 µg of pTRAD4-iPTEX88 was 
linearized with NheI to drive integration into the ptex88 locus. The linearized plasmid 
was electroporated into wild-type P. berghei parasites, which were immediately 
administered intravenously into Balb/c mice. One day after transfection, mice were 
administered pyrimethamine to select for parasites harboring the targeting plasmid. 
Pyrimethamine-resistant parasites were recovered 10 days after infection. Parasite 
genomic DNA was extracted and integration of the targeting construct into the 
endogenous Pbptex88 locus was examined by diagnostic PCR, which confirmed that 
the wild-type locus had been disrupted by the targeting construct as it could no longer 
by amplified by PCR (Figure 5.1B). This transgenic parasite line was termed 
PbPTEX88 iKD. 
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Figure 5.1: Generation of an inducible PTEX88 knockdown line in P. berghei 
A: Schematic representation of the targeting construct used to generate the 
PbPTEX88 iKD line. Successful integration results in the ptex88 gene being under 
control of a minimal promoter (solid black arrow) and the TRAD transactivator under 
the ptex88 5' UTR. Arrows indicate binding sites for diagnostic PCR primers. 
B: Diagnostic PCR on parasite genomic DNA using indicated primer combinations 
demonstrate correct integration of the targeting construct. Absence of a product using 
primer combination A/B in PbPTEX88 iKD gDNA indicates this line is clonal. 
C: Quantitative RT-PCR on parasite material isolated from PbPTEX88 iKD parasites 
shows a significant knockdown of ptex88 transcript in parasites exposed to ATc. n=4, 
p<0.01 as determined by unpaired t-test. 
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To confirm whether ptex88 expression could be regulated, Balb/c mice were 
administered 1x106 PbPTEX88 iKD parasites after pre-treatment with either ATc  
(0.2mg/mL in 5% (w/v) sucrose) or the vehicle control (5% (w/v) sucrose). Five days 
after infection, mice were humanely culled. Blood was harvested by cardiac puncture 
and further cultured in vitro in the presence or absence of ATc  (1 µg/mL) to allow 
the development of schizonts.  At this point, RNA was extracted from parasites, from 
which cDNA was synthesized and used in qRT-PCR reactions using oligonucleotides 
to ptex88 (O587F/O588R) or gapdh (O567F/O568R) to determine ptex88 expression 
levels. The expression levels of ptex88 were normalised against the gapdh house-
keeping gene, with gene expression values calculated based on the 2-ΔΔCt method 
(Livak and Schmittgen, 2001). The qRT-PCR and analysis to measure ptex88 
expression was performed by Sreejoyee Ghosh at Deakin University. It was found 
that ptex88 transcripts were 4-fold lower in parasites treated with ATc relative to the 
untreated parasites (Figure 5.1C). This showed that ptex88 levels could be regulated 
and this system could be used for further functional analysis of PTEX88.  
 
5.2.2. PTEX88 does not function in global protein export 
Having demonstrated that the expression of P. berghei PTEX88 could be controlled 
by the addition of ATc, the ability of parasites to export proteins into the host cell 
when PTEX88 was conditionally regulated was investigated. PbPTEX88 iKD 
parasites treated with ATc or vehicle control were fixed and labeled with antisera 
against P. berghei proteins PbANKA_122900 and PbANKA_114540, which localize 
to membranous structures in the erythrocyte cytoplasm. The export of these two 
proteins has previously been shown to be affected in P. berghei parasites 
conditionally depleted of HSP101 (Elsworth et al., 2014b). However, quantification 
of IFA images revealed there was no significant decrease in the export of either of 
these proteins when PTEX88 expression was reduced (Figure 5.2A). This was 
consistent with the data generated in P. falciparum, which did not show a defect in 
protein export by immunofluorescence when PTEX88 was depleted. Given that there 
are only a few antibodies available to exported proteins in P.berghei, a FACS-based 
method (Elsworth et al., 2014b) to quantitate parasite-encoded proteins exposed on 
the surface of infected erythrocytes was also employed.  This methodology provides a 
means to assess global protein export of proteins localized to the infected erythrocyte 
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surface. In this case, six individual experiments were performed with three mice per 
treatment group (ATc or vehicle control) infected intraperitoneally with 1x106 
parasites and analysed 5 days after infection. Parasites were treated with either semi-
immune serum or naïve serum (negative control) to label parasite proteins on the 
erythrocyte surface and the level of recognition of these proteins was measured by 
flow cytometry. A mixed ANOVA test was used to calculate the results of the six 
experiments, which showed that while in some cases the degree of export to the 
erythrocyte surface was less in ATc-treated parasites than control parasites, overall 
there was not a significant decrease in parasite proteins exported to the erythrocyte 
surface when PTEX88 was depleted (Figure 5.2B).  
 
5.2.3. Growth of P. berghei is reduced upon depletion of PTEX88 in vivo 
To assess the effect of the PTEX88 knockdown on P. berghei parasite growth, female 
Balb/c mice between 5-6 weeks of age were randomized into groups of five mice and 
then administered drinking water containing either ATc or vehicle control. After 48 
hours pre-treatment with this drinking water, mice were infected intraperitoneally 
with 1x106 parasitized PbPTEX88 iKD erythrocytes or wild-type PbANKA as a 
control. From 3 days post infection, parasitemias were monitored daily by Giemsa-
stained tail blood smears. There was a clear and significant reduction in the 
parasitemias of mice infected with PbPTEX88 iKD and exposed to ATc (Figure 
5.3A), whilst wild-type parasites and vehicle-treated PbANKA parasites were 
unaffected by the presence of ATc (Figure 5.3B).  
 
Since depletion of HSP101 affects the ability of parasites to successfully transition 
from ring to trophozoite stages, it was explored whether the delay in the growth of 
PbPTEX88 iKD parasites treated with ATc in vivo was also attributable to the 
parasites stalling at particular developmental stages. For these experiments, 
merozoites that had been treated with or without ATc were intravenously injected into 
Balb/c mice that had been pre-treated with ATc or vehicle control and allowed to 
invade new erythrocytes. Since the more mature stages of P. berghei sequester in 
vivo, blood was harvested from these mice nine hours after infection when the 
parasites were still at late ring stage and cultured in vitro in the presence or absence of 
ATc to monitor the development of parasites as they matured into schizonts.  Blood  
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Figure 5.2: Effect of PTEX88 knockdown on protein export in P. berghei 
A: Immunofluorescence assays showing the P. berghei proteins PBANKA_114540 
and PBANKA_122900 are still exported after conditional depletion of PTEX88 in 
PbPTEX88iKD parasites using ATc. Export was measured by calculating MFI, 
shown as the mean + SEM. NS, not significant. 
B: Surface labelling of parasite antigens on PbPTEX88 iKD parasites harvested 
between 4 or 5 days post infection compared with infected erythrocytes not exposed 
to ATc as measured by FACS (n=6). A mixed ANOVA was used to test for statistical 
significance (p=0.06). 
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Figure 5.3: Knockdown of PTEX88 in P. berghei impacts growth of P. berghei in 
vivo 
Parasitemia of Balb/c mice administered either ATc (dashed line) or vehicle control 
(solid line) after intraperitoneal administration of 1x106 asynchronous (A) PbPTEX88 
iKD parasites, or (B) wild-type (WT) parasites. Each data point represents the mean ± 
SEM, n=6 mice per group. ***P<0.001 as determined by unpaired t-test.  
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was smeared every three hours and stained with Giemsa and at each time point, 
parasites were counted and the developmental stage was noted (Figure 5.4). At all 
points throughout the life cycle, there was no obvious difference in the development  
between ATc-treated and untreated parasites. ATc-treated parasites reached 
schizogony at the same time  (Figure 5.4), and were morphoplogically 
indistinguishable from those grown in the absence of ATc, suggesting that the delay 
in growth observed with ATc-treated PbPTEX88 iKD parasites in mice was not 
because the parasites stalled at a particular stage of the cell cycle. 
 
5.2.4. PTEX88-depleted parasites multiply at a reduced rate in vivo 
Given the above findings, it was reasoned that delay of parasite growth in vivo could 
be attributable to one of the following factors, those being fewer merozoites produced 
per cycle leading to fewer invasion events, an increase in the length of cell cycle 
resulting in fewer parasite generations over time, or increased parasite clearance. To 
examine these possibilities, synchronous infections of ATc and vehicle-treated mice 
were established by intravenous inoculation with PbPTEX88 iKD merozoites and 
parasites were either followed for two cycles in vivo whilst synchronicity was 
preserved. At 3-hour intervals, tail blood was smeared to monitor parasite 
development and parasitemia. These experiments revealed that newly invaded ring-
stage parasites appeared in the circulation of all mice at the same time for both cycles 
(Figure 5.5A), and parasitemia remained constant between treatment groups 
throughout the ring-stage and trophozoite stage. When parasites reached schizogony, 
more parasites appeared in the circulation of ATc-treated mice, as shown through 
Giemsa staining of tail blood. These late stages of infection were further investigated, 
with counts showing a 2.5-fold increase in the number of schizonts in the circulation. 
Interestingly, the fold increase in parasitemia from one cycle to the next was 
significantly lower in mice treated with ATc (Figure 5.5B). However the length of the 
cycle was not affected, as the spike in parasitemia corresponding to invasion appeared 
at the same length of time after the initial infection, suggesting that parasite egress 
and invasion of new erythrocytes was occurring at the same time (Figure 5.5A). This 
is consistent with the in vitro growth experiments above, which also demonstrated 
that knockdown of PTEX88 did not affect the time to schizogony.  Investigation of 
the schizonts produced in ATc-treated or untreated mice showed that the number of  
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Figure 5.4: Depletion of PTEX88 in P. berghei does not alter parasite growth in 
vitro 
Infection was initiated by intravenous injection of purified merozoites into mice pre-
treated with ATc or vehicle control and at 9 hpi, parasites were harvested and cultured 
in vitro for the remainder of the cell cycle in the presence or absence of ATc. ER, 
early ring; LR, late ring; ET, early trophozoite; LT, late trophozoite; ES, early 
schizont; LS, late schizont. A minimum of 200 parasitised cells was counted for each 
timepoint. 
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Figure 5.5: Depletion of PTEX88 in P. berghei reduces parasite amplification in 
vivo but not via extension of the cell cycle 
A: Representative growth curves of PbPTEX88 iKD parasites grown in the presence 
or absence of ATc from two independent experiments initiated by intravenous 
injection of purified merozoites. The appearance of new ring stages in Giemsa smears 
indicates that invasion had occurred and hence the length of previous cycle.  
B: Conditional depletion of PTEX88 leads to a lower fold-increase in parasitemia in 
synchronous infections initiated by intravenous injection of merozoites. Error bars 
represent SEM. p=0.0125 as determined by unpaired t-test. 
C: Conditional depletion of PTEX88 does not impact on merozoite formation within 
schizonts (n=25). Error bars represent SEM. NS; not significant as determined by 
unpaired t-test. 
D: Conditional depletion of PTEX88 leads to an increase in circulating schizonts in 
synchronous infections initiated by intravenous injection of merozoites. Error bars 
represent SEM. p=0.0033 as determined by unpaired t-test. 
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Figure 5.6: Conditional depletion of PTEX88 affects parasite burden and 
virulence 
A: Parasitemia and B: Survival curves of C57Bl/6 mice administered either ATc 
(dashed lines) or vehicle control (solid lines) after intraperitoneal administration of 
1x106 PbPTEX88 iKD parasites. Crosses represent the number of deaths. *P<0.05, 
**P<0.01 as determined by unpaired t-test for parasitemias or by log-rank test for 
survival curves, which plots the % of mice that have not succumbed to cerebral 
malaria. 
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daughter merozoites present in each schizont was not different between treatment 
groups (Figure 5.5C). Together these data suggest that the growth defect seen in vivo 
when PTEX88 levels are decreased is not due to failure of the parasite to develop and 
mature to schizogony, nor is it due to the number of merozoites produced in  
schizonts, but rather due to a decreased multiplication rate from cycle to cycle. This 
does not appear to be related to an invasion defect, and instead the increased 
appearance of schizonts in the peripheral circulation in vivo (Figure 5.5D) suggests 
that it may be due to a reduction in the ability of mature parasites to sequester. As a 
consequence, the parasites would be more susceptible to splenic clearance prior to 
egress, which would have the net affect of decreasing the number of invasion events 
occurring in the following cycle. 
 
5.2.5. PTEX88 is important for parasite virulence 
Given that parasite sequestration is linked to virulence, further investigations of the 
PbPTEX88 iKD parasites were performed in mice to determine the consequences of 
conditional depletion of PTEX88 on parasite burden and virulence. For these 
experiments, C57Bl/6 mice were used as these are susceptible to experimental 
cerebral malaria (ECM) (Mackey et al., 1980). In humans, cerebral malaria is a severe 
consequence of malaria infection that presents with numerous neurological 
symptoms, which can progress to coma and is often fatal (Newton et al., 2000). Mice 
exhibit similar visible symptoms of cerebral malaria, such as ruffling of the fur, 
wobbled gait, hunching, limb paralysis and ataxia. These symptoms usually present 5-
10 days after infection (Engwerda et al., 2005a). Once mice exhibit symptoms of 
cerebral malaria, they are humanely culled as the development of cerebral malaria is 
irreversible and the disease progresses to the development of coma and ultimately a 
rapid death. 
 
To test the virulence of parasites depleted of PTEX88, groups of six female C57Bl/6 
mice at 6 weeks of age were either pretreated with ATc or vehicle control 24 hours 
prior to intraperitoneal infection with 1x106 PbPTEX88 iKD parasitized erythrocytes. 
To assess parasite virulence, mice were monitored for cerebral malaria symptoms 
from day 3 post-infection. Mice were humanely culled when displaying cerebral 
malaria symptoms or when the parasitemia exceeded 20 %. Knockdown of PTEX88 
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caused a comparable growth delay in C57Bl/6 mice as previously observed in Balb/c 
mice (Figure 5.6A) but strikingly, no C57Bl/6 mice treated with ATc succumbed to 
cerebral malaria (Figure 5.6B), surviving without symptoms of cerebral malaria until 
day 11 post-infection, when they were humanely culled as their parasitemias had 
exceeded 20%. Statistical analysis of parasite survival was performed using a 
Wilcoxon log-rank test (n=6 mice per group), which showed a significant difference 
between treatment groups (p<0.01). Together these data suggested that PTEX88 plays 
a role in parasite virulence. 
 
5.2.6. Parasites lacking PTEX88 have impaired cytoadhesion properties 
The absence of cerebral malaria and the in vivo growth defects associated with 
knockdown of PTEX88 suggested that the parasitized erythrocytes may be failing to 
properly cytoadhere to the microvasculature of the mouse, leading to failure of 
parasites to sequester in the brain and other organs and subsequently be cleared 
through the spleen. To test this, another experiment was performed by pre-treating 
C57Bl/6 mice with ATc or vehicle control and infecting each mouse with 1x106 
PbPTEX88 iKD parasites. From day 3, parasitemia was monitored daily by Giemsa 
staining of tail blood. Analysis of the parasitemias indicated that the knockdown of 
PTEX88 was quite strong, as the parasitemia of the ATc-treated mice was an average 
of only 0.96% at harvest, compared to 6.76% in the vehicle-treated mice (Figure 
5.7A). However, instead of allowing the infections to progress to the development of 
cerebral malaria symptoms, on day 5 post infection, mice were humanely culled. 
Perfusion of organs was performed by intracardial administration of phosphate-
buffered saline to clear the vasculature of non-sequestered cells. Spleen, lung and 
adipose tissue was removed and the spleen was weighed. As expected, untreated mice 
infected with PTEX88 iKD parasites displayed splenomegaly when compared to 
naïve mice. Surprisingly, the spleens harvested from ATc treated mice that had been 
infected with the PTEX88iKD parasites showed a similar weight to that of the 
untreated mice (Figure 5.7B). RNA was also extracted from the organs and qRT-PCR 
was performed on synthesized cDNA. The parasite load in the organs was then 
determined by measuring the levels of parasite 18s ribosomal RNA relative to the 
mouse hprt housekeeping gene (Suarez et al., 2013). The qRT-PCR revealed that the 
parasite load in the lung and the adipose was significantly reduced in mice treated 
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Figure 5.7: Depletion of PTEX88 reduces cytoadherence of infected erythrocytes 
in peripheral tissues  
A: Parasitemia and B: Spleen weight of C57Bl/6 mice administered either ATc or 
vehicle control after intraperitoneal administration of 1x106 PbPTEX88 iKD 
parasites. ***P<0.001 as determined by unpaired t-test for parasitemias. 
C: The parasite load in indicated tissues of mice was determined by normalizing the 
expression levels of parasite 18S ribosomal RNA against the mouse hrpt house-
keeping gene and expressed as a percentage of the parasite load in mice infected with 
untreated PbPTEX88 iKD parasites. Error bars indicate SEM. Statistical significance 
was determined by unpaired t-test, NS: not significant. 
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with ATc, however the parasite load in the spleen was comparable, consistent with the 
spleen weight being similar between the two groups of infected mice (Figure 5.7C).  
 
As it could not be ruled out that the significant decreases in the parasite load in the 
lungs and adipose of mice infected with parasites depleted of PTEX88 were partially 
a consequence of the large discrepancy in parasitemia, the experiment was repeated, 
however this time the ATc treated mice received a 50-fold higher inoculum of 
PbPTEX88 iKD parasites (5x107) than the vehicle control group so that on the day of 
harvest the parasitemias were similar (Figure 5.8A). Again the weights of the spleens 
at harvest were similar between treatment groups (Figure 5.8B). qRT-PCR again 
showed that parasite load in the adipose tissue and spleen was decreased, however the 
decrease was no longer significant (Figure 5.8C) . However the parasite load in the 
spleen was significantly increased in ATc-treated mice, suggesting that there was an 
increased splenic clearance of parasites in the ATc-treated mice.  
 
A third experiment was performed to further investigate the parasite load in each 
organ. In this experiment, both ATc-treated and vehicle-treated mice were treated 
with an equal inoculum of 1x106 parasites. Parasitemia was decreased in the ATc-
treated mice, although not to the same extent as was seen in the initial experiment 
(Figure 5.9A). Investigation of parasite load in the organs by qRT-PCR revealed a 
significant decrease in the parasite load in the adipose tissue of ATc-treated mice, 
while the parasite load in both the lungs and the spleens of ATc-treated mice were 
comparable to the vehicle-treated mice (Figure 5.9B). Together these three 
experiments suggested that parasites depleted of PTEX88 through administration of 
ATc are less able to sequester in peripheral tissues such as adipose and lung, resulting 
in an increased clearance of these parasites by the spleen. 
 
5.2.7. P. berghei PTEX88 knockdown parasites still generate a robust pro-
inflammatory immune response 
In addition to assessing parasite load in the third experiment described in 5.2.6, 
cytokine and chemokine analysis of the spleen and serum was undertaken and the 
proportion of splenic cell populations was ascertained to determine whether knocking  
 
 
  Chapter 5 
 
 124 
 
 
 
 
 
 
Figure 5.8: Equalised parasitemia in ATc-treated mice results in lower parasite 
burden in adipose tissue and lung but an increase in parasite load in the spleen  
A: Parasitemias of C57Bl/6 mice administered either ATc (dashed lines) or vehicle 
control (solid lines) after intraperitoneal administration of 5x107 or 1x106 PbPTEX88 
iKD parasites, respectively. By day 5 post-infection, when tissues were harvested to 
assess parasite load, the blood parasitemia between the two lines was equivalent.  
B: The parasite load in indicated tissues was determined by normalizing the 
expression levels of parasite 18S ribosomal RNA against the mouse hrpt house-
keeping gene. Error bars indicate SEM. Statistical significance was determined by 
unpaired t-test, NS: not significant. 
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down PTEX88 influenced the generation of an immune response.  As cerebral malaria 
is caused not only by sequestration of parasites within cerebral tissue, but also a 
significant pro-inflammatory immune response to the infection, it was of interest to 
see whether modulation of the pro-inflammatory immune response influenced the 
absence of cerebral malaria in mice infected with PTEX88-depleted parasites.  

These experiments, performed in collaboration with Dr Rachel Lundie at The Burnet 
Institute, revealed that there was no significant difference in the levels of 26 cytokines 
or chemokines in the spleens and serum between ATc and vehicle-control treated 
mice, with the only exception being IL-6, which was significantly increased in the 
serum of mice infected with parasites conditionally depleted of PTEX88 (Figure 5.9C 
and data not shown). Immune cell populations in the spleen were also analysed by 
flow cytometry. There were no significant differences in dendritic cell (DC) subsets 
(conventional versus plasmacytoid), CD4+ or CD8+ T cells, B cells, NK cells or 
neutrophils (data not shown). Measurement of MHC Class II, CD86 or CD40 
expression on CD8+ DCs or CD8- DCs did not reveal a difference in the activation 
status of these DCs (data not shown). There was, however, a significant increase of 
CD40 expression on plasmacytoid DCs in spleens of mice treated with ATc, a 
surprising finding given that this subset of DCs is not known to present parasite 
antigens to T cells during a blood-stage infection (Sponaas et al., 2006). The only 
other notable difference in the spleen between the two treatment groups was a 
significantly higher proportion of CD11c+MHCII+ DCs, CD11clowCD11bhigh-
Ly6C+CD64+ macrophages, and Ly6Chigh monocytes (Figure 5.9D). These cells 
traffic to the sites of infection or inflammation and differentiate into classical 
macrophages that secrete pro-inflammatory cytokines (Murray and Wynn, 2011). 
Spleens of ATc-treated mice also contained significantly lower proportion of Ly6Clow 
monocytes, which secrete anti-inflammatory cytokines (Yang et al., 2014, Shi and 
Pamer, 2011).  Together, these data suggested that the absence of cerebral malaria in 
ATc-treated mice was not the result of a reduced pro-inflammatory immune response, 
but is more likely due to reduced sequestration of parasites in the vasculature of the 
host leading to increased clearance in the spleen, leading to increased recruitment of 
immune cells in the spleen to clear the parasites by phagocytosis. 
 
 
  Chapter 5 
 
 126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Chapter 5 
 
 127 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Knockdown of PTEX88 does not impact on the ability of the parasite 
to generate a robust pro-inflammatory immune response from the host 
A: Parasitemia of C57Bl/6 mice (n=5) administered either ATc (dashed lines) or 
vehicle control (solid lines) after intraperitoneal administration of 1x106 PbPTEX88 
iKD parasites. The lower panel shows the parasitemia curves on mice from which the 
cerebral malaria studies were performed as a comparison (Figure 5.5).  
B: Parasite load in tissues harvested at day 5 post-infection from mice in A, upper 
panel. 
C: Graphs showing the spleen cyotokine and chemokine levels of mice infected with 
parasites with wild-type (-ATc) or depleted PTEX88 (+ATc) expression. Shown are 
the plots for IL-6, IL-10, IL-18, TNF-a and IFN-g. Additional cytokines and 
chemokines for which plots are not shown include GM-CSF, IL-1b, IL12p70, IL-2, 
IL-4, IL-5, IL-9, IL13, IL17, IL-22, Eotaxin, CXCL1, IP10, MCP-1, MCP-3, MIP1a, 
MIP1b, MIP2 and Rantes. PB: Pre-bleed, D5 PI: Day 5 Post-infection 
D: Graphs showing cell populations in the spleen at day 5 post-infection (means ± 
SD). 
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5.3. Discussion 
 
This Chapter aimed to use inducible knockdown techniques to understand the role of 
PTEX88 in an in vivo setting. The inability to generate a knockout using standard 
double crossover homologous recombination necessitated the use of such an  
approach, although during the time of this study, ptex88-null parasites were 
successfully generated (Matz et al., 2013). While the use of inducible knockdown 
techniques do not always offer as strong a phenotype as genuine knockouts and  
cannot be considered genuine null mutants, the inducible nature of these systems do 
offer some advantages. The short-term nature of the inducible knockdown reduces the 
likelihood of the parasite adapting compensatory mechanisms to adapt to the complete 
loss of a gene, a phenomenon that has previously been observed in Apicomplexa 
(Frénal and Soldati-Favre, 2015). Thus the knockdown of PTEX88 through the 
addition of ATc can be used to tease out the function of PTEX88 as this limits the 
opportunity for the parasite to adapt to the loss of the gene. 
Knockdown of P. berghei PTEX88 with ATc resulted in a significant reduction in 
parasite growth in vivo, a finding consistent with that observed with ptex88-null 
parasites (Matz et al., 2013). However, this contrasted with the data generated by 
knocking down the P. falciparum PTEX88 orthologue in Chapter 4. Further analysis 
from synchronous infections in vivo demonstrated that this reduction in growth was 
not attributable to an extension in the length of the asexual replicative cycle, nor was 
it due to a reduction in the number of daughter merozoites present in the developed 
schizont. Instead it revealed that there was a defect in establishing infections to the 
same degree in the following cycle. This was unlikely to be due to a defect in invasion 
as merozoites pre-treated with ATc were able to invade erythrocytes with the same 
efficiency as wild-type merozoites, and moreover, invasion was not impaired in P. 
falciparum parasites depleted of PTEX88. Thus the most likely reasoning for the 
growth defect observed in vivo is that late-stage parasites were removed from the 
circulation due to a failure of the parasites to cytoadhere in the vasculature of the host, 
a process that would not affect the growth and replication of the parasite in vitro. 
 
To test whether parasite cytoadherence was affected with loss of PTEX88, the 
parasite load was measured in peripheral organs where parasites are known to 
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sequester, in this case the lungs and adipose tissue (Franke-Fayard et al., 2005). These 
experiments revealed reduced parasite load in these organs, an observation also seen 
with ptex88 null parasites that were generated during the time of this study (Matz et 
al., 2015). Consistent with the loss of sequestration in these tissues was the increased 
parasite load in the spleens of mice treated with ATc. This suggests that the parasites 
that fail to sequester in peripheral tissues remain in the circulation and are carried to 
the spleen, where they are removed from circulation and destroyed by splenic 
macrophages.  
 
Consistent with the loss of sequestered PTEX88-depleted parasites was the reduction 
in the virulence of the parasites in C57Bl/6 mice. Cerebral malaria is caused primarily 
by a pro-inflammatory immune response to parasite infection, with the sequestration 
of parasites in cerebral tissue leading to localized inflammatory responses thereby 
causing cerebral damage and neurological pathology. Pathological investigation of the 
brains to confirm whether there were reduced parasites in the brains of ATc-treated 
mice was not possible due to a lack of reagents required to perform 
immunohistochemistry, however analysis on the brains of mice infected with ptex88-
null parasites showed a reduction in sequestered parasites both by 
immunohistochemistry and qRT-PCR (Matz et al., 2015), even when the peripheral 
parasitemia in mice infected with ptex88-null parasites was comparable to mice 
infected with wild-type parasites. The similar cerebral malaria phenotypes observed 
with both parasite lines suggest that the ATc-treated PbPTEX88 iKD parasites 
generated in this Chapter also fail to sequester within the brain and this may 
contribute to the absence of cerebral malaria symptoms. 
 
In parallel, the nature of the immune response was investigated in infected mice to 
determine whether PTEX88 may be involved in modulating the immune response of 
the host and thus impacting on the ability of mice to succumb to cerebral malaria. 
This was assessed by measuring the levels of pro-inflammatory cytokines and 
chemokines in the serum and spleens of infected mice. Surprisingly, all of these 
remained unaltered when PTEX88 was knocked down, with the exception of IL-6, 
which was significantly increased, suggesting that there is no reduction in the pro-
inflammatory response when PTEX88 is depleted. This suggested that the absence of 
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cerebral malaria in ATc-treated mice was specifically due to the inability of PTEX88-
deficient parasites to cytoadhere, and was not due to an alteration in the immune 
response. In addition, proportions of cell populations in the spleen were analysed as 
these are implicated in mounting an immune response to malaria infection and 
clearing parasites. Of particular interest are dendritic cells, an immune cell that 
digests foreign material and present them to Helper T cells to initiate an innate 
immune response. The populations of different types of dendritic cells were 
investigated and it was shown that there were largely no differences in the population 
of dendritic cells in the spleens of mice treated with ATc or vehicle control, with the 
exception of a significant increase of CD40 expression on plasmacytoid DCs in the 
spleens of mice treated with ATc, a surprising finding given that this subset of DCs is 
not known to present parasite antigens to T cells during a blood-stage infection 
(deWalick et al., 2007, Lundie et al., 2008). The only other notable difference in the 
spleen between the two treatment groups was a significantly higher proportion of 
CD11c+MHCII+ DCs, CD11clowCD11bhighLy6C+CD64+ macrophages, and Ly6Chigh 
monocytes, which typically traffic to the sites of infection or inflammation and 
differentiate into classical macrophages that secrete pro-inflammatory cytokines 
(Murray and Wynn, 2011, López-Bravo and Ardavín, 2008). There was also a 
significantly lower proportion of Ly6Clow monocytes, which are important for the 
secretion of anti-inflammatory cytokines (Yang et al., 2014) in the spleens of mice 
infected with parasites conditionally depleted of PTEX88. These findings suggested 
that PTEX88 does not actively modulate the immune response of the host, and that 
the differences observed in the proportion of cells within the spleens between 
treatment groups was likely due to the need to clear an increased number of parasites 
within the spleen. A recent study showed that avirulent forms of the rodent malaria P. 
yoelii cause greater remodeling of the spleen and as a consequence are more readily 
taken up by the spleen (Huang et al., 2016). Furthermore, it was shown that the 
avirulent strains of the parasite exhibited reduced deformability and as a result were 
cleared more readily (Huang et al., 2016). The rigidity of PTEX88-depleted parasites 
was not tested in this thesis, though it would be worthy of further study to see whether 
PTEX88 plays a role in regulating the deformability of the host erythrocyte. 
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While the experiments performed in this Chapter have suggested that PTEX88 plays a 
role in mediating sequestration of parasites within the microvasculature of the host, it 
is unclear how this relates to its role as a constituent of PTEX. While only limited 
reagents were available to look at export of specific proteins by immunofluorescence, 
the export of two proteins, known to localize to membranous structures in the infected 
erythrocyte cytosol, were unaffected by the loss of PTEX88. As immunofluorescence 
cannot accurately measure subtle differences in the export of individual proteins, a 
FACS-based strategy was also employed to measure the cumulative affect on global 
protein export by measuring the presentation of parasite proteins on the surface of the 
host erythrocyte. While there were less parasite proteins present on the surface of 
erythrocytes infected with PTEX88-deficient parasites in some experiments, the 
overall decrease in antigen presentation was not significantly decreased. This may be 
because PTEX88 is involved in the export of only a subset of cargo to the infected 
erythrocyte surface (and this excludes PbANKA_122900 and PbANKA_114540) or 
that these proteins are not presented correctly on the infected erythrocyte surface and 
thus not functional. Furthermore, parasites lacking PTEX88 also appeared to export a 
variety of fluorescent chimeric proteins, with no difference observed between ptex88-
null parasites and wild-type parasites when subjected to live cell imaging (Matz et al., 
2015). However in this study and the study by Matz et al (Matz et al., 2015), only a 
small propotion of the whole exportome was analysed, and therefore further reagents 
will be required to ascertain what role PTEX88 may be playing in protein export and 
how this relates to the defects seen in parasite sequestration. 
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6.1. Introduction 
In Chapter 3, potential interacting partners of PTEX88 in P. falciparum were 
identified by immunoprecipitating PTEX88-HA with anti-HA antibodies and 
revealing the identification of the co-immunoprecipitated proteins by mass 
spectrometry. Whilst that experiment demonstrated the specific interaction between 
PTEX88 and the other known constituents of PTEX, it also revealed a number of 
other proteins that specifically co-immunoprecipitated with PTEX88 and are of 
interest as these may represent new components of PTEX that have not been formally 
identified previously. While PTEX is unique to malaria parasites, the extensive 
exportome and the complex nature of the proteins it traffics suggests that the 
translocation machinery may be considerably more complex than the five known 
components it is currently believed to be comprised of. Indeed, many other protein 
translocation systems comprise of a higher number of components that contribute to 
translocation of particular cargo or under different conditions (Schnell and Hebert, 
2003). 
 
The three proteins that were identified as possible components of PTEX due to their 
specific interaction with PTEX88 (see Table 3.1) are PV1 (PF3D7_1129100), EXP3 
(PF3D7_1024800) and PDI-8 (PF3D7_0827900). Each of these proteins harbours a 
signal peptide at their N-terminus but no PEXEL motif and thus could potentially 
localise to the parasitophorous vacuole space.  Interestingly PV1 and PDI-8, have 
been previously identified as part of the proteome of the parasitophorous vacuolar 
space (Nyalwidhe and Lingelbach, 2006, Chu et al., 2011). PV1 has been 
characterised to some extent in P. falciparum, with attempts to delete the gene being 
unsuccessful, suggesting that PV1 is essential in the blood stages of infection (Chu et 
al., 2011). PDI-8 is a protein unique to P. falciparum, that had previously been 
localised to the endoplasmic reticulum by IFA (Mahajan et al., 2006) and thus its 
appearance in the PV proteome was perhaps a surprising finding.  However, 
recombinant PDI-8 had shown enzymatic activity in the oxidation and reduction of 
disulphide bonds (Mahajan et al., 2006), and this is of interest as the unfolding of 
cargo required to make proteins competent for export may be a redox-sensitive 
process. Little is known about EXP3 as it has not previously been characterised and 
the in silico data that exists sheds little light about its potential function.  
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This Chapter aims to gain further insight into the potential functions of these proteins 
in both P. falciparum and P. berghei through the use of ribozyme-mediated 
knockdown and gene knockout approaches, respectively (Kooij et al., 2012). 
Assessing whether depletion of these proteins alters parasite growth and protein 
export will provide insight into whether these proteins may be acting as part of the 
protein export machinery.   
 
6.2. Results 
6.2.1. Generation of targeting plasmids for P. falciparum inducible gene 
knockdown 
Both PDI-8 and EXP3 were targeted for inducible knockdown in P. falciparum using 
the glmS ribozyme. PV1 was not targeted for knockdown in P. falciparum due to time 
constraints. The last ~1 kb of the PDI-8 genomic sequence was amplified by PCR 
from 3D7 genomic DNA using oligonucleotides O533F and O534R and cloned into 
the pTEX150-HA-glmS plasmid (Elsworth et al., 2014b) using the NotI and PstI 
restriction sites, so that the glmS ribozyme would be incorporated into the 3’ 
untranslated region of pdi-8 messenger RNA, and PDI-8 would also be expressed 
with a triple hemagglutinin tag at its C-terminus (Figure 6.1A). The cloning strategy 
for inducible knockdown of EXP3 in P. falciparum was similar, whereby the last ~1 
kb of the EXP3 genomic sequence was amplified by PCR using oligonucleotides 
O535F and O536R and cloned into the pTEX150-HA-glmS plasmid using the NotI 
and PstI restriction sites. After confirmation of correct ligation and absence of 
mutations by DNA sequencing, the targeting plasmids were named pPDI8-HA-glmS 
and pEXP3-HA-glmS.  
 
Each plasmid (100 µg) was prepared and separately transfected into wild-type P. 
falciparum. One day after transfection, WR99210 was added to select for parasites 
harbouring the human dihydrofolate reductase (hDHFR) selection cassette. After 
three rounds of cycling in the presence and absence of selective pressure to select 
against parasites expressing the selectable marker off episomes, drug-resistant 
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parasites were harvested and lysates were analysed by Western blot using antibodies 
against the HA epitope tag to determine whether integration had occurred.  
 
Western blotting of parasite lysates made from two independent parasite lines 
transfected with pPDI8-HA-glmS and probed with anti-HA antibodies failed to detect 
a species at 58 kDa, corresponding to epitope-tagged PDI-8 (Figure 6.1B). This 
suggested that either the pdi-8 gene is not amenable to genetic manipulation, or that 
the C-terminus of PDI-8 could not be epitope-tagged without interfering with the 
function of the protein. Further attempts to perform glmS-mediated knockdown of 
PDI-8 would have required an alternate targeting strategy, such as the removal of the 
HA-epitope tag. However this would have necessitated the generation of an antibody 
against PDI-8 in order to measure knockdown of protein expression. An alternative 
strategy is the placement of the HA epitope tag either at the N-terminus or within the 
protein itself. Given that both of these strategies can be technically difficult and/or 
time consuming and may not be successful, they were not pursued further in these 
studies.  
 
In contrast, Western blot analysis of lysate from parasites transfected with pEXP3-
HA-glmS and probed with anti-HA antibodies detected a species at ~175 kDa, the 
predicted molecular weight for epitope-tagged PfEXP3 (Figure 6.1B). These parasites 
were cloned by limiting dilution to attain a single clonal parasite population, which 
was confirmed by Western blotting and analytical PCR of parasite genomic DNA 
using primers to detect whether the correct integration event had occurred  (Figure 
6.1C). This parasite line was subsequently termed PfEXP3-HA-glmS. 
 
6.2.2. Determining localisation of PfEXP3 
To determine the localisation of PfEXP3, IFA was performed on fixed ring-stage 
PfEXP3-HA-glmS parasites using antibodies against the HA epitope to label PfEXP3-
HA and against the PVM marker EXP2 (Figure 6.1D). IFA showed that EXP3-HA 
appeared to be co-localising with EXP2. This suggested that EXP3 may indeed 
localise at the PVM, which would be consistent with it forming part of the 
translocation machinery. 
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Figure 6.1: Generating conditional knockdown mutants of PfPDI-8 and PfEXP3 
A: Schematic representation of the targeting construct used to generate the 
conditional knockdown parasites in P. falciparum. Successful integration results in 
the gene of interest (GOI) being expressed in frame with a C-terminal triple 
hemagglutinin (HA) epitope tag, followed by a stop codon (red). The glmS ribozyme 
is incorporated into the 3’ UTR of transgenic parasites. Oligonucleotide binding sites 
for diagnostic PCRs are shown. 
B: Western blot analysis of parasite lysate using anti-HA antibodies confirms that the 
targeting construct has successfully integrated into the pfexp3 locus but not into the 
pfpdi-8 locus. PTEX88-HA parasite lysate was used as a control. EXP2 serves as a 
loading control. The band marked * represents full-length epitope-tagged PfEXP3. 
The bands marked ** may represent processed forms of PfEXP3 
C: Diagnostic PCR on genomic DNA from PfEXP3-glmS and 3D7 P. falciparum 
gDNA   using the indicated primer combinations confirms correct integration of the 
targeting construct. Absence of a product using primer combination A/D in PfEXP3-
glmS gDNA indicates this parasite line is clonal. 
D: Immunofluorescence analysis on PfEXP3-glmS parasites confirms PfEXP3 
localises to the PVM where it co-localises with EXP2. DAPI denotes the parasite 
nucleus. DIC; differential interference contrast, scale bar = 5 µm. 
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6.2.3. Characterising the knockdown of PfEXP3 
In order to assess the effect of PfEXP3 knockdown on the parasite, parasites were 
treated with glucosamine. Analysis of the available transcriptomic data from 
PlasmoDB (Aurrecoechea et al., 2009) suggested that EXP3 had a similar 
transcription profile to that of PTEX88, and thus to achieve optimal knockdown, 
glucosamine should be added during the trophozite stage to ensure that new pfexp3 
transcript made in schizogony is immediately degraded to achieve minimal translation 
of EXP3 protein. Three independent experiments were performed whereby 
synchronous early trophozoite stage PfEXP3-HA-glmS parasites were cultured in the 
absence of glucosamine or with 0.3 mM or 2.5 mM glucosamine for 48 hours. 
Parasite lysate was analysed by Western blot using anti-HA antibodies to measure the 
level of EXP3 expression.  This revealed that EXP3 levels could be efficiently 
depleted with glucosamine treatment in a dose dependent manner (Figure 6.2A). 
Maximal loss of PfEXP3 was achieved with addition of 2.5 mM glucosamine, with 
~85 % loss of EXP3 protein relative to the untreated control (Figure 6.2B).  
 
In order to determine the effect of PfEXP3 loss on parasite growth, parasite lactate 
dehydrogenase (pLDH) activity assays were performed on parasites harvested from 
the aforementioned experiments. These assays revealed that there was no significant 
difference in pLDH levels in parasites treated with 2.5 mM glucosamine relative to 
untreated parasites (Figure 6.2C). This was corroborated by analysis of Giemsa-
stained blood smears taken periodically through the 48-hour incubation, which 
showed that parasites treated with 2.5 mM glucosamine were not morphologically 
altered and progressed through the blood-stage life cycle (data not shown). This 
suggested that PfEXP3 did not appear to be important for maintenance of normal 
growth in vitro or that the residual amount of EXP3 being expressed was sufficient 
for parasite growth in vitro. 
 
It was speculated that EXP3 may form part of the protein export machinery due to its 
interaction with PTEX88, matching transcription profile with PTEX88, HSP101 and 
PTEX150, and its localisation at the PVM. Therefore, to determine whether it may be 
involved in protein export, PfEXP3-HA-glmS parasites were treated with 2.5 mM 
glucosamine or left untreated and fixed at various time points after invasion in the  
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Figure 6.2: PfEXP3 knockdown does not affect parasite growth  
A: Representative Western blot showing levels of tagged PfEXP3 in EXP3-glmS 
parasites after incubation with the indicated concentration of glucosamine. EXP2 was 
used as a loading control. GlcN, glucosamine. 
B: Densitometry performed on Western blots to quantify the protein levels of tagged 
PTEX88 in the control PTEX88-HA line and the PTEX88-glmS line. The protein 
level of PfEXP3 decreases in the EXP3-glmS with increasing GlcN concentrations by 
up to 85% when compared to the sample without GlcN (n=3). 
C: Lactate dehydrogenase (LDH) activity assay of infected erythrocytes assayed 
approximately 24 hours after parasite invasion indicate that growth of EXP3-glmS 
parasites is unaffected upon glucosamine treatment (n=3). 
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Figure 6.3: PfEXP3 knockdown does not affect protein export 
Immunofluorescence assays showing that exported proteins A: PfEMP1, B: RESA, 
C: SBP1 are still exported after knockdown of PfEXP3. Mean fluorescence intensity 
was calculated for RESA, whilst the number of foci and Maurer’s clefts was 
calculated for PfEMP1 and SBP1 respectively. Boxes and whiskers delineate 25-75th 
and 10-90 percentiles, respectively. p>0.05 for all proteins tested as determined by 
unpaired t-test 
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following cycle. Export of PfEMP1, RESA and SBP1 was investigated by IFA at time 
points when there is maximal export of these proteins (Figure 6.3 A-C, left panels). 
Quantification of the images generated by immunofluorescence revealed that there 
was no significant loss of export of these proteins when PfEXP3 was depleted, 
suggesting that it is likely not to be involved in global protein export (Figure 6.3 A-C, 
right panels).  
 
6.2.4. Generation of targeting plasmids for P. berghei gene knockouts 
In P. berghei, PV1 and EXP3 were targeted for deletion using the pBAT transfection 
plasmid (Kooij et al., 2012). To create a plasmid for targeted deletion of PbPV1, 1.2 
kb of sequence in the Pbpv1 5’ untranslated region (UTR) was PCR amplified from P. 
berghei ANKA gDNA using the primers O649F and O650R. The resulting product 
was ligated into SacII and HpaI sites of pBAT. Following confirmation of a 
successful ligation, 1.2 kb from the Pbpv1 3’ UTR was amplified by PCR using the 
primers O651F and O652R and cloned into the intermediate vector using the AvrII 
and PstI restriction to create the final targeting vector, termed pBAT-PV1KO. The 
cloning strategy to target PbEXP3 for deletion was similar. For this, 1.2 kb of 
sequence in the Pbexp3 5’ untranslated region was PCR amplified from P. berghei 
ANKA gDNA using the primers O680F and O681R. The resulting product was 
ligated into SacII and HpaI sites of pBAT. Following confirmation of a successful 
ligation, 1.2 kb from the Pbexp3 3’ UTR was amplified by PCR using the primers 
O682F and O683R and cloned into the intermediate vector using the AvrII and PstI 
restriction to create the final targeting vector, termed pBAT-EXP3KO. 
 
After both pBAT-PV1KO and pBAT-EXP3KO were created, both plasmids were 
modified to incorporate an exported GFP cassette in place of the cytosolic GFP that 
exists in the pBAT plasmid. To do this, the pef1α-PfKAHRP-GFP (Haase et al., 2013) 
was digested with KpnI and XhoI to release a cassette containing the ef1α 
bidirectional promoter and the P. falciparum KAHRP signal sequence fused to GFP, 
as the KAHRP signal sequence has been demonstrated to sufficiently guide 
fluorescent reporter protein into the erythrocyte cytosol (Kalanon et al., 2016, Haase 
et al., 2013) (Figure 6.4A). This sequence was blunted using Klenow fragment. The 
pBAT knockout plasmids were digested with PvuII and BamHI, which was also 
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blunted using Klenow fragment. These fragments were ligated to form the final 
plasmid, termed pBAT-PV1KO-Kss-GFP and pBAT-EXP3KO-Kss-GFP.  
 
Prior to transfection, the targeting plasmids were digested with SacII and XhoI to 
drive integration into the endogenous locus. The plasmids were transfected into wild-
type P. berghei parasites and one day after transfection, pyrimethamine was added to 
the drinking water of mice to select for parasites harbouring the targeting plasmids. 
Initial analysis of parasite genomic DNA by PCR confirmed the integration of the 
targeting plasmids. Both parasite lines were subsequently cloned out by intravenous 
injection of a single parasite into the tail veins of Balb/c mice. Analytical PCR was 
performed on the genomic DNA of parasites recovered from these infections, which 
confirmed that, in both cases, the targeting plasmid had integrated into the 
endogenous locus resulting in the deletion of either PV1 or EXP3 and that the lines 
were clonal (Figure 6.4B and 6.4C). The parasite lines were subsequently termed 
PbPV1 KO and PbEXP3 KO.  
 
The targeting constructs pBAT-PV1KO-Kss-GFP and pBAT-EXP3KO-Kss-GFP 
were designed to integrate into the endogenous P. berghei locus by double crossover 
homologous recombination such that successful replacement of the targeted gene 
would result in expression of fluorescent mCherry protein under the control of the 
endogenous promoter (Figure 6.4A). To further confirm that the targeting constructs 
had correctly integrated, infected erythrocytes were stained with DAPI and live-cell 
imaging was performed to visualise the fluorescent mCherry and GFP proteins within 
the infected erythrocyte. Live imaging showed mCherry present in the cytosol of 
PbPV1 KO and PbEXP3 KO parasites, suggesting that these constructs had correctly 
integrated (Figure 6.4B and 6.4C). Unfortunately, the GFP signal was comparatively 
weak when viewed by live-cell imaging, which would make imaging of the exported 
GFP difficult.  
 
6.2.5. Characterisation of PbEXP3 KO 
Data generated from knocking down EXP3 in P. falciparum suggested that EXP3 is 
not required for maintenance of normal parasite growth in vitro. To determine 
whether EXP3 may aid in maintaining optimal parasite growth in vivo and to  
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Figure 6.4: Generating knockouts of PV1 and EXP3 in P. berghei 
A: Schematic representation of targeting constructs used to generate gene knockouts 
in P. berghei. Successful integration results in replacement of the gene of interest with 
the plasmid backbone of the targeting construct, containing triple c-Myc (purple) 
tagged mCherry, an exported GFP cassette and a selectable marker (Toxoplasma 
gondii dihydrofolate reductase-thymidyline synthase). Oligonucleotide binding sites 
for diagnostic PCRs are shown. Pb 3’UTR; Plasmodium berghei-
hydroxymethylpterin pyrophosphokinase-dihydropteroate-synthetase. 
B: The pbpv1 locus could be disrupted. Diagnostic PCR on genomic DNA from 
PbPV1 KO parasites using the indicated primer combinations confirms correct 
integration of the targeting plasmid and disruption of the pbpv1 locus. Absence of a 
product using primer combination A/D in PbPV1 KO gDNA indicates this parasite 
line is clonal. Live cell imaging showed expression of mCherry indicating integration 
of the targeting construct and weak expression of the exported GFP. Scale bar = 5µm. 
C: The pbexp3 locus could be disrupted. Diagnostic PCR on genomic DNA from 
PbEXP3 KO parasites using the indicated primer combinations confirms correct 
integration of the targeting plasmid and disruption of the pbexp3 locus. Absence of a 
product using primer combination A/D in PbEXP3 KO gDNA indicates this parasite 
line is clonal. Live cell imaging showed expression of mCherry indicating integration 
of the targeting construct and weak expression of the exported GFP. Scale bar = 5 
µm. 
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investigate whether EXP3 may play a role aiding in parasite virulence, C57Bl/6 mice 
(n=6 per group) were infected with 1x106 wild-type PbANKA or PbEXP3 KO  
parasites. From 3 days post infection, tail blood was analysed daily by flow cytometry 
to measure the parasitemia using previously established methods (Lelliott et al., 
2014). This analysis showed that deletion of PbEXP3 did not alter the growth of the 
parasite in vivo as the parasitemias of the mice infected with PbEXP3 KO parasites 
were comparable to mice infected with wild-type parasites (Figure 6.5A). The 
development of cerebral malaria symptoms was also monitored in these mice. All 
PbEXP3 KO-infected mice succumbed to cerebral malaria between 5 and 7 days post 
infection, which was similar to mice infected with wild-type parasites, suggesting that 
PbEXP3 does not play a role in mediating parasite virulence (Figure 6.5B).  
 
To assess whether the loss of EXP3 was affecting protein export in P. berghei, IFA 
was performed PbEXP3 KO parasites and PbANKA wild-type parasites, using 
antibodies against PbANKA_114540, PbANKA_122900 or GFP. Quantification of 
the images generated showed that loss of EXP3 did not alter the export of 
PbANKA_114540 and PbANKA_122900 relative to wild-type parasites (Figure 6.6). 
Immunolabelling of GFP showed disperse labelling in the erythrocyte cytosol with no 
obvious accumulation at the host-parasite interface or in the secretory pathway of the 
parasite that would suggest that export of GFP was compromised with the loss of 
PbEXP3 (Figure 6.6). However as GFP is not present in wild-type parasites, it was 
not possible to quantitate the GFP in the erythrocyte cytosol in the PbEXP3 KO 
parasites compared to wild-type parasites.  Similar to the results observed in P. 
falciparum, these data suggested that EXP3 is not playing a role in regulating protein 
export but with so few reagents available to investigate protein export in P. berghei, 
the role of EXP3 in protein translocation, if any, remains unclear.  
 
6.2.6. Characterisation of PbPV1 KO 
In order to determine whether PbPV1 is required for normal parasite growth in vivo or 
for parasite virulence, two experiments were performed whereby C57Bl/6 mice (n=6 
per group) were infected with 1x106 wild-type PbANKA or PbPV1 KO parasites. 
From 3 days post infection, tail blood was analysed daily by flow cytometry to  
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Figure 6.5: Deletion of PbEXP3 does not affect parasite growth or virulence 
A: Parasitemia and B: Survival curves of C57Bl/6 mice (n=6 per group) after 
intraperitoneal administration of 1x106 PbEXP3 KO or PbANKA parasites. Crosses 
represent the number of deaths. An unpaired t-test showed no significant difference 
(NS, P>0.05) in parasitemias between PbEXP3 KO and wild-type parasites, and a 
log-rank test showed no significant difference in the number of mice that succumbed 
to cerebral malaria.  
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Figure 6.6: Deletion of PbEXP3 does not affect protein export 
Immunofluorescence assays showing the P. berghei proteins PBANKA_114540 and 
PBANKA_122900, as well as an exported GFP reporter protein are still exported after 
deletion of EXP3 in P. berghei. Export of PBANKA_114540 and PBANKA_122900 
was measured by calculating MFI, shown as the mean + SEM and compared to export 
in wild-type parasites. An unpaired t-test confirmed there was no significant 
difference in protein export in PbEXP3 KO parasites compared to wild-type parasites. 
DAPI denotes the parasite nucleus. DIC; differential interference contrast, scale bar = 
5µm. 
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measure the parasitemia. This analysis showed that deletion of PbPV1 did not alter 
the growth of the parasite in vivo as the parasitemias of the mice infected with PbPV1 
KO parasites remained similar to mice infected with wild-type parasites (Figure 
6.7A). 
 
The development of cerebral malaria symptoms was also monitored in these mice. All 
wild-type mice succumbed to cerebral malaria between 5 and 7 days post infection, 
whereas mice infected with PbPV1 KO parasites succumbed to cerebral malaria 
between 7 and 9 days post infection (Figure 6.7B). Statistical analysis of parasite 
survival was performed using a Wilcoxon log-rank test (n=11 for PbANKA, n=10 for 
PbPV1 KO), which showed a significant difference between treatment groups 
(p<0.0001), suggesting that PbPV1 contributes to parasite virulence. It should be 
noted that one mouse infected with PbPV1 KO parasites was humanely culled due to 
exhibiting severe symptoms of anemia but did not exhibit any symptoms of cerebral 
malaria (Figure 6.7B). Irrespective, survival of mice infected with PbPV1 KO 
parasites was significantly improved relative to wild-type-infected mice whether the 
mouse culled due to anemia is included in the analysis or not (p<0.0001).   
 
To assess whether the loss of PV1 was affecting protein export and whether a defect 
in protein export may explain the loss of virulence in these parasites, IFA was 
performed on blood infected with PbPV1 KO parasites or wild-type parasites, using 
antibodies against PbANKA_114540, PbANKA_122900 or GFP. Quantification of 
the images generated showed that loss of PV1 did not alter the export of 
PbANKA_114540 and PbANKA_122900 relative to wild-type parasites, while 
immunolabelling of GFP showed disperse labelling in the erythrocyte cytosol with no 
obvious accumulation at the host-parasite interface or in the secretory pathway of the 
parasite that would suggest that export of GFP was compromised with the loss of 
PbPV1 (Figure 6.8). Together these data suggest that PbPV1 is not involved in global 
protein export in manner similar to that of PTEX150 and HSP101 (Elsworth et al., 
2014b, Beck et al., 2014).  
 
 
 
 
  Chapter 6 
 
 149 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Deletion of PbPV1 affects parasite virulence 
A: Parasitemia and B: Survival curves of C57Bl/6 mice after intraperitoneal 
administration of 1x106 PbPV1 KO or PbANKA parasites (n=11 PbANKA, n=10 
PbPV1 KO). Crosses represent the number of deaths. The number of total deaths 
indicates mice succumbing to both cerebral malaria and anemia.  An unpaired t-test 
showed no significant difference in parasitemias at all time points. ***P<0.001, as 
determined by log-rank test for survival curves, which plots the % of mice that have 
not succumbed to cerebral malaria.  
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Figure 6.8: Knockout of PbPV1 does not affect protein export 
Immunofluorescence assays showing the P. berghei proteins PBANKA_114540 and 
PBANKA_122900, as well as an exported GFP reporter protein are still exported after 
deletion of PV1 in P. berghei. Export of PBANKA_114540 and PBANKA_122900 
was measured by calculating MFI, shown as the mean + SEM and compared to export 
in wild-type parasites. An unpaired t-test confirmed there was no significant 
difference in protein export in PbPV1 KO parasites compared to wild-type parasites. 
DAPI denotes the parasite nucleus. DIC; differential interference contrast, scale bar = 
5µm. 
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6.3. Discussion 
This Chapter aimed to functionally characterise proteins shown to interact with 
PTEX88 to see whether they may play roles in protein export and hence whether they  
may be additional components of PTEX. The initial discovery of PTEX identified 
three core constituents, HSP101, PTEX150 and EXP2, and two putative components, 
PTEX88 and TRX2, through a number of proteomic approaches (de Koning-Ward et 
al., 2009). While TRX2 and PTEX88 have since been validated as genuine 
components of PTEX (Matthews et al., 2013), it is not known whether these five 
components constitute the entire translocon or whether there are additional 
components that make up the translocon. In order to understand how PTEX 
successfully traffics cargo into the host erythrocyte, it is important to understand the 
full composition of the translocon and how each component contributes to PTEX 
function. While extensive investigation of the interacting partners of HSP101 and 
PTEX150 has been performed, it is important to investigate the interacting partners of 
all known PTEX components, as some proteins may not directly interact with the core 
constituents of PTEX and thus their interactions may be too transient to have been 
identified in those studies. Indeed, the studies performed in Chapter 3 identified 
proteins that have not been previously identified as interacting partners of HSP101 
and PTEX150.  
 
In this Chapter, the interactome of PTEX88 was examined for proteins that may also 
form part of the translocon at the PVM. Three such proteins were identified and 
examined further to determine whether they localise to the PV/PVM and are crucial 
for parasite growth and protein export in the blood stages, as these are defining 
characteristics of other PTEX components.  
 
PV1, which was originally identified as a PV-resident protein by proteomic analysis 
of the PV space, has since been shown to interact with HSP101, PTEX150 and TRX2 
(de Koning-Ward et al., 2009, Matthews et al., 2013). Its interaction with PTEX88 
provides even further support that PV1 is a novel translocon component. In contrast to 
previous studies in P. falciparum, PV1 could be successfully deleted in P. berghei, a 
similar phenomenon to what has been observed with PTEX88 (Matz et al., 2013). The 
contrast between these species may be that P. falciparum has a more extensive 
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PEXEL exportome and as such PV1 may be required to aid in trafficking the greater 
number of PEXEL proteins across the PVM. It may also be that PV1 is not essential 
for parasite survival in P. falciparum, despite the failure thus far to create a viable 
knockout, given that this species is less tractable for genome editing.  
 
Two independent experiments showed that the growth of PbPV1 KO parasites was 
not impaired related to wild-type parasites in vivo. Nevertheless, loss of PV1 appeared 
to provide some protection from experimental cerebral malaria. However, IFA failed 
to show a defect in protein export in the PbPV1 KO parasites. In light of the results 
observed with conditional knockdown of PTEX88 in P. berghei, it could be 
interpreted that PV1 acts in a somewhat similar manner to PTEX88, in that it does not 
mediate export of all parasite proteins, as has been demonstrated for PTEX150 and 
HSP101. Experiments using semi-immune serum to label parasite proteins on the 
surface of the PbPV1 KO-infected erythrocyte were not performed in these studies 
due to time restraints, so it is hard to predict whether export of proteins targeted to the 
erythrocyte surface is compromised by the loss of PV1. As both the PV1 knockout 
and PTEX88 depleted parasites were compromised in their ability to cause 
experimental cerebral malaria, it would be interesting to see whether cytoadherence is 
also affected phenotypes of the PV1 knockout or whether the reduction in cerebral 
malaria is due to alterations in the pro-inflammatory response. Whether the loss of 
virulence associated with deletion of PV1 is linked to any defect in protein export also 
remains to be determined. 
 
The other protein identified and characterised here is a protein that has been termed 
EXP3. It is conserved across Plasmodium but available in silico predictive tools offer 
little insight into the potential function of EXP3, other than it contains a signal peptide 
and a transmembrane domain near its C-terminus. Attempts to functionally 
characterise this protein were performed in P. falciparum using ribozyme-mediated 
knockdown, and in P. berghei by generating Pbexp3-null parasites. EXP3 levels in P. 
falciparum were regulated by the addition of glucosamine, which showed a loss of 
~85% of PfEXP3 protein. However, no obvious growth phenotype was associated 
with this loss of protein, suggesting that PfEXP3 is not required for normal parasite 
growth and development in vitro. In contrast to PTEX88, PbEXP3 was also shown to 
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not be required for normal parasite growth in vivo, as PbEXP3 KO parasites grew at 
the same rate as WT parasites. Analysis of protein export by immunofluorescence in 
both species failed to show a defect in protein export in EXP3-depleted parasites. 
Furthermore, loss of EXP3 did not alter the virulence of P. berghei parasites. The 
absence of any obvious growth, virulence or protein export phenotype casts doubt on 
the role of EXP3 and the likelihood of it forming part of the protein export machinery. 
Further experiments are required to validate whether the interaction observed between 
EXP3 and PTEX88 is genuine, and whether it interacts with any other components of 
PTEX in order to determine whether EXP3 can be considered a component of PTEX.  
 
While PTEX has been validated as the gateway for all types of exported proteins to 
access the host erythrocyte, it remains unknown how PTEX actually functions to 
traffic proteins across the PVM. It has been speculated that HSP101 may be acting to 
unfold proteins prior to export, a requirement for successful traversal of proteins 
across the PVM (Gehde et al., 2009, de Koning-Ward et al., 2009). It is also thought 
that EXP2 is the membrane-spanning pore through which proteins transport into the 
host cell. However, the mechanisms by which proteins are trafficked to the translocon 
and are recognised by the translocon remain unknown. Furthermore, the presence of 
different types of exported proteins, in particular the proteins containing the PEXEL 
motif and those lacking the motif, creates further doubt about how the translocon 
recognises these different signals to ensure all proteins are exported correctly. PTEX 
may utilise additional components such as PV1 and EXP3 to act as receptors to 
facilitate the docking of exported substrates or to recruit particular cargo to the 
translocon for export. Given that PV1 has been demonstrated to interact with 
HSP101, PTEX150 (Bullen et al., 2012), TRX2 (Matthews et al., 2013) and now 
PTEX88, this protein can now be assigned as a genuine component of PTEX, 
however further analysis will be required to determine whether EXP3 indeed forms 
part of this machinery. The experiments performed in this Chapter showed no obvious 
phenotype that directly suggests these proteins are acting as part of the translocon, so 
further analysis is required to confirm their specific functions within the parasite and 
their overall contribution to protein export.  
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PTEX88 was originally identified as a putative component of PTEX through 
proteomic analyses of the proteins that co-immunoprecipitated with both HSP101 and 
PTEX150. In an attempt to demonstrate conservation of the protein export machinery 
in the rodent malaria species P. berghei, mutant parasites expressing HA epitope 
tagged versions of all components, including PTEX88, were generated (Matthews et 
al., 2013). This enabled immunoprecipitation of each PTEX component to be 
performed using anti-HA antibodies and it was found that PTEX88 interacted 
specifically with two components of the complex for which antibodies were available 
for analysis, those being HSP101 and EXP2. This validated PTEX88 as part of PTEX 
in P. berghei. In this study, a similar approach was taken to epitope tag PTEX88 in P. 
falciparum, and proteomic analysis of proteins co-precipitating with PTEX88 indeed 
confirmed that PTEX88 can pull down the four other members of the PTEX complex 
and hence forms part of the translocation machinery in this species. Native-PAGE 
experiments also demonstrated that PTEX88 exists in a high molecular weight 
complex with the other components of PTEX but in contrast to the core constituents 
of PTEX, which all appear to exist in oligomeric forms within the complex, PTEX88 
assembles within the translocon in a monomeric state. Both biochemical and 
proteomic approaches reveal that PTEX88 interacts directly with HSP101, which are 
both peripherally associated with the PVM, and this has led to the generation of an 
updated model for the assembly of PTEX (Figure 3.11). While more information has 
been uncovered about the interactions between the known constituents of PTEX, it 
still remains to be determined how TRX2 interacts with the rest of the complex.  
 
By determining the interactome of PTEX88, this study also revealed that PTEX 
comprises of more than the originally defined five members. A new member, termed 
PV1 can now also be assigned as a PTEX component as it could co-
immunoprecipitate all of the other PTEX components (Matthews et al., 2013, de 
Koning-Ward et al., 2009, Bullen et al., 2012) and it is similarly localized at the 
PV/PVM (Chu et al., 2011). Interestingly, genetic deletion of PV1 was possible in P. 
berghei which contrasts with a previous publication that showed that PV1 is essential 
for P. falciparum (Chu et al., 2011). Due to the substantially larger exportome, it is 
possible that PV1 plays a more crucial role in the survival of P. falciparum, however 
due to time constraints, the essentiality of PV1 in P. falciparum was not tested further 
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in these studies using conditional regulation systems. However in the PbPV1 
knockout parasites, the P. berghei exported proteins and GFP reporter protein all 
appeared to be exported to the same degree as in wild-type parasites. While deletion 
of PV1 did not alter growth in P. berghei, PV1-null parasites exhibited reduced 
virulence, although this could not be linked to protein export. The nature of the loss of 
virulence is not known as sequestration and immune analysis was not performed on 
mice infected with PbPV1 knockout parasites due to time constraints, although the 
data generated in these studies indicate it is likely to function in an auxiliary role, 
similar to TRX2 and PTEX88.  
 
The functions of HSP101, EXP2 and TRX2 had previously been predicted on the 
basis of conserved functional domains and homology to well-characterised proteins 
(de Koning-Ward et al., 2009). The function of PTEX88 could not be predicted by 
bioinformatic modeling as this protein is not only unique to Plasmodium, but analysis 
of the PTEX88 protein sequence using a variety of bioinformatic software also failed 
to identify any conserved functional domains. Originally PTEX88 was assumed to 
play an essential role in protein export, as attempts to delete PTEX88 in P. berghei 
had been unsuccessful (Matthews et al., 2013), although PTEX88-null parasites have 
since been generated elsewhere using novel selection techniques (Matz et al., 2013). 
To understand the role that PTEX88 plays in protein export, the level of PTEX88 
expression was regulated in this study using inducible knockdown strategies in both 
P. falciparum and P. berghei. The glmS ribozyme was used to knock down PTEX88 
in P. falciparum, achieving 95% loss of PTEX88 protein when parasites were treated 
with glucosamine. There were no defects in parasite growth after glucosamine 
treatment, suggesting that PTEX88 is not required for maintenance of normal parasite 
growth in vitro. Furthermore, analysis of several known exported proteins showed 
that loss of PTEX88 did not alter the export of these proteins, suggesting that 
PTEX88, in contrast to both HSP101 and PTEX150, is not required for their export 
(Elsworth et al., 2014b, Beck et al., 2014). In contrast, knockdown of PTEX88 in P. 
berghei resulted in a significant decrease in parasite growth, which is in keeping with 
results observed by Matz et al with PTEX88-null parasites (Matz et al., 2013). 
Knockdown of PTEX88 in P. berghei by treatment with ATc did not affect export of 
two known exported proteins, both of which contain PEXEL motifs and localize to 
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punctate, cleft-like structures in the erythrocyte cytosol (Haase et al., 2013). Parasite 
proteins presented on the erythrocyte surface were also found to be exported to 
similar levels upon depletion of PTEX88. These results again showed a vastly 
different phenotype to that observed with the knockdown of HSP101 in P. berghei, 
where these proteins failed to reach the erythrocyte (Elsworth et al., 2014b). Matz et 
al (Matz et al., 2015) also reported that PTEX88-null P. berghei parasites could 
export a variety of exported chimeric proteins, suggesting that no particular class of 
exported proteins was affected by loss of PTEX88, which led the authors to question 
whether PTEX88 was involved in protein export at all. 
 
The contrast in growth phenotypes between P. falciparum when cultivated in vitro 
and P. berghei knockdown and/or knockout lines when grown in vivo suggested that 
PTEX88 might play a more important role in an in vivo environment. To investigate 
the nature of the growth phenotypes observed, synchronous infections were 
established in mice, which revealed that the inability for PTEX88-depleted parasites 
to grow at the same rate as wild-type parasites was not due to an invasion defect or a 
developmental defect, but instead was due to a reduced number of invasion events 
resulting from increased clearance of parasites as a consequence of a parasite 
sequestration defect. Consistent with this, P. falciparum trophozoites depleted of 
PTEX88 by the addition of glucosamine also failed to adhere to CD36 under flow 
conditions. The apparent failure for parasites to cytoadhere in both species suggests a 
specific role for PTEX88 in mediating cytoadhesion.  
 
The ability for parasitized erythrocytes to adhere to the vasculature is conferred by the 
presentation of ligands on the surface of the erythrocyte, which interact with receptors 
present on the vascular endothelium, including CD36, CSA and ICAM-1. PfEMP1 is 
the ligand that confers cytoadhesion in P. falciparum, but it is unique to this species. 
P. berghei-infected erythrocytes also adhere to CD36, however, the ligand(s) 
mediating this is not known (Franke-Fayard et al., 2005). Surprisingly, PfEMP1 
export was not affected in parasites depleted of PTEX88. This suggested that the 
cytoadhesion defect observed was not the result of a decrease in PfEMP1 export, 
consistent with the defect also observed in PfEMP1-deficient P. berghei but rather 
other mechanisms. It has been shown that the rigidity of the infected erythrocyte 
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affects its ability to adhere within the tissues (Dondorp et al., 1997, Cooke et al., 
2004b, Glenister et al., 2002). It is possible that PTEX88 is aiding in the export of one 
or more proteins that mediate the rigidity of the host erythrocyte. Assays to test the 
rigidity of infected erythrocyte have been developed and would be useful for 
confirming that the decrease in cytoadherence upon loss of PTEX88 is due to reduced 
rigidity of the host erythrocyte (Nash et al., 1989, Maier et al., 2008, Mills et al., 
2007, Hodder et al., 2009).  In P. falciparum, proteins known to increase the rigidity 
of the erythrocyte include RESA, PfEMP3, KAHRP and STEVOR, among others 
(Maier et al., 2009 for a review). While export of both RESA and KAHRP were not 
affected by the loss of PTEX88 in these studies, it is possible that PTEX88 is 
important in mediating the export of one or more of the remaining proteins involved 
in rigidity. Confirmation of this was not performed as it would require either an 
antibody reagent against these proteins or by generating parasite lines containing 
exported chimeric reporter proteins to analyse the effect of PTEX88 knockdown on 
specific proteins. 
 
Strikingly, mice infected with PTEX88-depleted parasites were protected from 
experimental cerebral malaria (ECM). While the mice also exhibited reduced 
parasitemias, this could not explain the protection from ECM as Matz et al (Matz et 
al., 2015) showed that mice infected with a higher dose of PTEX88-null parasites 
remained free of all ECM symptoms despite their parasitemias being comparable to 
wild-type-infected mice. Thus, PTEX88 contributes to the virulence of the parasite. 
One factor leading to ECM is the sequestration of parasites within the brain. In the 
study by Matz et al (Matz et al., 2015), mice infected with PTEX88-null parasites 
showed a reduction of parasites sequestering in cerebral tissue using 
immunohistochemistry but the brains were otherwise indistinguishable by histology. 
Due to the lack of a suitable immunolabelling agent, these experiments could not be 
performed in the studies described herein, although the reduction in parasite load 
observed in peripheral tissues of ATc treated mice suggests that knockdown of 
PTEX88 was directly affecting parasite sequestration in a number of tissues. ECM is 
caused primarily by a pro-inflammatory immune response to infection, but analysis of 
serum and spleen cytokines revealed that there was no significant difference in the 
levels of a number of pro-inflammatory cytokines, suggesting that the absence of 
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cerebral malaria symptoms in mice infected with PTEX88-depleted parasites was not 
due to a reduction in the pro-inflammatory response. However cerebral malaria is also 
caused by the influx of CD8+ T-cells into the brain (Yañez et al., 1996) and it would 
be worth investigating whether the lack of ECM symptoms in ATc-treated mice is due 
to a reduction in the localized adaptive immune response. Taken together, the 
available evidence indicates that the lack of ECM symptoms observed in PTEX88-
depleted mice is specifically due to the failure for parasites to sequester within 
cerebral tissue. 
 
While the data generated in this thesis have shown that PTEX88 is not involved in 
global protein export in the same manner described for both HSP101 and PTEX150, 
the findings lead to speculation about the role that PTEX88 may play in the PTEX 
complex. The marked differences in growth phenotypes between parasites cultured in 
vitro and parasites grown in vivo leads to the possibility that the role of PTEX88 may 
only become prominent in vivo under particular conditions faced by the parasite and 
hence examination of protein export in P. falciparum cultured in vitro would fail to 
reveal this role. In mitochondria, for example, the Tim8p-Tim13p complex is 
recruited to the mitochondrial inner membrane to facilitate protein translocation 
specifically during periods of low membrane potential (Paschen et al., 2000). Thus, 
particular stresses placed upon the parasite, such as febrile conditions, may necessitate 
the recruitment of accessory proteins to the translocon. Another possibility is that 
PTEX88 is involved in regulating the efficiency of many or all proteins to be 
exported, with the differences in protein export upon depletion of PTEX88 being so 
subtle that the differences are not detectable with the available tools for measuring 
protein export but the net cumulative effect is sufficient to give rise to defects in 
cytoadherence and virulence. For example, a number of exported proteins contribute 
to remodelling the cytoskeleton of P. falciparum-infected erythrocytes and the proper 
trafficking, folding and presentation of PfEMP1 on the erythrocyte surface. As a 
combination of skeletal remodeling and deposition of knobs accounts for dramatic 
increases in rigidity and facilitates adhesion to endothelial cell ligands by distributing 
the tensional forces imposed on individual PfEMP1 molecules across the entire knob 
region and through to the cytoskeleton (Zhang et al., 2015), subtle changes to the 
quantity, timing or folding of exported proteins could hamper the ability of the 
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parasite to cytoadhere.  
 
Another possibility is that PTEX88 acts as a receptor for particular protein or subset 
of proteins not examined here. Substrate-specific receptors exist in other translocation 
systems, such as the peroxisomal translocon, which harbours two distinct receptors, 
Pex5 and Pex7 that act as receptors for specific subsets of cargo (Stanley et al., 2007). 
PTEX is responsible for trafficking all classes of exported proteins, including 
PEXEL-negative proteins, but the mechanisms by which these different classes of 
proteins are identified by PTEX are unknown. As export of both classes of proteins 
was unaffected by depletion of PTEX88, the possibility that PTEX88 is aiding in 
recognizing either of these classes of exported proteins can be discounted. 
Additionally, it is unlikely that PTEX88 is serving as a PTEX receptor/adaptor for 
PfEMP1 as PTEX88-glmS parasites treated with glucosamine still express PfEMP1 
on the infected erythrocyte surface and P. berghei lack PfEMP1. A comparison of 
proteins that traffic to the erythrocyte surface when PTEX88 is depleted 
from P. falciparum and P. berghei would be the most direct way to determine 
whether the same protein(s) is responsible for the loss of sequestration of P. berghei 
in vivo and cytoadhesion to CD36 in vitro or whether the cytoadhesive effect is an 
indirect one. The development of more complex screening methods to look at the 
whole exportome may, therefore, reveal more about a role for PTEX88 in protein 
export. 
 
In summary, the work presented in this thesis confirms that PTEX88 is a genuine 
component of PTEX, although it plays a less essential role than other components. 
While the identification of PTEX as the gateway for all exported proteins to access 
the host erythrocyte validated it as an excellent target for the development of new 
antimalarial therapies, the results generated in these studies suggest that targeting 
PTEX88 may protect individuals from experiencing severe disease but it would not 
kill the parasite and instead other PTEX components would serve as better targets to 
quash infections and prevent the spread of this deadly pathogen. 
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